{"PMC7336084": [], "PMC7525250": [["IntroductionSurfactants are molecules with amphipathic properties having hydrophilic and hydrophobic moieties that reduce surface and interfacial tension between liquids or biphasic systems as liquid/gas, liquid/liquid and solid/liquid.", [["surface", "ANATOMY", 122, 129], ["IntroductionSurfactants", "SIMPLE_CHEMICAL", 0, 23], ["solid", "SIMPLE_CHEMICAL", 223, 228], ["amphipathic properties", "TREATMENT", 43, 65], ["hydrophilic and hydrophobic moieties", "TREATMENT", 73, 109], ["interfacial tension between liquids", "TREATMENT", 134, 169], ["biphasic systems", "TREATMENT", 173, 189], ["liquid/gas", "TEST", 193, 203], ["interfacial tension", "OBSERVATION", 134, 153]]], ["Based on the origin, the surfactants have been classified into chemical surfactants and biosurfactants (BSs) [1].", [["surfactants", "SIMPLE_CHEMICAL", 25, 36], ["biosurfactants", "SIMPLE_CHEMICAL", 88, 102], ["BSs", "SIMPLE_CHEMICAL", 104, 107], ["the surfactants", "TREATMENT", 21, 36], ["chemical surfactants", "TREATMENT", 63, 83], ["origin", "ANATOMY_MODIFIER", 13, 19]]], ["BSs are secondary metabolites obtained from several microorganisms including bacteria, fungi and yeasts; classified based on their chemical composition and their origin from microbes, including Pseudomonas aeruginosa, Bacillus subtilis and Lactobacillus sp.", [["BSs", "CHEMICAL", 0, 3], ["BSs", "SIMPLE_CHEMICAL", 0, 3], ["Pseudomonas aeruginosa", "ORGANISM", 194, 216], ["Bacillus subtilis", "ORGANISM", 218, 235], ["Lactobacillus sp", "ORGANISM", 240, 256], ["Pseudomonas aeruginosa", "SPECIES", 194, 216], ["Bacillus subtilis", "SPECIES", 218, 235], ["Pseudomonas aeruginosa", "SPECIES", 194, 216], ["Bacillus subtilis", "SPECIES", 218, 235], ["secondary metabolites", "PROBLEM", 8, 29], ["several microorganisms", "PROBLEM", 44, 66], ["bacteria", "PROBLEM", 77, 85], ["fungi", "PROBLEM", 87, 92], ["yeasts", "PROBLEM", 97, 103], ["Pseudomonas aeruginosa", "PROBLEM", 194, 216], ["Bacillus subtilis", "PROBLEM", 218, 235], ["Lactobacillus sp", "PROBLEM", 240, 256], ["secondary metabolites", "OBSERVATION", 8, 29]]], ["BSs are used in a wide range of applications since it is eco-friendly and biodegradable than synthetic surfactants.", [["BSs", "SIMPLE_CHEMICAL", 0, 3], ["synthetic surfactants", "TREATMENT", 93, 114], ["wide", "OBSERVATION_MODIFIER", 18, 22]]], ["In recent years this has attracted broad interest due to their unique properties like specificity, low toxicity and smooth preparation.", [["toxicity", "DISEASE", 103, 111], ["low toxicity", "PROBLEM", 99, 111], ["smooth preparation", "TREATMENT", 116, 134], ["low toxicity", "OBSERVATION_MODIFIER", 99, 111], ["smooth", "OBSERVATION_MODIFIER", 116, 122]]], ["The unique features of BS opted for industrial applications such as petroleum, fertilizers, cosmetics, chemicals, foods, pharmaceuticals and more.", [["petroleum", "SIMPLE_CHEMICAL", 68, 77], ["BS", "TEST", 23, 25], ["industrial applications", "TREATMENT", 36, 59], ["petroleum, fertilizers", "TREATMENT", 68, 90], ["cosmetics", "TREATMENT", 92, 101], ["pharmaceuticals", "TREATMENT", 121, 136]]], ["They are also used as emulsifiers, demulsifiers, foaming agents, food ingredients and detergents.", [["demulsifiers", "SIMPLE_CHEMICAL", 35, 47], ["emulsifiers", "TREATMENT", 22, 33], ["demulsifiers", "TREATMENT", 35, 47], ["foaming agents", "TREATMENT", 49, 63]]], ["Generally, the BSs are used in hand washes and for personal hygiene purposes in order to prevent the viral transmission, get rid of viral disease symptoms, acts as drug transport and also as anti-viral facemasks [4].", [["hand", "ANATOMY", 31, 35], ["BSs", "CHEMICAL", 15, 18], ["viral disease", "DISEASE", 132, 145], ["BSs", "SIMPLE_CHEMICAL", 15, 18], ["hand", "ORGANISM_SUBDIVISION", 31, 35], ["hand washes", "TREATMENT", 31, 42], ["personal hygiene purposes", "TREATMENT", 51, 76], ["the viral transmission", "PROBLEM", 97, 119], ["viral disease symptoms", "PROBLEM", 132, 154], ["drug transport", "TREATMENT", 164, 178], ["anti-viral facemasks", "TREATMENT", 191, 211]]], ["An essential property of BS is the surface and interfacial tension.", [["surface", "ANATOMY", 35, 42], ["BS", "SIMPLE_CHEMICAL", 25, 27], ["surface", "CELLULAR_COMPONENT", 35, 42], ["interfacial tension", "PROBLEM", 47, 66], ["essential", "OBSERVATION_MODIFIER", 3, 12], ["property", "OBSERVATION_MODIFIER", 13, 21], ["BS", "OBSERVATION", 25, 27], ["surface", "OBSERVATION_MODIFIER", 35, 42], ["interfacial tension", "OBSERVATION", 47, 66]]], ["Surface tension is defined as the tension created between attractive intermolecular forces in a molecule.", [["Surface tension", "PROBLEM", 0, 15], ["tension", "OBSERVATION", 8, 15], ["tension", "OBSERVATION_MODIFIER", 34, 41], ["attractive", "OBSERVATION_MODIFIER", 58, 68], ["intermolecular forces", "OBSERVATION", 69, 90]]], ["The ability to minimize the surface tension determined by the concentration of the surface-active compound called critical micelle concentration (CMC).", [["surface", "ANATOMY", 28, 35], ["surface", "ANATOMY", 83, 90], ["the surface tension", "PROBLEM", 24, 43], ["critical micelle concentration (CMC)", "TREATMENT", 114, 150]]], ["The CMC is the minimum concentration required to reduce the surface tension and induce micelle formation.", [["surface", "ANATOMY", 60, 67], ["micelle", "SIMPLE_CHEMICAL", 87, 94], ["the surface tension", "TREATMENT", 56, 75], ["induce micelle formation", "PROBLEM", 80, 104], ["CMC", "OBSERVATION", 4, 7], ["surface tension", "OBSERVATION", 60, 75], ["micelle formation", "OBSERVATION", 87, 104]]], ["The primary function of BS is to control the attachment and detachment of microorganisms from the surfaces [5].", [["BS", "TEST", 24, 26], ["detachment of microorganisms", "PROBLEM", 60, 88], ["detachment", "OBSERVATION", 60, 70]]], ["The structure of BS depends upon the presence of hydrophobic and hydrophilic moieties.", [["hydrophobic and hydrophilic moieties", "PROBLEM", 49, 85], ["BS", "OBSERVATION", 17, 19], ["hydrophobic", "OBSERVATION_MODIFIER", 49, 60], ["hydrophilic moieties", "OBSERVATION", 65, 85]]], ["Hydrophilic moiety consists of peptides, amino acids, mono-, di- and polysaccharides, whereas hydrophobic consist of saturated and unsaturated fatty acids.", [["amino acids", "CHEMICAL", 41, 52], ["mono-, di- and polysaccharides", "CHEMICAL", 54, 84], ["fatty acids", "CHEMICAL", 143, 154], ["amino acids", "CHEMICAL", 41, 52], ["saturated and unsaturated fatty acids", "CHEMICAL", 117, 154], ["amino acids", "AMINO_ACID", 41, 52], ["mono-", "SIMPLE_CHEMICAL", 54, 59], ["polysaccharides", "SIMPLE_CHEMICAL", 69, 84], ["unsaturated fatty acids", "SIMPLE_CHEMICAL", 131, 154], ["amino acids", "TEST", 41, 52], ["mono-", "TEST", 54, 59], ["di", "TEST", 61, 63], ["polysaccharides", "PROBLEM", 69, 84], ["unsaturated fatty acids", "PROBLEM", 131, 154], ["fatty acids", "OBSERVATION", 143, 154]]], ["The BS are differentiated based on molecular mass were the lower molecular mass molecules reduce the surface, and interfacial tension and the higher molecular weight efficiently function as emulsion balancing agents.", [["surface", "ANATOMY", 101, 108], ["surface", "CELLULAR_COMPONENT", 101, 108], ["molecular mass", "PROBLEM", 35, 49], ["the lower molecular mass molecules", "PROBLEM", 55, 89], ["interfacial tension", "PROBLEM", 114, 133], ["emulsion balancing agents", "TREATMENT", 190, 215], ["BS", "ANATOMY", 4, 6], ["differentiated", "OBSERVATION_MODIFIER", 11, 25], ["molecular", "OBSERVATION_MODIFIER", 35, 44], ["mass", "OBSERVATION", 45, 49], ["lower", "OBSERVATION_MODIFIER", 59, 64], ["molecular", "OBSERVATION_MODIFIER", 65, 74], ["mass", "OBSERVATION", 75, 79], ["surface", "OBSERVATION_MODIFIER", 101, 108], ["interfacial tension", "OBSERVATION", 114, 133], ["higher", "OBSERVATION_MODIFIER", 142, 148]]], ["Based on molecular mass the BSs are classified as glycolipids, phospholipid, lipoprotein or lipopeptide, polysaccharide-lipid complex or microbial cell surface.", [["cell surface", "ANATOMY", 147, 159], ["BSs", "SIMPLE_CHEMICAL", 28, 31], ["glycolipids", "SIMPLE_CHEMICAL", 50, 61], ["phospholipid", "SIMPLE_CHEMICAL", 63, 75], ["lipoprotein", "SIMPLE_CHEMICAL", 77, 88], ["lipopeptide", "SIMPLE_CHEMICAL", 92, 103], ["polysaccharide", "SIMPLE_CHEMICAL", 105, 119], ["microbial cell surface", "CELLULAR_COMPONENT", 137, 159], ["lipid complex", "PROTEIN", 120, 133], ["molecular mass the BSs", "PROBLEM", 9, 31], ["glycolipids", "TEST", 50, 61], ["lipopeptide", "TREATMENT", 92, 103], ["polysaccharide-lipid complex", "TREATMENT", 105, 133], ["molecular", "OBSERVATION_MODIFIER", 9, 18], ["mass", "OBSERVATION", 19, 23], ["microbial cell", "OBSERVATION", 137, 151], ["surface", "OBSERVATION_MODIFIER", 152, 159]]], ["Microorganisms also produce chemical-based surfactants known as polymeric microbial surfactants (PMS).", [["polymeric microbial surfactants", "SIMPLE_CHEMICAL", 64, 95], ["PMS", "SIMPLE_CHEMICAL", 97, 100], ["chemical-based surfactants", "TREATMENT", 28, 54], ["polymeric microbial surfactants", "TREATMENT", 64, 95]]], ["Hence, the physiochemical properties of BSs and their biomedical applications with the source and chemical structure have been distinguished.", [["BSs", "CHEMICAL", 40, 43], ["BSs", "SIMPLE_CHEMICAL", 40, 43], ["their biomedical applications", "TREATMENT", 48, 77]]], ["The classification of BSs from various organisms and studies with biomedical importance has been tabulated in Table 1.IntroductionCoronavirus Disease 2019 (COVID-19), caused by a new strain of coronavirus emerged in December 2019 and became a global pandemic.", [["COVID-19", "CHEMICAL", 156, 164], ["coronavirus", "DISEASE", 193, 204], ["BSs", "CANCER", 22, 25], ["coronavirus", "ORGANISM", 193, 204], ["BSs", "PROBLEM", 22, 25], ["various organisms", "PROBLEM", 31, 48], ["studies", "TEST", 53, 60], ["IntroductionCoronavirus Disease", "PROBLEM", 118, 149], ["COVID", "TEST", 156, 161], ["a new strain of coronavirus", "PROBLEM", 177, 204], ["a global pandemic", "PROBLEM", 241, 258], ["global", "OBSERVATION_MODIFIER", 243, 249], ["pandemic", "OBSERVATION", 250, 258]]], ["The COVID-19 has grown to be a global public-health emergency [6].", [["COVID-19", "CHEMICAL", 4, 12], ["COVID-19", "DNA", 4, 12], ["The COVID", "TEST", 0, 9]]], ["The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a new member of the genus beta coronavirus which exhibits faster human to human transmission leading to a world-wide public health emergency [7, 8].", [["acute respiratory syndrome coronavirus", "DISEASE", 11, 49], ["severe acute respiratory syndrome coronavirus 2", "ORGANISM", 4, 51], ["SARS-CoV-2", "ORGANISM", 53, 63], ["beta coronavirus", "ORGANISM", 94, 110], ["human", "ORGANISM", 133, 138], ["human", "ORGANISM", 142, 147], ["beta coronavirus", "SPECIES", 94, 110], ["human", "SPECIES", 133, 138], ["human", "SPECIES", 142, 147], ["severe acute respiratory syndrome coronavirus", "SPECIES", 4, 49], ["SARS-CoV-2", "SPECIES", 53, 63], ["beta coronavirus", "SPECIES", 94, 110], ["human", "SPECIES", 133, 138], ["human", "SPECIES", 142, 147], ["The severe acute respiratory syndrome coronavirus", "PROBLEM", 0, 49], ["SARS-CoV", "TEST", 53, 61], ["the genus beta coronavirus", "PROBLEM", 84, 110], ["severe", "OBSERVATION_MODIFIER", 4, 10], ["acute", "OBSERVATION_MODIFIER", 11, 16], ["respiratory syndrome", "OBSERVATION", 17, 37], ["genus beta coronavirus", "OBSERVATION", 88, 110]]], ["Once infected, the patient mainly relies on the immune system to resist SARS-CoV-2, with the supportive treatment being prescribed if complications occur [9].", [["immune system", "ANATOMY", 48, 61], ["SARS", "DISEASE", 72, 76], ["patient", "ORGANISM", 19, 26], ["patient", "SPECIES", 19, 26], ["SARS-CoV", "SPECIES", 72, 80], ["infected", "PROBLEM", 5, 13], ["the immune system", "TREATMENT", 44, 61], ["CoV", "TEST", 77, 80], ["the supportive treatment", "TREATMENT", 89, 113], ["infected", "OBSERVATION", 5, 13]]], ["Meanwhile, scientists con\ufb01rmed that the \ufb01rst step in the SARS-CoV-2 pathogenesis is the speci\ufb01c interaction of the virus with angiotensin-converting enzyme 2 (ACE2), a master regulator of the renin-angiotensin system (RAS) of host cells through its spike protein [10].", [["cells", "ANATOMY", 231, 236], ["SARS", "DISEASE", 57, 61], ["angiotensin", "CHEMICAL", 126, 137], ["angiotensin", "CHEMICAL", 198, 209], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 126, 157], ["ACE2", "GENE_OR_GENE_PRODUCT", 159, 163], ["renin-angiotensin system", "GENE_OR_GENE_PRODUCT", 192, 216], ["RAS", "GENE_OR_GENE_PRODUCT", 218, 221], ["host cells", "CELL", 226, 236], ["angiotensin-converting enzyme 2", "PROTEIN", 126, 157], ["ACE2", "PROTEIN", 159, 163], ["renin", "PROTEIN", 192, 197], ["host cells", "CELL_TYPE", 226, 236], ["the SARS", "TEST", 53, 61], ["the virus", "PROBLEM", 111, 120], ["angiotensin", "TREATMENT", 126, 137], ["the renin-angiotensin system", "TREATMENT", 188, 216], ["host cells", "PROBLEM", 226, 236], ["its spike protein", "TEST", 245, 262], ["host cells", "OBSERVATION", 226, 236]]], ["Once the virus enters the lungs, the immune system sends a large number of immune cells to kill the virus [11].", [["lungs", "ANATOMY", 26, 31], ["immune system", "ANATOMY", 37, 50], ["immune cells", "ANATOMY", 75, 87], ["lungs", "ORGAN", 26, 31], ["immune cells", "CELL", 75, 87], ["immune cells", "CELL_TYPE", 75, 87], ["immune cells", "PROBLEM", 75, 87], ["virus", "OBSERVATION", 9, 14], ["lungs", "ANATOMY", 26, 31], ["large", "OBSERVATION_MODIFIER", 59, 64], ["immune cells", "OBSERVATION", 75, 87]]], ["Once the cytokine storm is formed, the immune system is exaggerated and kills the healthy cells [12].", [["immune system", "ANATOMY", 39, 52], ["cells", "ANATOMY", 90, 95], ["cells", "CELL", 90, 95], ["cytokine", "PROTEIN", 9, 17], ["healthy cells", "CELL_TYPE", 82, 95]]], ["Besides, the ability of the virus to evade, the immune system is hugely problematic when considering appropriate treatment and vaccine options.", [["immune system", "ANATOMY", 48, 61], ["the virus", "PROBLEM", 24, 33], ["appropriate treatment", "TREATMENT", 101, 122], ["vaccine options", "TREATMENT", 127, 142]]], ["SARS-CoV-2 debilitates the equilibrium maintained by the immune system and triggers the cytokine storm.", [["immune system", "ANATOMY", 57, 70], ["SARS", "DISEASE", 0, 4], ["SARS-CoV-2", "ORGANISM", 0, 10], ["cytokine", "PROTEIN", 88, 96], ["cytokine storm", "OBSERVATION", 88, 102]]], ["The significant difficulties found in COVID-19 patients have been linked to the cytokine storm.", [["patients", "ORGANISM", 47, 55], ["cytokine", "PROTEIN", 80, 88], ["patients", "SPECIES", 47, 55], ["The significant difficulties", "PROBLEM", 0, 28], ["significant", "OBSERVATION_MODIFIER", 4, 15], ["difficulties", "OBSERVATION", 16, 28], ["cytokine storm", "OBSERVATION", 80, 94]]], ["In-depth research is required to effectively manage the cytokine storm while maintaining the immune system balance.", [["immune system", "ANATOMY", 93, 106], ["immune system", "ANATOMICAL_SYSTEM", 93, 106], ["cytokine", "PROTEIN", 56, 64], ["the cytokine storm", "PROBLEM", 52, 70], ["cytokine storm", "OBSERVATION", 56, 70]]], ["Upon binding, the spike protein is cleaved into two and this induces a conformational change facilitating the fusion of the virus and its entry into the cell.", [["cell", "ANATOMY", 153, 157], ["cell", "CELL", 153, 157], ["spike protein", "PROTEIN", 18, 31], ["the spike protein", "PROBLEM", 14, 31], ["a conformational change", "PROBLEM", 69, 92], ["the fusion of the virus", "TREATMENT", 106, 129], ["cell", "ANATOMY", 153, 157]]], ["Recently, Vellingiri et al. [6] comprehensively discussed about the viral transcription, translation and expression of viral proteins in the cells.", [["cells", "ANATOMY", 141, 146], ["cells", "CELL", 141, 146], ["viral proteins", "PROTEIN", 119, 133], ["the viral transcription", "PROBLEM", 64, 87], ["viral proteins in the cells", "PROBLEM", 119, 146], ["viral proteins", "OBSERVATION", 119, 133], ["cells", "ANATOMY", 141, 146]]], ["BSs in medical application has elevated during the past decade.", [["BSs", "CHEMICAL", 0, 3], ["BSs", "SIMPLE_CHEMICAL", 0, 3], ["elevated", "OBSERVATION_MODIFIER", 31, 39]]], ["BS acts as a therapeutic agent due to its anti-viral, anti-bacterial and anti-fungal property in fighting many diseases [13].", [["BS", "CHEMICAL", 0, 2], ["a therapeutic agent", "TREATMENT", 11, 30], ["its anti-viral", "TREATMENT", 38, 52], ["anti-bacterial", "TREATMENT", 54, 68], ["anti-fungal property", "TREATMENT", 73, 93]]], ["Hence this review focuses on the anti-inflammatory and anti-viral properties of the BSs and its potential uses against as a strategy to treat or prevent COVID-19 disease.Anti-inflammatory potential of BSsPhospholipase A2 (PLA2) functions in arachidonic acid (AA) secretion.", [["arachidonic acid", "CHEMICAL", 241, 257], ["AA", "CHEMICAL", 259, 261], ["arachidonic acid", "CHEMICAL", 241, 257], ["BSs", "SIMPLE_CHEMICAL", 84, 87], ["BSsPhospholipase A2", "GENE_OR_GENE_PRODUCT", 201, 220], ["PLA2", "GENE_OR_GENE_PRODUCT", 222, 226], ["arachidonic acid", "SIMPLE_CHEMICAL", 241, 257], ["AA", "SIMPLE_CHEMICAL", 259, 261], ["BSsPhospholipase A2", "PROTEIN", 201, 220], ["PLA2", "PROTEIN", 222, 226], ["the anti-inflammatory", "TREATMENT", 29, 50], ["the BSs", "TREATMENT", 80, 87], ["a strategy", "TREATMENT", 122, 132], ["COVID-19 disease", "PROBLEM", 153, 169], ["BSsPhospholipase A2 (PLA2) functions in arachidonic acid (AA) secretion", "PROBLEM", 201, 272], ["arachidonic acid", "OBSERVATION", 241, 257]]], ["Various types of PLA2 collectively called as cytosolic Phospholipase-A2 (cPLA2).", [["cytosolic", "ANATOMY", 45, 54], ["PLA2", "GENE_OR_GENE_PRODUCT", 17, 21], ["cytosolic Phospholipase-A2", "GENE_OR_GENE_PRODUCT", 45, 71], ["cPLA2", "GENE_OR_GENE_PRODUCT", 73, 78], ["PLA2", "PROTEIN", 17, 21], ["cytosolic Phospholipase-A2", "PROTEIN", 45, 71], ["cPLA2", "PROTEIN", 73, 78], ["PLA2", "TEST", 17, 21], ["cytosolic Phospholipase", "TEST", 45, 68]]], ["Inflammatory response occurs due to the release of AA that is converted to inflammatory mediators.", [["AA", "CHEMICAL", 51, 53], ["AA", "SIMPLE_CHEMICAL", 51, 53], ["inflammatory mediators", "PROTEIN", 75, 97], ["Inflammatory response", "PROBLEM", 0, 21], ["AA", "PROBLEM", 51, 53], ["inflammatory mediators", "PROBLEM", 75, 97], ["inflammatory", "OBSERVATION_MODIFIER", 75, 87]]], ["AA acts as a precursor of eicosanoids secretion which functions in maintenance of inflammatory process.", [["AA", "CHEMICAL", 0, 2], ["AA", "SIMPLE_CHEMICAL", 0, 2], ["eicosanoids secretion", "PROBLEM", 26, 47], ["inflammatory process", "PROBLEM", 82, 102], ["inflammatory", "OBSERVATION", 82, 94]]], ["Mechanistically, structural features of BSs were detected by toll like receptors (TLR-2) and the BSs communicate with the cell membranes and macromolecules and inhibit cPLA2 that initiate anti-inflammatory responses.", [["cell membranes", "ANATOMY", 122, 136], ["BSs", "GENE_OR_GENE_PRODUCT", 40, 43], ["toll like receptors", "GENE_OR_GENE_PRODUCT", 61, 80], ["TLR-2", "GENE_OR_GENE_PRODUCT", 82, 87], ["BSs", "GENE_OR_GENE_PRODUCT", 97, 100], ["cell membranes", "CELLULAR_COMPONENT", 122, 136], ["cPLA2", "GENE_OR_GENE_PRODUCT", 168, 173], ["BSs", "PROTEIN", 40, 43], ["toll like receptors", "PROTEIN", 61, 80], ["TLR", "PROTEIN", 82, 85], ["BSs", "PROTEIN", 97, 100], ["cPLA2", "PROTEIN", 168, 173], ["BSs", "PROBLEM", 40, 43], ["TLR", "TEST", 82, 85], ["the cell membranes", "TREATMENT", 118, 136], ["cPLA2", "PROBLEM", 168, 173], ["anti-inflammatory responses", "TREATMENT", 188, 215], ["cell membranes", "OBSERVATION", 122, 136]]], ["In an in vitro model, the pro-inflammatory cytokines was secreted by neutrophils when induced with trehalolipids synthesized by Rhodococcus ruber [14].", [["neutrophils", "ANATOMY", 69, 80], ["trehalolipids", "CHEMICAL", 99, 112], ["trehalolipids", "CHEMICAL", 99, 112], ["neutrophils", "CELL", 69, 80], ["trehalolipids", "SIMPLE_CHEMICAL", 99, 112], ["Rhodococcus ruber", "ORGANISM", 128, 145], ["pro-inflammatory cytokines", "PROTEIN", 26, 52], ["neutrophils", "CELL_TYPE", 69, 80], ["Rhodococcus ruber", "SPECIES", 128, 145], ["Rhodococcus ruber", "SPECIES", 128, 145], ["the pro-inflammatory cytokines", "PROBLEM", 22, 52], ["trehalolipids", "TREATMENT", 99, 112]]], ["The glycolipids from R. ruber were induced in mononuclear cells and it was revealed to mediate the production of interleukin-12 (IL-12), interleukin-18 (IL-18) and ROS [15] and stimulated the production of TNF-\u03b1, IL-1\u03b2 and IL-6 [16].", [["mononuclear cells", "ANATOMY", 46, 63], ["R. ruber", "ORGANISM", 21, 29], ["mononuclear cells", "CELL", 46, 63], ["interleukin-12", "GENE_OR_GENE_PRODUCT", 113, 127], ["IL-12", "GENE_OR_GENE_PRODUCT", 129, 134], ["interleukin-18", "GENE_OR_GENE_PRODUCT", 137, 151], ["IL-18", "GENE_OR_GENE_PRODUCT", 153, 158], ["ROS", "SIMPLE_CHEMICAL", 164, 167], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 206, 211], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 213, 218], ["IL-6", "GENE_OR_GENE_PRODUCT", 223, 227], ["mononuclear cells", "CELL_TYPE", 46, 63], ["interleukin-12", "PROTEIN", 113, 127], ["interleukin-18", "PROTEIN", 137, 151], ["IL-18", "PROTEIN", 153, 158], ["TNF", "PROTEIN", 206, 209], ["IL-1\u03b2", "PROTEIN", 213, 218], ["R. ruber", "SPECIES", 21, 29], ["R. ruber", "SPECIES", 21, 29], ["The glycolipids", "TREATMENT", 0, 15], ["interleukin", "TEST", 113, 124], ["IL", "TEST", 129, 131], ["interleukin", "TEST", 137, 148], ["IL", "TEST", 153, 155], ["ROS", "TEST", 164, 167], ["TNF", "TEST", 206, 209], ["IL", "TEST", 213, 215], ["IL", "TEST", 223, 225], ["mononuclear cells", "OBSERVATION", 46, 63]]], ["Administration of surfactin in rat and fish models decreased the pro-inflammatory cytokines with an increase in the levels of anti-inflammatory cytokines [17, 18].", [["surfactin", "CHEMICAL", 18, 27], ["surfactin", "CHEMICAL", 18, 27], ["surfactin", "SIMPLE_CHEMICAL", 18, 27], ["rat", "ORGANISM", 31, 34], ["fish", "ORGANISM", 39, 43], ["pro-inflammatory cytokines", "PROTEIN", 65, 91], ["anti-inflammatory cytokines", "PROTEIN", 126, 153], ["rat", "SPECIES", 31, 34], ["rat", "SPECIES", 31, 34], ["surfactin in rat", "TREATMENT", 18, 34], ["fish models", "PROBLEM", 39, 50], ["the pro-inflammatory cytokines", "TREATMENT", 61, 91], ["anti-inflammatory cytokines", "TREATMENT", 126, 153], ["pro-inflammatory cytokines", "OBSERVATION", 65, 91], ["increase", "OBSERVATION_MODIFIER", 100, 108]]], ["The BS surfactin from Bacillus subtilis was observed to suppress lipopolysaccharide induced signaling pathways, impaired macrophage function and IL-12 expression, decreased TLR-4 protein expression with an increase in the anti-inflammatory effect [19].", [["macrophage", "ANATOMY", 121, 131], ["BS surfactin", "CHEMICAL", 4, 16], ["lipopolysaccharide", "CHEMICAL", 65, 83], ["BS surfactin", "SIMPLE_CHEMICAL", 4, 16], ["Bacillus subtilis", "ORGANISM", 22, 39], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 65, 83], ["macrophage", "CELL", 121, 131], ["IL-12", "GENE_OR_GENE_PRODUCT", 145, 150], ["TLR-4", "GENE_OR_GENE_PRODUCT", 173, 178], ["TLR", "PROTEIN", 173, 176], ["Bacillus subtilis", "SPECIES", 22, 39], ["Bacillus subtilis", "SPECIES", 22, 39], ["The BS surfactin", "TREATMENT", 0, 16], ["Bacillus subtilis", "PROBLEM", 22, 39], ["lipopolysaccharide induced signaling pathways", "PROBLEM", 65, 110], ["impaired macrophage function", "PROBLEM", 112, 140], ["IL", "TEST", 145, 147], ["decreased TLR", "PROBLEM", 163, 176], ["the anti-inflammatory effect", "TREATMENT", 218, 246], ["impaired", "OBSERVATION_MODIFIER", 112, 120], ["macrophage", "OBSERVATION_MODIFIER", 121, 131], ["increase", "OBSERVATION_MODIFIER", 206, 214], ["anti-inflammatory effect", "OBSERVATION", 222, 246]]], ["Surfactin from Staphylococcus aureus significantly reduced the pro-inflammatory cytokines, obstructed the lipoteichoic acid -induced signaling pathway, increased STAT-3 phosphorylation and blocked the expression of heme oxygenase-1 (HO-1).", [["Surfactin", "CHEMICAL", 0, 9], ["lipoteichoic acid", "CHEMICAL", 106, 123], ["Surfactin", "CHEMICAL", 0, 9], ["Surfactin", "SIMPLE_CHEMICAL", 0, 9], ["Staphylococcus aureus", "ORGANISM", 15, 36], ["lipoteichoic acid", "SIMPLE_CHEMICAL", 106, 123], ["STAT-3", "GENE_OR_GENE_PRODUCT", 162, 168], ["heme oxygenase-1", "GENE_OR_GENE_PRODUCT", 215, 231], ["HO-1", "GENE_OR_GENE_PRODUCT", 233, 237], ["pro-inflammatory cytokines", "PROTEIN", 63, 89], ["STAT-3", "PROTEIN", 162, 168], ["heme oxygenase-1 (HO-1", "PROTEIN", 215, 237], ["Staphylococcus aureus", "SPECIES", 15, 36], ["Staphylococcus aureus", "SPECIES", 15, 36], ["Surfactin", "TREATMENT", 0, 9], ["Staphylococcus aureus", "PROBLEM", 15, 36], ["the pro-inflammatory cytokines", "TEST", 59, 89], ["the lipoteichoic acid", "TEST", 102, 123], ["increased STAT", "PROBLEM", 152, 166], ["heme oxygenase", "TEST", 215, 229], ["Staphylococcus aureus", "OBSERVATION", 15, 36], ["pro-inflammatory cytokines", "OBSERVATION", 63, 89], ["heme oxygenase", "OBSERVATION", 215, 229]]], ["It has been established that surfactin as an anti-inflammatory and neuroprotective agent [20].", [["surfactin", "CHEMICAL", 29, 38], ["surfactin", "CHEMICAL", 29, 38], ["surfactin", "SIMPLE_CHEMICAL", 29, 38], ["surfactin", "TREATMENT", 29, 38], ["an anti-inflammatory and neuroprotective agent", "TREATMENT", 42, 88]]], ["Similarly, limited studies were conducted and they revealed the potential effect of BSs from yeast species with anti-inflammatory activity.", [["BSs", "CHEMICAL", 84, 87], ["BSs", "SIMPLE_CHEMICAL", 84, 87], ["yeast", "SPECIES", 93, 98], ["yeast", "SPECIES", 93, 98], ["limited studies", "TEST", 11, 26], ["BSs", "PROBLEM", 84, 87], ["yeast species", "PROBLEM", 93, 106], ["anti-inflammatory activity", "TREATMENT", 112, 138], ["yeast species", "OBSERVATION", 93, 106], ["anti-inflammatory activity", "OBSERVATION", 112, 138]]], ["Sophorolipids (SLs) from C. bombicola decreased immunoglobulin E (IgE) level, mRNA expression of TLR-2, IL-6 and STAT3 and lung inflammation [21, 22].", [["lung", "ANATOMY", 123, 127], ["Sophorolipids", "CHEMICAL", 0, 13], ["lung inflammation", "DISEASE", 123, 140], ["Sophorolipids", "CHEMICAL", 0, 13], ["Sophorolipids", "SIMPLE_CHEMICAL", 0, 13], ["C. bombicola", "ORGANISM", 25, 37], ["immunoglobulin E", "GENE_OR_GENE_PRODUCT", 48, 64], ["IgE", "GENE_OR_GENE_PRODUCT", 66, 69], ["TLR-2", "GENE_OR_GENE_PRODUCT", 97, 102], ["IL-6", "GENE_OR_GENE_PRODUCT", 104, 108], ["STAT3", "GENE_OR_GENE_PRODUCT", 113, 118], ["lung", "ORGAN", 123, 127], ["immunoglobulin E", "PROTEIN", 48, 64], ["IgE", "PROTEIN", 66, 69], ["TLR", "PROTEIN", 97, 100], ["IL-6", "PROTEIN", 104, 108], ["STAT3", "PROTEIN", 113, 118], ["C. bombicola", "SPECIES", 25, 37], ["C. bombicola", "SPECIES", 25, 37], ["Sophorolipids (SLs)", "TREATMENT", 0, 19], ["C. bombicola decreased immunoglobulin E (IgE)", "TREATMENT", 25, 70], ["mRNA expression", "TEST", 78, 93], ["TLR", "TEST", 97, 100], ["IL", "TEST", 104, 106], ["STAT3 and lung inflammation", "PROBLEM", 113, 140], ["lung", "ANATOMY", 123, 127], ["inflammation", "OBSERVATION", 128, 140]]], ["Hence, the study demonstrated that SLs down-regulate the IgE coding genes, thereby acting as an anti-inflammatory agent and potential therapeutic compound [21, 23].", [["IgE", "GENE_OR_GENE_PRODUCT", 57, 60], ["IgE coding genes", "DNA", 57, 73], ["the study", "TEST", 7, 16], ["SLs", "TEST", 35, 38], ["the IgE coding genes", "TREATMENT", 53, 73], ["an anti-inflammatory agent", "TREATMENT", 93, 119]]], ["In an experimental rat model, SLs reduced sepsis-related mortality and observed predicted to display anti-inflammatory effects [24, 25].", [["sepsis", "DISEASE", 42, 48], ["rat", "ORGANISM", 19, 22], ["rat", "SPECIES", 19, 22], ["rat", "SPECIES", 19, 22], ["SLs reduced sepsis", "PROBLEM", 30, 48], ["reduced", "OBSERVATION_MODIFIER", 34, 41], ["sepsis", "OBSERVATION", 42, 48]]], ["Similarly, in another rat model study, SLs resulted in an improved survival rate, decreased nitric oxide and modulated inflammatory responses [26].", [["nitric oxide", "CHEMICAL", 92, 104], ["nitric oxide", "CHEMICAL", 92, 104], ["rat", "ORGANISM", 22, 25], ["nitric oxide", "SIMPLE_CHEMICAL", 92, 104], ["rat", "SPECIES", 22, 25], ["rat", "SPECIES", 22, 25], ["another rat model study", "TEST", 14, 37], ["decreased nitric oxide", "TREATMENT", 82, 104], ["modulated inflammatory responses", "PROBLEM", 109, 141], ["improved", "OBSERVATION_MODIFIER", 58, 66], ["survival", "OBSERVATION", 67, 75], ["nitric oxide", "OBSERVATION", 92, 104], ["inflammatory", "OBSERVATION_MODIFIER", 119, 131]]], ["Natural and synthetic SLs were demonstrated to show a prominent anti-inflammatory activity, spermicidal and anti-HIV activity [27].", [["a prominent anti-inflammatory activity", "PROBLEM", 52, 90], ["prominent", "OBSERVATION_MODIFIER", 54, 63], ["anti-inflammatory activity", "OBSERVATION", 64, 90]]], ["The SLs reduce the expression of inflammatory cytokines [28] and these findings indicate that SLs would be a promising therapy for anti-inflammatory or immunomodulation in chronic inflammatory conditions.", [["SLs", "SIMPLE_CHEMICAL", 94, 97], ["inflammatory cytokines", "PROTEIN", 33, 55], ["inflammatory cytokines", "PROBLEM", 33, 55], ["a promising therapy", "TREATMENT", 107, 126], ["anti-inflammatory or immunomodulation", "TREATMENT", 131, 168], ["chronic inflammatory conditions", "PROBLEM", 172, 203], ["inflammatory", "OBSERVATION_MODIFIER", 33, 45], ["chronic", "OBSERVATION_MODIFIER", 172, 179], ["inflammatory", "OBSERVATION", 180, 192]]], ["MELs are secreted by Pseudomonas antarctica, which has also inhibited the inflammatory mediators, thereby creating anti-inflammatory action [29].", [["MELs", "SIMPLE_CHEMICAL", 0, 4], ["Pseudomonas antarctica", "ORGANISM", 21, 43], ["inflammatory mediators", "PROTEIN", 74, 96], ["Pseudomonas antarctica", "SPECIES", 21, 43], ["Pseudomonas antarctica", "SPECIES", 21, 43], ["Pseudomonas antarctica", "PROBLEM", 21, 43], ["the inflammatory mediators", "PROBLEM", 70, 96], ["Pseudomonas antarctica", "OBSERVATION", 21, 43], ["inflammatory", "OBSERVATION_MODIFIER", 74, 86], ["anti-inflammatory", "OBSERVATION_MODIFIER", 115, 132]]], ["From these studies, it is clarified that the BSs from bacterial and yeast species showed an anti-inflammatory activity and suggested to be potential therapeutic candidate in treating inflammatory diseases.", [["inflammatory diseases", "DISEASE", 183, 204], ["BSs", "GENE_OR_GENE_PRODUCT", 45, 48], ["yeast species", "ORGANISM", 68, 81], ["yeast", "SPECIES", 68, 73], ["yeast", "SPECIES", 68, 73], ["these studies", "TEST", 5, 18], ["the BSs", "TEST", 41, 48], ["bacterial and yeast species", "PROBLEM", 54, 81], ["inflammatory diseases", "PROBLEM", 183, 204], ["yeast species", "OBSERVATION", 68, 81], ["anti-inflammatory activity", "OBSERVATION", 92, 118], ["inflammatory", "OBSERVATION", 183, 195]]], ["Also, more studies need to be conducted on the effects of anti-inflammation using these BSs.BSs anti-inflammatory role against COVID-19Once the SARS-CoV-2 enters the human host cell through the ACE2 receptors, immediately the immune system deploys a large number of immune cells to respond against the virus especially by recruiting the antigen-presenting cells (APCs) [30].", [["cell", "ANATOMY", 177, 181], ["immune system", "ANATOMY", 226, 239], ["immune cells", "ANATOMY", 266, 278], ["antigen-presenting cells", "ANATOMY", 337, 361], ["APCs", "ANATOMY", 363, 367], ["COVID-19Once", "CHEMICAL", 127, 139], ["BSs", "SIMPLE_CHEMICAL", 88, 91], ["BSs", "SIMPLE_CHEMICAL", 92, 95], ["COVID-19Once", "GENE_OR_GENE_PRODUCT", 127, 139], ["SARS-CoV-2", "ORGANISM", 144, 154], ["human", "ORGANISM", 166, 171], ["host cell", "CELL", 172, 181], ["ACE2", "GENE_OR_GENE_PRODUCT", 194, 198], ["immune cells", "CELL", 266, 278], ["antigen-presenting", "GENE_OR_GENE_PRODUCT", 337, 355], ["cells", "CELL", 356, 361], ["APCs", "CELL", 363, 367], ["ACE2 receptors", "PROTEIN", 194, 208], ["immune cells", "CELL_TYPE", 266, 278], ["antigen-presenting cells", "CELL_TYPE", 337, 361], ["APCs", "CELL_TYPE", 363, 367], ["human", "SPECIES", 166, 171], ["human", "SPECIES", 166, 171], ["anti-inflammation", "TREATMENT", 58, 75], ["these BSs", "TEST", 82, 91], ["COVID", "TEST", 127, 132], ["the SARS", "TEST", 140, 148], ["CoV", "TEST", 149, 152], ["the ACE2 receptors", "TREATMENT", 190, 208], ["immune cells", "PROBLEM", 266, 278], ["the virus", "PROBLEM", 298, 307], ["anti-inflammatory", "OBSERVATION_MODIFIER", 96, 113], ["host cell", "OBSERVATION", 172, 181], ["large", "OBSERVATION_MODIFIER", 250, 255], ["immune cells", "OBSERVATION", 266, 278]]], ["It is reported that the COVID-19 positive patients have high levels of cytokine storm, which are also correlated with the viral load in COVID-19 patients [31].", [["COVID-19", "GENE_OR_GENE_PRODUCT", 24, 32], ["patients", "ORGANISM", 42, 50], ["patients", "ORGANISM", 145, 153], ["cytokine", "PROTEIN", 71, 79], ["patients", "SPECIES", 42, 50], ["patients", "SPECIES", 145, 153], ["the COVID", "TEST", 20, 29], ["high levels of cytokine storm", "PROBLEM", 56, 85], ["the viral load", "TEST", 118, 132], ["COVID", "TEST", 136, 141], ["cytokine storm", "OBSERVATION", 71, 85]]], ["When the cytokine storm is formed, the immune system is exaggerated and kills healthy cells [12].", [["immune system", "ANATOMY", 39, 52], ["cells", "ANATOMY", 86, 91], ["cells", "CELL", 86, 91], ["cytokine", "PROTEIN", 9, 17], ["healthy cells", "CELL_TYPE", 78, 91]]], ["Moreover, when the levels of IL-6 and lymphocytes are higher, it inadvertently results in increased pulmonary damage [32].", [["lymphocytes", "ANATOMY", 38, 49], ["pulmonary", "ANATOMY", 100, 109], ["pulmonary damage", "DISEASE", 100, 116], ["IL-6", "GENE_OR_GENE_PRODUCT", 29, 33], ["lymphocytes", "CELL", 38, 49], ["pulmonary", "ORGAN", 100, 109], ["IL-6", "PROTEIN", 29, 33], ["lymphocytes", "CELL_TYPE", 38, 49], ["IL", "TEST", 29, 31], ["lymphocytes", "PROBLEM", 38, 49], ["increased pulmonary damage", "PROBLEM", 90, 116], ["lymphocytes", "ANATOMY", 38, 49], ["increased", "OBSERVATION_MODIFIER", 90, 99], ["pulmonary", "ANATOMY", 100, 109], ["damage", "OBSERVATION", 110, 116]]], ["In addition to this, the ability of the virus to evade the immune system is hugely problematic when considering appropriate treatment and vaccine options.", [["immune system", "ANATOMY", 59, 72], ["the virus", "PROBLEM", 36, 45], ["appropriate treatment", "TREATMENT", 112, 133], ["vaccine options", "TREATMENT", 138, 153]]], ["The subsequent damage can be caused either by direct infection of SARS-CoV-2 in cells, by hypoxemia due to lung damage or by an indirect injury caused by the immune and cytokine responses [33].", [["cells", "ANATOMY", 80, 85], ["lung", "ANATOMY", 107, 111], ["infection", "DISEASE", 53, 62], ["SARS", "DISEASE", 66, 70], ["hypoxemia", "DISEASE", 90, 99], ["lung damage", "DISEASE", 107, 118], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 66, 76], ["cells", "CELL", 80, 85], ["lung", "ORGAN", 107, 111], ["cytokine", "PROTEIN", 169, 177], ["SARS-CoV", "SPECIES", 66, 74], ["The subsequent damage", "PROBLEM", 0, 21], ["direct infection of SARS", "PROBLEM", 46, 70], ["CoV", "TEST", 71, 74], ["hypoxemia", "PROBLEM", 90, 99], ["lung damage", "PROBLEM", 107, 118], ["an indirect injury", "PROBLEM", 125, 143], ["infection", "OBSERVATION", 53, 62], ["hypoxemia", "OBSERVATION", 90, 99], ["lung", "ANATOMY", 107, 111], ["damage", "OBSERVATION", 112, 118]]], ["Excessive amounts of cytokines, such as IL-1\u03b2 and IL-18, are produced during the cytokine storm and may cause irrevocable damage to various organs.", [["organs", "ANATOMY", 140, 146], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 40, 45], ["IL-18", "GENE_OR_GENE_PRODUCT", 50, 55], ["organs", "ORGAN", 140, 146], ["cytokines", "PROTEIN", 21, 30], ["IL-1\u03b2", "PROTEIN", 40, 45], ["IL-18", "PROTEIN", 50, 55], ["cytokine", "PROTEIN", 81, 89], ["Excessive amounts of cytokines", "PROBLEM", 0, 30], ["IL", "TEST", 40, 42], ["the cytokine storm", "TREATMENT", 77, 95], ["irrevocable damage to various organs", "PROBLEM", 110, 146], ["amounts", "OBSERVATION_MODIFIER", 10, 17], ["cytokines", "OBSERVATION", 21, 30]]], ["It is well-known that the BSs have a major role in defense against pathogenic infection as well as induce anti-inflammation in the human body [34].", [["body", "ANATOMY", 137, 141], ["infection", "DISEASE", 78, 87], ["BSs", "GENE_OR_GENE_PRODUCT", 26, 29], ["human", "ORGANISM", 131, 136], ["BSs", "PROTEIN", 26, 29], ["human", "SPECIES", 131, 136], ["human", "SPECIES", 131, 136], ["pathogenic infection", "PROBLEM", 67, 87], ["pathogenic", "OBSERVATION_MODIFIER", 67, 77], ["infection", "OBSERVATION", 78, 87], ["anti-inflammation", "OBSERVATION_MODIFIER", 106, 123]]], ["The glycolipid and lipopeptide types of BSs have been effectively employed towards treating various anti-microbial diseases [35].", [["BSs", "CHEMICAL", 40, 43], ["glycolipid", "SIMPLE_CHEMICAL", 4, 14], ["BSs", "SIMPLE_CHEMICAL", 40, 43], ["The glycolipid and lipopeptide types of BSs", "TREATMENT", 0, 43], ["various anti-microbial diseases", "PROBLEM", 92, 123]]], ["One of its types, the surfactin which is a natural cyclic lipopeptide has shown to have various biological properties like anti-viral, anti-fungal, anti-cancer which is initiated by suppressing the signaling of cell survivals, platelet aggregation and reducing the cytokine storm by proposing anti-inflammatory effects [36].", [["cell", "ANATOMY", 211, 215], ["platelet", "ANATOMY", 227, 235], ["surfactin", "CHEMICAL", 22, 31], ["cyclic lipopeptide", "CHEMICAL", 51, 69], ["platelet aggregation", "DISEASE", 227, 247], ["surfactin", "CHEMICAL", 22, 31], ["surfactin", "SIMPLE_CHEMICAL", 22, 31], ["anti-cancer", "CANCER", 148, 159], ["cell", "CELL", 211, 215], ["platelet", "CELL", 227, 235], ["cytokine", "PROTEIN", 265, 273], ["the surfactin", "TREATMENT", 18, 31], ["a natural cyclic lipopeptide", "TREATMENT", 41, 69], ["anti-viral, anti-fungal", "TREATMENT", 123, 146], ["anti-cancer", "TREATMENT", 148, 159], ["cell survivals", "TREATMENT", 211, 225], ["platelet aggregation", "PROBLEM", 227, 247], ["the cytokine storm", "TREATMENT", 261, 279], ["anti-viral", "OBSERVATION", 123, 133], ["cell survivals", "OBSERVATION", 211, 225], ["cytokine storm", "OBSERVATION", 265, 279]]], ["Hence the use of BS would be a possible way to minimize the impact of cytokine storm caused due to SARS-CoV-2 infection in the COVID-19 affected patients.", [["infection", "DISEASE", 110, 119], ["SARS-CoV-2", "ORGANISM", 99, 109], ["patients", "ORGANISM", 145, 153], ["cytokine", "PROTEIN", 70, 78], ["patients", "SPECIES", 145, 153], ["SARS-CoV", "SPECIES", 99, 107], ["BS", "TREATMENT", 17, 19], ["cytokine storm", "PROBLEM", 70, 84], ["SARS", "PROBLEM", 99, 103], ["CoV", "PROBLEM", 104, 107], ["2 infection", "PROBLEM", 108, 119], ["the COVID", "TEST", 123, 132], ["infection", "OBSERVATION", 110, 119]]], ["We propose a hypothetical mechanism of action of BS in reducing the inflammation in the COVID-19 disease.", [["BS", "CHEMICAL", 49, 51], ["inflammation", "DISEASE", 68, 80], ["BS", "SIMPLE_CHEMICAL", 49, 51], ["COVID-19 disease", "CANCER", 88, 104], ["action of BS", "TREATMENT", 39, 51], ["the inflammation", "PROBLEM", 64, 80], ["the COVID-19 disease", "PROBLEM", 84, 104], ["inflammation", "OBSERVATION", 68, 80], ["19 disease", "OBSERVATION", 94, 104]]], ["Upon binding of the SARS-CoV-2\u2019s the S (Spike) protein, it is cleaved into two; this induces a conformational change facilitating the fusion of the virus and its entry into the cell.", [["cell", "ANATOMY", 177, 181], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 20, 30], ["cell", "CELL", 177, 181], ["SARS-CoV-2", "DNA", 20, 30], ["S (Spike) protein", "PROTEIN", 37, 54], ["the SARS", "TEST", 16, 24], ["CoV", "TEST", 25, 28], ["the S (Spike) protein", "PROBLEM", 33, 54], ["a conformational change", "PROBLEM", 93, 116], ["the fusion of the virus", "TREATMENT", 130, 153], ["cell", "ANATOMY", 177, 181]]], ["The NF-\u03baB pathway is a common pathway implicated in many pathologies and is activated by viral N, S, 3a and 7a proteins.", [["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 4, 9], ["N, S, 3a", "GENE_OR_GENE_PRODUCT", 95, 103], ["7a", "GENE_OR_GENE_PRODUCT", 108, 110], ["NF-\u03baB", "PROTEIN", 4, 9], ["viral N, S, 3a and 7a proteins", "PROTEIN", 89, 119], ["many pathologies", "PROBLEM", 52, 68], ["pathologies", "OBSERVATION", 57, 68]]], ["NF-\u03baB, upon activation, enters the nucleus and catalyzes the transcription of pro-IL-1\u03b2 and procaspase-1.", [["nucleus", "ANATOMY", 35, 42], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 0, 5], ["nucleus", "CELLULAR_COMPONENT", 35, 42], ["pro-IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 78, 87], ["procaspase-1", "GENE_OR_GENE_PRODUCT", 92, 104], ["NF-\u03baB", "PROTEIN", 0, 5], ["pro-IL-1\u03b2", "PROTEIN", 78, 87], ["procaspase-1", "PROTEIN", 92, 104], ["pro-IL", "TEST", 78, 84], ["procaspase", "TREATMENT", 92, 102], ["nucleus", "ANATOMY", 35, 42]]], ["When additional signals like increased Ca2+ and ROS are detected, the pro-IL-1\u03b2 and procaspase 1 are cleaved into IL-1\u03b2 and caspase 1.", [["Ca2", "CHEMICAL", 39, 42], ["ROS", "CHEMICAL", 48, 51], ["Ca2+", "CHEMICAL", 39, 43], ["Ca2+", "SIMPLE_CHEMICAL", 39, 43], ["ROS", "SIMPLE_CHEMICAL", 48, 51], ["pro-IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 70, 79], ["procaspase 1", "GENE_OR_GENE_PRODUCT", 84, 96], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 114, 119], ["caspase 1", "GENE_OR_GENE_PRODUCT", 124, 133], ["Ca2", "PROTEIN", 39, 42], ["pro-IL-1\u03b2", "PROTEIN", 70, 79], ["procaspase 1", "PROTEIN", 84, 96], ["IL-1\u03b2", "PROTEIN", 114, 119], ["caspase 1", "PROTEIN", 124, 133], ["increased Ca2", "TEST", 29, 42], ["the pro-IL", "TEST", 66, 76], ["procaspase", "TREATMENT", 84, 94], ["caspase", "TREATMENT", 124, 131]]], ["This results in the production of cytokines such as (TNF-\u03b1, IL-1B, IL-6, IL-2) and causes a cytokine storm that results in necrosis and cell death.", [["cell", "ANATOMY", 136, 140], ["necrosis", "DISEASE", 123, 131], ["death", "DISEASE", 141, 146], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 53, 58], ["IL-1B", "GENE_OR_GENE_PRODUCT", 60, 65], ["IL-6", "GENE_OR_GENE_PRODUCT", 67, 71], ["IL-2", "GENE_OR_GENE_PRODUCT", 73, 77], ["cell", "CELL", 136, 140], ["cytokines", "PROTEIN", 34, 43], ["TNF-\u03b1, IL-1B, IL-6", "PROTEIN", 53, 71], ["IL", "PROTEIN", 73, 75], ["cytokine", "PROTEIN", 92, 100], ["cytokines", "PROBLEM", 34, 43], ["TNF", "TEST", 53, 56], ["IL", "TEST", 60, 62], ["IL", "TEST", 67, 69], ["a cytokine storm", "PROBLEM", 90, 106], ["necrosis", "PROBLEM", 123, 131], ["cell death", "PROBLEM", 136, 146], ["cytokine storm", "OBSERVATION", 92, 106], ["necrosis", "OBSERVATION", 123, 131], ["cell death", "OBSERVATION", 136, 146]]], ["In COVID-19 patients it is observed that there is an inhibition in the production of heme, as it is responsible for the production of biliverdin, ferrous iron and carbon mono-oxide which could limit the inflammation and stress caused due to SARS-CoV-2 viral infection [[37], [38], [39]].", [["biliverdin", "CHEMICAL", 134, 144], ["ferrous iron", "CHEMICAL", 146, 158], ["carbon mono-oxide", "CHEMICAL", 163, 180], ["inflammation", "DISEASE", 203, 215], ["infection", "DISEASE", 258, 267], ["heme", "CHEMICAL", 85, 89], ["biliverdin", "CHEMICAL", 134, 144], ["ferrous iron", "CHEMICAL", 146, 158], ["carbon mono-oxide", "CHEMICAL", 163, 180], ["patients", "ORGANISM", 12, 20], ["heme", "SIMPLE_CHEMICAL", 85, 89], ["biliverdin", "SIMPLE_CHEMICAL", 134, 144], ["ferrous iron", "SIMPLE_CHEMICAL", 146, 158], ["carbon mono-oxide", "SIMPLE_CHEMICAL", 163, 180], ["SARS-CoV-2 viral", "ORGANISM", 241, 257], ["[37], [38], [39]]", "SIMPLE_CHEMICAL", 269, 286], ["heme", "PROTEIN", 85, 89], ["patients", "SPECIES", 12, 20], ["SARS-CoV", "SPECIES", 241, 249], ["biliverdin", "TREATMENT", 134, 144], ["ferrous iron", "TREATMENT", 146, 158], ["carbon mono-oxide", "TREATMENT", 163, 180], ["the inflammation", "PROBLEM", 199, 215], ["stress", "PROBLEM", 220, 226], ["SARS", "PROBLEM", 241, 245], ["CoV", "TEST", 246, 249], ["viral infection", "PROBLEM", 252, 267]]], ["If the BS is provided to the COVID-19 patients, then it could suppress the production of NF-\u03baB by stimulating the HO-1 and TH1 macrophage cells [40].", [["HO-1", "ANATOMY", 114, 118], ["TH1 macrophage cells", "ANATOMY", 123, 143], ["patients", "ORGANISM", 38, 46], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 89, 94], ["HO-1", "GENE_OR_GENE_PRODUCT", 114, 118], ["TH1 macrophage cells", "CELL", 123, 143], ["NF-\u03baB", "PROTEIN", 89, 94], ["TH1 macrophage cells", "CELL_LINE", 123, 143], ["patients", "SPECIES", 38, 46], ["the BS", "TEST", 3, 9], ["the HO", "TEST", 110, 116]]], ["This, in turn, would reduce the production of cytokines such as TNF-\u03b1, IL-1B, IL-6, IL-2, which will reduce the effect of cytokine storm in the COVID-19 patients.", [["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 64, 69], ["IL-1B", "GENE_OR_GENE_PRODUCT", 71, 76], ["IL-6", "GENE_OR_GENE_PRODUCT", 78, 82], ["IL-2", "GENE_OR_GENE_PRODUCT", 84, 88], ["patients", "ORGANISM", 153, 161], ["cytokines", "PROTEIN", 46, 55], ["TNF", "PROTEIN", 64, 67], ["IL", "PROTEIN", 84, 86], ["cytokine", "PROTEIN", 122, 130], ["patients", "SPECIES", 153, 161], ["the production of cytokines", "PROBLEM", 28, 55], ["TNF", "TEST", 64, 67], ["IL", "TEST", 71, 73], ["IL", "TREATMENT", 78, 80], ["IL", "TREATMENT", 84, 86], ["cytokine storm", "TREATMENT", 122, 136]]], ["Even it has been reported that as the BSs are known for its emulsification role in drugs or vaccines would be highly successful as they are produced naturally which contains non-toxic and non-pyrogenic immunological adjuvants when mixed with conventional antigens for treating COVID-19 disease [41].", [["COVID-19 disease", "DISEASE", 277, 293], ["BSs", "SIMPLE_CHEMICAL", 38, 41], ["drugs", "TREATMENT", 83, 88], ["vaccines", "TREATMENT", 92, 100], ["non-toxic and non-pyrogenic immunological adjuvants", "TREATMENT", 174, 225], ["conventional antigens", "TREATMENT", 242, 263], ["treating COVID-19 disease", "PROBLEM", 268, 293], ["non-toxic", "OBSERVATION_MODIFIER", 174, 183]]], ["Hence these pieces of evidence show that BSs play a huge role as immunosuppressive agents and could be highly used as a combinational drug to relieve inflammatory responses caused due to SARS-CoV-2 infection.BSs anti-viral activity against COVID-19Certain BSs inactivates viruses due to physio-chemical reactions [42].", [["BSs", "CHEMICAL", 41, 44], ["SARS-CoV-2 infection", "DISEASE", 187, 207], ["COVID-19Certain BSs", "CHEMICAL", 240, 259], ["BSs", "SIMPLE_CHEMICAL", 41, 44], ["SARS-CoV-2", "ORGANISM", 187, 197], ["BSs", "SIMPLE_CHEMICAL", 208, 211], ["COVID-19Certain BSs", "SIMPLE_CHEMICAL", 240, 259], ["SARS-CoV", "SPECIES", 187, 195], ["immunosuppressive agents", "TREATMENT", 65, 89], ["a combinational drug", "TREATMENT", 118, 138], ["inflammatory responses", "PROBLEM", 150, 172], ["SARS", "PROBLEM", 187, 191], ["CoV", "PROBLEM", 192, 195], ["2 infection", "PROBLEM", 196, 207], ["BSs anti-viral activity", "TEST", 208, 231], ["COVID", "TEST", 240, 245], ["BSs inactivates viruses", "PROBLEM", 256, 279], ["physio-chemical reactions", "PROBLEM", 287, 312], ["infection", "OBSERVATION", 198, 207]]], ["This hypothetical nature occurs only in enveloped viruses.", [["enveloped", "OBSERVATION_MODIFIER", 40, 49], ["viruses", "OBSERVATION", 50, 57]]], ["Generally, it is stated that BSs disturbs the viral membrane structures and disrupts the outer covering [27].", [["membrane structures", "ANATOMY", 52, 71], ["BSs", "SIMPLE_CHEMICAL", 29, 32], ["membrane structures", "CELLULAR_COMPONENT", 52, 71], ["BSs disturbs the viral membrane structures", "PROBLEM", 29, 71], ["viral membrane", "OBSERVATION", 46, 60]]], ["The hydrophilic nature of the BS occurs due to the presence of acetyl groups that promotes anti-viral activity [43].", [["BS", "CHEMICAL", 30, 32], ["acetyl", "CHEMICAL", 63, 69], ["acetyl", "CHEMICAL", 63, 69], ["acetyl", "SIMPLE_CHEMICAL", 63, 69], ["the BS", "PROBLEM", 26, 32], ["acetyl groups", "TREATMENT", 63, 76], ["hydrophilic", "OBSERVATION_MODIFIER", 4, 15], ["anti-viral activity", "OBSERVATION", 91, 110]]], ["Also, the hydrophobic nature with specific number of carbon atoms inactivates the virucidal effects [44].", [["carbon atoms", "CHEMICAL", 53, 65], ["carbon", "CHEMICAL", 53, 59], ["carbon atoms", "SIMPLE_CHEMICAL", 53, 65], ["carbon atoms", "PROBLEM", 53, 65], ["hydrophobic nature", "OBSERVATION_MODIFIER", 10, 28], ["carbon atoms", "OBSERVATION", 53, 65]]], ["High inactivation arises when the BS has a fatty acid chain with 15 carbon atoms and one negative charge; in addition, monomethyl esters showed viral inactivation in semliki forest virus [44].", [["BS", "CHEMICAL", 34, 36], ["fatty acid", "CHEMICAL", 43, 53], ["carbon atoms", "CHEMICAL", 68, 80], ["monomethyl esters", "CHEMICAL", 119, 136], ["fatty acid", "CHEMICAL", 43, 53], ["carbon", "CHEMICAL", 68, 74], ["monomethyl esters", "CHEMICAL", 119, 136], ["carbon atoms", "SIMPLE_CHEMICAL", 68, 80], ["monomethyl esters", "SIMPLE_CHEMICAL", 119, 136], ["semliki forest virus", "ORGANISM", 166, 186], ["semliki forest virus", "SPECIES", 166, 186], ["High inactivation", "PROBLEM", 0, 17], ["the BS", "TEST", 30, 36], ["a fatty acid chain", "PROBLEM", 41, 59], ["carbon atoms", "TEST", 68, 80], ["monomethyl esters", "TEST", 119, 136], ["viral inactivation in semliki forest virus", "PROBLEM", 144, 186], ["viral inactivation", "OBSERVATION", 144, 162], ["semliki forest virus", "OBSERVATION", 166, 186]]], ["The antiviral activity of BSs have been approved and patents obtained on treating various viruses [[45], [46]*, [47], [48], [49]].", [["BSs", "CHEMICAL", 26, 29], ["BSs", "SIMPLE_CHEMICAL", 26, 29], ["[45], [46]*", "SIMPLE_CHEMICAL", 99, 110], ["[47], [48], [49]]", "SIMPLE_CHEMICAL", 112, 129], ["The antiviral activity of BSs", "TREATMENT", 0, 29], ["treating various viruses", "PROBLEM", 73, 97]]], ["Evidential reports from these studies can be applied in SARS-CoV-2 since it is an enveloped virus hence the mechanism of action has been explained as follows.BSs anti-viral activity against COVID-19As the SARS-CoV-2 virus enters the host cell, the amphiphilic nature of BSs interacts with viral cell membrane and enters the bilayered lipid membrane that causes changes in permeability either by ion channel formation or disruption of the membrane system.", [["cell", "ANATOMY", 238, 242], ["BSs", "ANATOMY", 270, 273], ["cell membrane", "ANATOMY", 295, 308], ["lipid membrane", "ANATOMY", 334, 348], ["membrane system", "ANATOMY", 438, 453], ["COVID-19As", "CHEMICAL", 190, 200], ["SARS-CoV-2", "ORGANISM", 56, 66], ["BSs", "SIMPLE_CHEMICAL", 158, 161], ["COVID-19As", "ORGANISM", 190, 200], ["SARS-CoV-2 virus", "ORGANISM", 205, 221], ["host cell", "CELL", 233, 242], ["BSs", "GENE_OR_GENE_PRODUCT", 270, 273], ["cell membrane", "CELLULAR_COMPONENT", 295, 308], ["lipid membrane", "CELLULAR_COMPONENT", 334, 348], ["membrane", "CELLULAR_COMPONENT", 438, 446], ["COVID", "PROTEIN", 190, 195], ["BSs", "PROTEIN", 270, 273], ["CoV-2 virus", "SPECIES", 210, 221], ["SARS-CoV", "SPECIES", 56, 64], ["SARS-CoV-2 virus", "SPECIES", 205, 221], ["these studies", "TEST", 24, 37], ["CoV", "TEST", 61, 64], ["an enveloped virus", "PROBLEM", 79, 97], ["BSs anti-viral activity", "TEST", 158, 181], ["COVID", "TEST", 190, 195], ["the SARS", "TEST", 201, 209], ["CoV", "TEST", 210, 213], ["viral cell membrane", "TREATMENT", 289, 308], ["the bilayered lipid membrane", "TREATMENT", 320, 348], ["changes in permeability", "PROBLEM", 361, 384], ["disruption of the membrane system", "PROBLEM", 420, 453], ["enveloped", "OBSERVATION_MODIFIER", 82, 91], ["virus", "OBSERVATION", 92, 97], ["host cell", "OBSERVATION", 233, 242], ["viral cell membrane", "OBSERVATION", 289, 308], ["bilayered", "OBSERVATION_MODIFIER", 324, 333], ["lipid membrane", "OBSERVATION", 334, 348], ["membrane system", "OBSERVATION", 438, 453]]], ["A complete disintegration of the viral envelope and capsid protein occurs during high concentration of BSs.", [["BSs", "SIMPLE_CHEMICAL", 103, 106], ["capsid protein", "PROTEIN", 52, 66], ["the viral envelope", "PROBLEM", 29, 47], ["capsid protein", "PROBLEM", 52, 66], ["complete", "OBSERVATION_MODIFIER", 2, 10], ["disintegration", "OBSERVATION", 11, 25], ["viral envelope", "OBSERVATION", 33, 47], ["capsid protein", "OBSERVATION", 52, 66]]], ["The disruptions of the lipid envelope and spike protein are encapsulated into micelles and results in viral inactivity.", [["lipid envelope", "CELLULAR_COMPONENT", 23, 37], ["spike protein", "PROTEIN", 42, 55], ["the lipid envelope", "PROBLEM", 19, 37], ["spike protein", "PROBLEM", 42, 55], ["viral inactivity", "PROBLEM", 102, 118], ["lipid envelope", "OBSERVATION", 23, 37], ["viral inactivity", "OBSERVATION", 102, 118]]], ["This micelle formation has the capability to function as liposomes that could deliver the drug to the infection site and also protects during hazardous conditions [50].", [["micelle", "ANATOMY", 5, 12], ["micelle", "CHEMICAL", 5, 12], ["infection", "DISEASE", 102, 111], ["micelle", "CANCER", 5, 12], ["liposomes", "SIMPLE_CHEMICAL", 57, 66], ["This micelle formation", "PROBLEM", 0, 22], ["the infection site", "PROBLEM", 98, 116], ["infection", "OBSERVATION", 102, 111]]], ["Hence, the nature of BSs to form as micelles would be an effective drug delivery system in treating SARS-CoV-2 infection.", [["BSs", "CHEMICAL", 21, 24], ["SARS-CoV-2 infection", "DISEASE", 100, 120], ["BSs", "SIMPLE_CHEMICAL", 21, 24], ["SARS-CoV-2", "ORGANISM", 100, 110], ["SARS-CoV-2", "SPECIES", 100, 110], ["an effective drug delivery system", "TREATMENT", 54, 87], ["SARS", "PROBLEM", 100, 104], ["CoV-2 infection", "PROBLEM", 105, 120], ["infection", "OBSERVATION", 111, 120]]], ["Also, BS does not affect the viral replication but inactivates the viral effects before adsorption or penetration.", [["the viral replication", "PROBLEM", 25, 46], ["the viral effects", "PROBLEM", 63, 80], ["penetration", "PROBLEM", 102, 113], ["viral replication", "OBSERVATION", 29, 46]]], ["The mechanism of anti-viral activity by BS against SARS-CoV-2 is described in Figure 2.RecommendationsThe COVID-19 disease, which is spreading vigorously, has become a global threat across the world.", [["SARS-CoV-2", "ORGANISM", 51, 61], ["SARS-CoV", "SPECIES", 51, 59], ["anti-viral activity", "TREATMENT", 17, 36], ["BS", "TEST", 40, 42], ["SARS", "PROBLEM", 51, 55], ["CoV", "TEST", 56, 59], ["The COVID-19 disease", "PROBLEM", 102, 122], ["anti-viral activity", "OBSERVATION", 17, 36], ["global", "OBSERVATION_MODIFIER", 168, 174], ["threat", "OBSERVATION", 175, 181]]], ["Discovery of any medicine or vaccine against this disease will be a kingmaker for the people suffering from this deadly infection.", [["infection", "DISEASE", 120, 129], ["people", "ORGANISM", 86, 92], ["people", "SPECIES", 86, 92], ["any medicine", "TREATMENT", 13, 25], ["vaccine", "TREATMENT", 29, 36], ["this disease", "PROBLEM", 45, 57], ["this deadly infection", "PROBLEM", 108, 129]]], ["Hence, here we are recommending few products which will be produced using BS as a more potent way to get precautions or treatment from the SARS-CoV-2 infection.", [["SARS", "DISEASE", 139, 143], ["infection", "DISEASE", 150, 159], ["SARS-CoV-2", "ORGANISM", 139, 149], ["SARS-CoV", "SPECIES", 139, 147], ["few products", "TREATMENT", 32, 44], ["BS", "TREATMENT", 74, 76], ["precautions", "TREATMENT", 105, 116], ["treatment", "TREATMENT", 120, 129], ["the SARS", "PROBLEM", 135, 143], ["CoV", "PROBLEM", 144, 147], ["2 infection", "PROBLEM", 148, 159], ["infection", "OBSERVATION", 150, 159]]], ["The following guidelines are;\u2022The BS has multi-purpose use in various fields such as food, pharmacology, cosmetics, detergents and so on.", [["BS", "CHEMICAL", 34, 36]]], ["But its anti-inflammatory property would be a novel solution in targeting COVID-19 disease in multiple ways.\u2022As always, cleaning our hands will protect us from this virus.", [["a novel solution", "TREATMENT", 44, 60], ["targeting COVID", "TREATMENT", 64, 79], ["this virus", "PROBLEM", 160, 170], ["anti-inflammatory", "OBSERVATION_MODIFIER", 8, 25]]], ["The strategy of employing BS encoded handwash or hand sanitizers promises to be a more protective shield against SARS-CoV-2 virus.\u2022The amphiphilic nature of the BS makes it easier to interact with SARS-CoV-2\u2019s lipid bilayer and would enable the destruction of the viral genome, which would facilitate easy clearance of the virus.\u2022The propensity of BSs towards drug delivery is high, especially due to its emulsification property.\u2022Hence it is highly advisable that using or producing any drug from BSs along with conventional drugs or vaccines for COVID-19 will be beneficial because of its anti-viral and anti-inflammatory role against the SARS-CoV-2 virus.\u2022The list of clinical trials and ongoing trials about BSs as drugs against various respiratory disorders as well as for COVID-19 have been depicted in Table 2.\u2022As it is evident that BSs are eco-friendly and less toxic, it is recommended that its use in house-hold cleaning products or detergents will target and kill the SARS-CoV-2 virus.\u2022Another way of incorporating the BS in targeting the virus is its use as a medicated chewing gum.\u2022Incorporation of the BSs from microbes along with Indian medicinal plants promises to be highly instrumental in clearing the viral load efficiently from the human body.", [["hand", "ANATOMY", 49, 53], ["respiratory", "ANATOMY", 740, 751], ["body", "ANATOMY", 1257, 1261], ["SARS", "DISEASE", 113, 117], ["SARS", "DISEASE", 197, 201], ["BSs", "CHEMICAL", 348, 351], ["BSs", "CHEMICAL", 497, 500], ["COVID-19", "CHEMICAL", 547, 555], ["BSs", "CHEMICAL", 711, 714], ["respiratory disorders", "DISEASE", 740, 761], ["SARS", "DISEASE", 978, 982], ["COVID-19", "CHEMICAL", 547, 555], ["SARS-CoV-2 virus", "ORGANISM", 113, 129], ["BS", "SIMPLE_CHEMICAL", 161, 163], ["lipid bilayer", "CELLULAR_COMPONENT", 210, 223], ["BSs", "SIMPLE_CHEMICAL", 348, 351], ["BSs", "SIMPLE_CHEMICAL", 497, 500], ["COVID-19", "SIMPLE_CHEMICAL", 547, 555], ["SARS-CoV-2 virus", "ORGANISM", 640, 656], ["BSs", "SIMPLE_CHEMICAL", 711, 714], ["BSs", "SIMPLE_CHEMICAL", 839, 842], ["SARS-CoV-2 virus", "ORGANISM", 978, 994], ["BSs", "GENE_OR_GENE_PRODUCT", 1115, 1118], ["human", "ORGANISM", 1251, 1256], ["body", "ORGANISM_SUBDIVISION", 1257, 1261], ["viral genome", "DNA", 264, 276], ["CoV-2 virus", "SPECIES", 118, 129], ["CoV-2 virus", "SPECIES", 645, 656], ["CoV-2 virus", "SPECIES", 983, 994], ["human", "SPECIES", 1251, 1256], ["SARS-CoV-2 virus", "SPECIES", 113, 129], ["SARS-CoV-2 virus", "SPECIES", 640, 656], ["SARS-CoV-2 virus", "SPECIES", 978, 994], ["human", "SPECIES", 1251, 1256], ["hand sanitizers", "TREATMENT", 49, 64], ["SARS", "PROBLEM", 113, 117], ["CoV", "TEST", 118, 121], ["SARS", "TEST", 197, 201], ["CoV", "TEST", 202, 205], ["lipid bilayer", "TREATMENT", 210, 223], ["the viral genome", "PROBLEM", 260, 276], ["the virus", "PROBLEM", 319, 328], ["drug delivery", "TREATMENT", 360, 373], ["any drug from BSs", "PROBLEM", 483, 500], ["conventional drugs", "TREATMENT", 512, 530], ["vaccines", "TREATMENT", 534, 542], ["COVID", "TREATMENT", 547, 552], ["its anti-viral", "TREATMENT", 586, 600], ["anti-inflammatory role", "TREATMENT", 605, 627], ["the SARS", "PROBLEM", 636, 644], ["clinical trials", "TREATMENT", 670, 685], ["ongoing trials", "TREATMENT", 690, 704], ["BSs", "TREATMENT", 711, 714], ["drugs", "TREATMENT", 718, 723], ["various respiratory disorders", "PROBLEM", 732, 761], ["COVID", "TEST", 777, 782], ["cleaning products", "TREATMENT", 921, 938], ["detergents", "TREATMENT", 942, 952], ["the SARS", "TEST", 974, 982], ["incorporating the BS", "PROBLEM", 1011, 1031], ["the virus", "PROBLEM", 1045, 1054], ["a medicated chewing gum", "TREATMENT", 1069, 1092], ["the BSs", "PROBLEM", 1111, 1118], ["Indian medicinal plants", "TREATMENT", 1144, 1167], ["viral genome", "OBSERVATION", 264, 276], ["high", "OBSERVATION", 377, 381], ["emulsification", "OBSERVATION", 405, 419], ["virus", "OBSERVATION", 1049, 1054], ["viral load", "OBSERVATION", 1219, 1229], ["human body", "ANATOMY_MODIFIER", 1251, 1261]]]], "PMC7262297": [], "7e60ffb809cefe49d47ded66e33e3970ce76bb65": [["Molecular techniques have represented a major step forward in the diagnosis of viral respiratory infections.", [["respiratory", "ANATOMY", 85, 96], ["viral respiratory infections", "DISEASE", 79, 107], ["viral respiratory infections", "PROBLEM", 79, 107], ["viral", "OBSERVATION_MODIFIER", 79, 84], ["respiratory infections", "OBSERVATION", 85, 107]]], ["In this study two nucleic acid amplification tests (NAATs) were compared to conventional methods (immunofluorescence and viral culture).", [["nucleic acid", "CHEMICAL", 18, 30], ["this study", "TEST", 3, 13], ["two nucleic acid amplification tests", "TEST", 14, 50], ["conventional methods", "TEST", 76, 96], ["immunofluorescence", "TEST", 98, 116], ["viral culture", "TEST", 121, 134]]], ["Eighty nasopharyngeal aspirates were collected from children under six years attended for acute respiratory illness at the pediatric emergency room of a third level Hospital.", [["nasopharyngeal aspirates", "ANATOMY", 7, 31], ["respiratory", "ANATOMY", 96, 107], ["acute respiratory illness", "DISEASE", 90, 115], ["nasopharyngeal aspirates", "CANCER", 7, 31], ["children", "ORGANISM", 52, 60], ["children", "SPECIES", 52, 60], ["Eighty nasopharyngeal aspirates", "PROBLEM", 0, 31], ["acute respiratory illness", "PROBLEM", 90, 115], ["nasopharyngeal", "ANATOMY", 7, 21], ["aspirates", "OBSERVATION", 22, 31], ["acute", "OBSERVATION_MODIFIER", 90, 95], ["respiratory illness", "OBSERVATION", 96, 115]]], ["Both NAATs tested (Seeplex 1 and Clart 1 ) showed an overall higher performance regarding sensitivity (76% and 90%, respectively).", [["NAATs", "PROTEIN", 5, 10], ["Both NAATs", "TEST", 0, 10], ["Seeplex", "TEST", 19, 26], ["sensitivity", "TEST", 90, 101]]], ["Compared to Seeplex 1 , the Clart 1 system tripled the number of multiple detections (8 by SeeplexINTRODUCTIONRespiratory tract infections are the most frequent cause of illness in children, and most of them are of viral etiology [van de Pol et al., 2007; Mahony, 2008; Raymond et al., 2009; Vallieres and Renaud, 2013] .", [["SeeplexINTRODUCTIONRespiratory tract infections", "DISEASE", 91, 138], ["illness", "DISEASE", 170, 177], ["children", "ORGANISM", 181, 189], ["children", "SPECIES", 181, 189], ["SeeplexINTRODUCTIONRespiratory tract infections", "PROBLEM", 91, 138], ["multiple", "OBSERVATION_MODIFIER", 65, 73], ["most frequent", "OBSERVATION_MODIFIER", 147, 160], ["illness", "OBSERVATION", 170, 177]]], ["The most common respiratory viruses are Influenza A virus (FLUAV), Influenza B virus (FLUBV), Human parainfluenzavirus 1-4 (PIV-1-4), Human respiratory syncitial virus (RSV), Human metapneumovirus (hMPV), Enteroviruses (EV), Rhinoviruses (RV), Human coronaviruses (HCoV), Human bocaviruses (HBoV), and Human adenoviruses (AdV).", [["Influenza A virus", "DISEASE", 40, 57], ["Influenza B", "DISEASE", 67, 78], ["respiratory syncitial virus (RSV)", "DISEASE", 140, 173], ["Human metapneumovirus (hMPV), Enteroviruses (EV), Rhinoviruses (RV), Human coronaviruses (HCoV)", "DISEASE", 175, 270], ["Human bocaviruses (HBoV)", "DISEASE", 272, 296], ["Influenza A virus", "ORGANISM", 40, 57], ["FLUAV", "ORGANISM", 59, 64], ["Influenza B virus", "ORGANISM", 67, 84], ["FLUBV", "ORGANISM", 86, 91], ["Human parainfluenzavirus 1-4", "ORGANISM", 94, 122], ["PIV-1-4", "ORGANISM", 124, 131], ["Human respiratory syncitial virus", "ORGANISM", 134, 167], ["RSV", "ORGANISM", 169, 172], ["Human metapneumovirus", "ORGANISM", 175, 196], ["hMPV", "ORGANISM", 198, 202], ["Rhinoviruses", "ORGANISM", 225, 237], ["Human coronaviruses", "ORGANISM", 244, 263], ["HCoV", "CANCER", 265, 269], ["Human", "ORGANISM", 272, 277], ["bocaviruses", "GENE_OR_GENE_PRODUCT", 278, 289], ["HBoV", "ORGANISM", 291, 295], ["Human adenoviruses", "ORGANISM", 302, 320], ["AdV", "ORGANISM", 322, 325], ["Influenza A virus", "SPECIES", 40, 57], ["Influenza B virus", "SPECIES", 67, 84], ["Human", "SPECIES", 94, 99], ["parainfluenzavirus 1", "SPECIES", 100, 120], ["PIV-1", "SPECIES", 124, 129], ["Human", "SPECIES", 134, 139], ["respiratory syncitial virus", "SPECIES", 140, 167], ["RSV", "SPECIES", 169, 172], ["Human", "SPECIES", 175, 180], ["metapneumovirus", "SPECIES", 181, 196], ["hMPV", "SPECIES", 198, 202], ["Human", "SPECIES", 244, 249], ["Human", "SPECIES", 272, 277], ["Human", "SPECIES", 302, 307], ["Influenza A virus", "SPECIES", 40, 57], ["FLUAV", "SPECIES", 59, 64], ["Influenza B virus", "SPECIES", 67, 84], ["FLUBV", "SPECIES", 86, 91], ["Human parainfluenzavirus 1-4 (PIV-1-4", "SPECIES", 94, 131], ["Human respiratory syncitial virus", "SPECIES", 134, 167], ["RSV", "SPECIES", 169, 172], ["Human metapneumovirus", "SPECIES", 175, 196], ["hMPV", "SPECIES", 198, 202], ["EV", "SPECIES", 220, 222], ["RV", "SPECIES", 239, 241], ["Human coronaviruses", "SPECIES", 244, 263], ["HCoV", "SPECIES", 265, 269], ["Human bocaviruses", "SPECIES", 272, 289], ["HBoV", "SPECIES", 291, 295], ["Human adenoviruses", "SPECIES", 302, 320], ["AdV", "SPECIES", 322, 325], ["The most common respiratory viruses", "PROBLEM", 0, 35], ["Influenza A virus (FLUAV", "TEST", 40, 64], ["Influenza B virus (FLUBV", "TEST", 67, 91], ["Human parainfluenzavirus", "TEST", 94, 118], ["PIV", "TEST", 124, 127], ["Human respiratory syncitial virus (RSV)", "PROBLEM", 134, 173], ["Human metapneumovirus (hMPV)", "PROBLEM", 175, 203], ["Enteroviruses", "PROBLEM", 205, 218], ["Rhinoviruses (RV)", "TREATMENT", 225, 242], ["Human coronaviruses (HCoV)", "TREATMENT", 244, 270], ["Human bocaviruses (HBoV)", "TREATMENT", 272, 296], ["Human adenoviruses", "TREATMENT", 302, 320], ["respiratory viruses", "OBSERVATION", 16, 35], ["respiratory", "ANATOMY", 140, 151], ["syncitial virus", "OBSERVATION", 152, 167], ["metapneumovirus", "OBSERVATION", 181, 196], ["RV", "ANATOMY", 239, 241]]], ["As infections caused by respiratory viruses show similar clinical manifestations, microbiological studies must be performed to identify the etiology [Caliendo, 2011; Pagarolas and Sune, 2014] .INTRODUCTIONDiagnosis of viral respiratory infections is traditionally performed using conventional methods based on viral culture (VC), or antigen detection such as immunofluorescence assays (IF).", [["respiratory", "ANATOMY", 224, 235], ["infections", "DISEASE", 3, 13], ["respiratory viruses", "DISEASE", 24, 43], ["viral respiratory infections", "DISEASE", 218, 246], ["infections", "PROBLEM", 3, 13], ["respiratory viruses", "PROBLEM", 24, 43], ["similar clinical manifestations", "PROBLEM", 49, 80], ["microbiological studies", "TEST", 82, 105], ["Pagarolas", "TREATMENT", 166, 175], ["viral respiratory infections", "PROBLEM", 218, 246], ["conventional methods", "TREATMENT", 280, 300], ["viral culture", "TEST", 310, 323], ["antigen detection", "TEST", 333, 350], ["immunofluorescence assays", "TEST", 359, 384], ["respiratory viruses", "OBSERVATION", 24, 43], ["viral", "OBSERVATION_MODIFIER", 218, 223], ["respiratory infections", "OBSERVATION", 224, 246]]], ["VC remains the gold-standard but it requires trained personnel, results may take a few days, and not all viruses can multiply in culture.", [["VC", "TEST", 0, 2], ["all viruses", "PROBLEM", 101, 112], ["culture", "TEST", 129, 136]]], ["Additionally, they are not available for all viruses and lack sensitivity for others [Ginocchio and McAdam, 2011] .INTRODUCTIONNucleic acid amplification tests (NAATs) have become an alternative that offers high sensitivity and specificity when compared to conventional methods [Elnifro et al., 2000; Mahony, 2008; Ginocchio and McAdam, 2011] .", [["INTRODUCTIONNucleic acid", "CHEMICAL", 115, 139], ["all viruses", "PROBLEM", 41, 52], ["INTRODUCTIONNucleic acid amplification tests", "TEST", 115, 159], ["high sensitivity", "PROBLEM", 207, 223]]], ["Numerous tests have been developed using multiplex PCR to detect several viruses, including those that are not detected either by VC or by immunoassays.", [["Numerous tests", "TEST", 0, 14], ["multiplex PCR", "TEST", 41, 54], ["several viruses", "PROBLEM", 65, 80], ["immunoassays", "TEST", 139, 151], ["several", "OBSERVATION_MODIFIER", 65, 72], ["viruses", "OBSERVATION", 73, 80]]], ["Although PCR-based techniques were initially limited by the few types of viruses that could be detected in a single test [Liolios et al., 2001; Coiras et al., 2004; Bellau-Pujol et al., 2005; Freymuth et al., 2006] , numerous multiplex PCR tests have been developed, allowing more than 10 viruses to be detected in a single assay.", [["PCR", "TEST", 9, 12], ["viruses", "PROBLEM", 73, 80], ["a single test", "TEST", 107, 120], ["numerous multiplex PCR tests", "TEST", 217, 245], ["viruses", "OBSERVATION", 73, 80]]], ["Amplicon detection can be performed by hybridization using microarrays [Henrickson et al., 2007; Raymond et al., 2009; Cannon et al., 2010; Renois et al., 2010; Frobert et al., 2011; Culebras et al., 2013; Pillet et al., 2013] or semiconductor-based DNA microspheres [Mahony et al., 2007] .", [["DNA", "CELLULAR_COMPONENT", 250, 253], ["Amplicon detection", "TEST", 0, 18], ["semiconductor", "TEST", 230, 243]]], ["Several respiratory virus panels (RVP) have been commercialized, such as xTAG 1 RVP from Luminex 1 [Mahony et al., 2007; Pabbaraju et al., 2008; Gadsby et al., 2010; Balada-Llasat et al., 2011; Kim et al., 2013; Pillet et al., 2013] , Multicode PLx RVP from Eragen [Balada-Llasat et al., 2011] , and Resplex 1 II from Qiagen [Li et al., 2007; Balada-Llasat et al., 2011; Pillet et al., 2013] .", [["Several respiratory virus panels", "TEST", 0, 32], ["RVP", "TEST", 34, 37], ["Balada", "TEST", 166, 172], ["Multicode", "TEST", 235, 244], ["RVP", "TEST", 249, 252], ["Eragen", "TEST", 258, 264], ["Balada", "TEST", 266, 272], ["Balada", "TEST", 343, 349], ["respiratory virus", "OBSERVATION", 8, 25]]], ["Other NAATs are the multiplex ligationdependent probe amplification system (MLPA) [Reijans et al., 2008; Bruijnesteijn van Coppenraet et al., 2010; Pillet et al., 2013] and the dual priming oligonucleotide (DPO) system [Roh et al., 2008; Bruijnesteijn van Coppenraet et al., 2010; Zhang et al., 2012; Cho et al., 2013; Kim et al., 2013; Pillet et al., 2013] .", [["NAATs", "GENE_OR_GENE_PRODUCT", 6, 11], ["NAATs", "DNA", 6, 11], ["the dual priming oligonucleotide (DPO)", "TREATMENT", 173, 211]]], ["PCR-based systems generate a diagnostic result within only one working day, but implementation in a laboratory routine may not be costeffective.INTRODUCTIONThis study assessed two multiplex PCR-based techniques commercially available, namely Clart 1 and Seeplex 1 .", [["PCR", "TEST", 0, 3], ["a laboratory routine", "TEST", 98, 118], ["INTRODUCTIONThis study", "TEST", 144, 166], ["multiplex PCR", "TEST", 180, 193]]], ["Both NAATs have been studied previously [Roh et al., 2008; Bruijnesteijn van Coppenraet et al., 2010; Renois et al., 2010; Frobert et al., 2011; Zhang et al., 2012; Cho et al., 2013; Culebras et al., 2013; Kim et al., 2013; Pillet et al., 2013] and, in the present work, they were compared with each other and also with two conventional methods for the diagnosis of viral respiratory infections.", [["respiratory", "ANATOMY", 372, 383], ["viral respiratory infections", "DISEASE", 366, 394], ["NAATs", "GENE_OR_GENE_PRODUCT", 5, 10], ["NAATs", "PROTEIN", 5, 10], ["viral respiratory infections", "PROBLEM", 366, 394], ["viral", "OBSERVATION_MODIFIER", 366, 371], ["respiratory infections", "OBSERVATION", 372, 394]]], ["The aim of this work was to discuss the clinical interpretation of the results obtained by NAATs on the basis of our two-decade experience on conventional methods.", [["conventional methods", "TREATMENT", 142, 162]]], ["The benefits and pitfalls of molecular techniques are also discussed.SamplesEighty nasopharyngeal aspirates were collected from children under six years attended for acute respiratory illness at the pediatric emergency room of a third level Hospital, from October to November 2008 and from February to March 2009.", [["nasopharyngeal aspirates", "ANATOMY", 83, 107], ["respiratory", "ANATOMY", 172, 183], ["acute respiratory illness", "DISEASE", 166, 191], ["nasopharyngeal aspirates", "CANCER", 83, 107], ["children", "ORGANISM", 128, 136], ["children", "SPECIES", 128, 136], ["molecular techniques", "TREATMENT", 29, 49], ["SamplesEighty nasopharyngeal aspirates", "PROBLEM", 69, 107], ["acute respiratory illness", "PROBLEM", 166, 191], ["nasopharyngeal", "ANATOMY", 83, 97], ["aspirates", "OBSERVATION", 98, 107], ["acute", "OBSERVATION_MODIFIER", 166, 171], ["respiratory illness", "OBSERVATION", 172, 191]]], ["Consecutive specimens, with more than 25 cells/field by microscopic observation and sufficient residual volume (300 mL), were selected.", [["specimens", "ANATOMY", 12, 21], ["cells", "ANATOMY", 41, 46], ["cells", "CELL", 41, 46], ["Consecutive specimens", "TEST", 0, 21], ["microscopic observation", "TEST", 56, 79]]], ["These specimens were processed within the same working day or stored at \u00fe4\u02daC during the weekends (maximum 72 hr).", [["specimens", "ANATOMY", 6, 15], ["specimens", "CANCER", 6, 15]]], ["Epidemiological data were collected.Viral Isolation and Antigen DetectionSamples were assessed using D3 DFA Metapneumovirus Identification Kit (Diagnostics Hybrids, Athens, OH), RSV Direct IF (bioM erieux, Marcyl'Etoile, France), and Respiratory Panel 1 Viral Screening & Identification IFA kit (Millipore, Light Diagnostics, Temecula, CA) to detect AdV, FLUAV, FLUBV, PIV-1,2,3 and RSV according to the manufacturer's instructions.", [["AdV", "ORGANISM", 350, 353], ["RSV", "ORGANISM", 383, 386], ["Millipore, Light Diagnostics, Temecula, CA", "PROTEIN", 296, 338], ["RSV", "SPECIES", 178, 181], ["AdV", "SPECIES", 350, 353], ["FLUAV", "SPECIES", 355, 360], ["RSV", "SPECIES", 383, 386], ["Epidemiological data", "TEST", 0, 20], ["Viral Isolation", "TREATMENT", 36, 51], ["Antigen DetectionSamples", "TEST", 56, 80], ["Respiratory Panel", "TEST", 234, 251], ["Viral Screening", "TEST", 254, 269], ["IFA kit", "TEST", 287, 294], ["Light Diagnostics", "TEST", 307, 324], ["PIV", "TREATMENT", 369, 372], ["RSV", "TREATMENT", 383, 386], ["Respiratory", "ANATOMY", 234, 245]]], ["For viral isolation, these samples were cultured using six cell lines: MRC5, A549, HEP2, MDCK, LLCMK2, and RD (Vircell S.L Santa Fe, Granada, Spain).", [["samples", "ANATOMY", 27, 34], ["cell lines", "ANATOMY", 59, 69], ["MRC5", "ANATOMY", 71, 75], ["A549", "ANATOMY", 77, 81], ["MDCK", "ANATOMY", 89, 93], ["cell lines", "CELL", 59, 69], ["MRC5", "CELL", 71, 75], ["A549", "CELL", 77, 81], ["HEP2", "CELL", 83, 87], ["MDCK", "CELL", 89, 93], ["LLCMK2", "CELL", 95, 101], ["cell lines", "CELL_LINE", 59, 69], ["MRC5", "CELL_LINE", 71, 75], ["A549", "CELL_LINE", 77, 81], ["HEP2", "CELL_LINE", 83, 87], ["MDCK", "CELL_LINE", 89, 93], ["LLCMK2", "CELL_LINE", 95, 101], ["viral isolation", "TREATMENT", 4, 19], ["these samples", "TEST", 21, 34], ["six cell lines", "TEST", 55, 69], ["MRC5", "TEST", 71, 75], ["A549", "TEST", 77, 81], ["HEP2", "TEST", 83, 87], ["MDCK", "TEST", 89, 93], ["LLCMK2", "TEST", 95, 101]]], ["All cell cultures were examined daily for cytopathic effect during two weeks.", [["cell cultures", "ANATOMY", 4, 17], ["cell cultures", "CELL", 4, 17], ["cell cultures", "CELL_LINE", 4, 17], ["All cell cultures", "TEST", 0, 17], ["cytopathic effect", "PROBLEM", 42, 59]]], ["Definitive identification was assessed by IF.Nucleic Acid DetectionNucleic acid was extracted from 200 mL of clinical samples using EZ1 Virus Mini Kit v2.0 and Bio Robot EZ-1 (Qiagen, Hilden, Germany), according to the manufacturer's instructions.", [["samples", "ANATOMY", 118, 125], ["Acid DetectionNucleic acid", "CHEMICAL", 53, 79], ["Nucleic Acid DetectionNucleic acid", "SIMPLE_CHEMICAL", 45, 79], ["IF", "PROTEIN", 42, 44], ["Nucleic Acid DetectionNucleic acid", "TREATMENT", 45, 79], ["clinical samples", "TEST", 109, 125], ["EZ1 Virus", "TREATMENT", 132, 141], ["Bio Robot EZ", "TREATMENT", 160, 172]]], ["The extracts were stored at \u00c080\u02daC until use.", [["extracts", "ANATOMY", 4, 12], ["extracts", "ORGANISM_SUBSTANCE", 4, 12]]], ["Molecular viral detection was performed using two NAATs: Seeplex 1 RV12 ACE Detection Kit (Seegene, Seoul, South Korea) and Clart 1 Pneumovir Kit (Genomica, Madrid, Spain), following the manufacturer's instructions.Nucleic Acid DetectionThe Seeplex 1 method is based on the DPO system and amplicon detection is performed by fully automated capillary electrophoresis separation (MultiNA, Shimad-zuBiotech, Kyoto, Japan).", [["capillary", "TISSUE", 340, 349], ["Molecular viral detection", "TEST", 0, 25], ["Seeplex", "TREATMENT", 57, 64], ["Nucleic Acid Detection", "TREATMENT", 215, 237], ["the DPO system", "TEST", 270, 284], ["amplicon detection", "TEST", 289, 307], ["automated capillary electrophoresis separation", "TREATMENT", 330, 376], ["MultiNA", "TEST", 378, 385], ["viral", "OBSERVATION", 10, 15]]], ["The Clart 1 system is based on microarray technology and analysis of the resulting hybridization pattern is performed using optical equipment (Clondiag Chip Technologies, Jena, Germany).", [["microarray technology", "TEST", 31, 52], ["the resulting hybridization pattern", "PROBLEM", 69, 104]]], ["Both assays detect FLUAV, FLUBV, AdV, hMPV, HCoV-229E, PIV-1, PIV-2, PIV-3, RSVa, RSVb, and RV.", [["FLUAV", "GENE_OR_GENE_PRODUCT", 19, 24], ["FLUBV", "GENE_OR_GENE_PRODUCT", 26, 31], ["AdV", "ORGANISM", 33, 36], ["hMPV", "ORGANISM", 38, 42], ["HCoV-229E", "GENE_OR_GENE_PRODUCT", 44, 53], ["PIV-1", "GENE_OR_GENE_PRODUCT", 55, 60], ["PIV-2", "GENE_OR_GENE_PRODUCT", 62, 67], ["PIV-3", "GENE_OR_GENE_PRODUCT", 69, 74], ["RSVa", "GENE_OR_GENE_PRODUCT", 76, 80], ["RSVb", "GENE_OR_GENE_PRODUCT", 82, 86], ["RSVa", "DNA", 76, 80], ["RSVb", "DNA", 82, 86], ["FLUAV", "SPECIES", 19, 24], ["AdV", "SPECIES", 33, 36], ["hMPV", "SPECIES", 38, 42], ["HCoV-229E", "SPECIES", 44, 53], ["Both assays", "TEST", 0, 11], ["FLUAV", "TEST", 19, 24], ["FLUBV", "TEST", 26, 31], ["hMPV", "TEST", 38, 42], ["HCoV", "TEST", 44, 48], ["PIV", "TEST", 55, 58], ["PIV", "TEST", 62, 65], ["PIV", "TREATMENT", 69, 72], ["RV", "ANATOMY", 92, 94]]], ["Seeplex 1 also detects HCoV-NL63 and HCoV-OC43, and differentiates between species of RV (A and B).", [["Seeplex 1", "GENE_OR_GENE_PRODUCT", 0, 9], ["HCoV-NL63", "GENE_OR_GENE_PRODUCT", 23, 32], ["HCoV-OC43", "CELL", 37, 46], ["HCoV", "PROTEIN", 23, 27], ["NL63", "PROTEIN", 28, 32], ["HCoV", "PROTEIN", 37, 41], ["OC43", "DNA", 42, 46], ["HCoV", "SPECIES", 23, 27], ["HCoV-OC43", "SPECIES", 37, 46], ["HCoV", "TEST", 23, 27], ["NL63", "TEST", 28, 32], ["HCoV", "TEST", 37, 41], ["RV", "TEST", 86, 88], ["RV", "ANATOMY", 86, 88]]], ["Clart 1 also detects HBoV, Influenza C virus (FLUCV), EV, PIV-4 A/B, and differentiates between hMPVa and hMPVb.", [["Clart 1", "GENE_OR_GENE_PRODUCT", 0, 7], ["HBoV", "ORGANISM", 21, 25], ["Influenza C virus", "ORGANISM", 27, 44], ["FLUCV", "ORGANISM", 46, 51], ["PIV-4", "ORGANISM", 58, 63], ["B", "CELL", 66, 67], ["hMPVa", "GENE_OR_GENE_PRODUCT", 96, 101], ["hMPVb", "GENE_OR_GENE_PRODUCT", 106, 111], ["hMPVa", "PROTEIN", 96, 101], ["hMPVb", "PROTEIN", 106, 111], ["Influenza C virus", "SPECIES", 27, 44], ["HBoV", "SPECIES", 21, 25], ["Influenza C virus", "SPECIES", 27, 44], ["FLUCV", "SPECIES", 46, 51], ["HBoV", "PROBLEM", 21, 25], ["Influenza C virus", "PROBLEM", 27, 44], ["PIV", "TREATMENT", 58, 61], ["hMPVa", "TEST", 96, 101], ["hMPVb", "TREATMENT", 106, 111], ["HBoV", "OBSERVATION", 21, 25]]], ["Both assays included an internal control to detect amplification inhibition.", [["Both assays", "TEST", 0, 11], ["an internal control", "TREATMENT", 21, 40]]], ["Both NAATs gave qualitative results only.Data AnalysisEpidemiological data, such as age, sex, date of sample collection and clinical diagnosis, were collected.", [["NAATs", "PROTEIN", 5, 10], ["Data AnalysisEpidemiological data", "TEST", 41, 74], ["sample collection", "TEST", 102, 119]]], ["Statistical analyses were performed using the Vassar Stats website (http://vassarstats.net/).Data AnalysisIn this work a result was considered clinically relevant or true positive when a respiratory virus was detected by IF and/or VC regardless of NAATs results or by both NAATs (criterion of positivity).Overall Viral DetectionThe range of viruses detected differed depending on the virus and the method used (Table I) .", [["Statistical analyses", "TEST", 0, 20], ["a respiratory virus", "PROBLEM", 185, 204], ["viruses", "PROBLEM", 341, 348], ["the virus", "PROBLEM", 380, 389], ["Viral", "OBSERVATION", 313, 318], ["range", "OBSERVATION_MODIFIER", 332, 337], ["viruses", "OBSERVATION", 341, 348]]], ["Of 80 samples included in this study, viral detection was obtained in 37, 40, and 62 samples by IF/VC, Seeplex 1 and Clart 1 , respectively.", [["samples", "ANATOMY", 6, 13], ["samples", "ANATOMY", 85, 92], ["samples", "CANCER", 6, 13], ["this study", "TEST", 26, 36], ["viral detection", "TEST", 38, 53], ["VC", "TEST", 99, 101], ["Seeplex", "TEST", 103, 110]]], ["Either NAAT yielded a positive result in 40 samples that were negative by IF/VC.", [["samples", "ANATOMY", 44, 51], ["NAAT", "CHEMICAL", 7, 11], ["NAAT", "SIMPLE_CHEMICAL", 7, 11], ["NAAT", "PROTEIN", 7, 11], ["IF", "PROTEIN", 74, 76], ["NAAT", "TEST", 7, 11]]], ["Only three samples (4%) were negative by all the techniques assessed (Table I) .Overall Viral DetectionSeeplex 1 and Clart 1 detected 11 and 57 viruses more than IF/VC, respectively.", [["samples", "ANATOMY", 11, 18], ["Overall Viral DetectionSeeplex", "TEST", 80, 110], ["Clart", "TEST", 117, 122], ["Viral", "OBSERVATION", 88, 93]]], ["RVs were the viruses most frequently detected by PCR although only two were recovered by IF/VC (Table I) .", [["RVs", "GENE_OR_GENE_PRODUCT", 0, 3], ["IF", "PROTEIN", 89, 91], ["RVs", "PROBLEM", 0, 3], ["the viruses", "PROBLEM", 9, 20], ["PCR", "TEST", 49, 52], ["viruses", "OBSERVATION", 13, 20]]], ["Multiple detection was obtained in 30 samples by NAATs while IF/VC did not achieve multiple recovery in any case.", [["samples", "ANATOMY", 38, 45], ["Multiple detection", "TEST", 0, 18]]], ["Inhibition was observed in 19 samples, 10 by Seeplex 1 (12.5%) and 11 by Clart 1 (14%); two of these samples were inhibited by both methods.Comparison of Results Obtained By IF/VC and NAATsAccording to the established criterion of positivity, 46 (57.5%) samples were considered positive for a respiratory virus; 36 by IF/VC regardless of NAAT results and 10 by two NAATs only.", [["samples", "ANATOMY", 30, 37], ["samples", "ANATOMY", 101, 108], ["samples", "ANATOMY", 254, 261], ["respiratory virus", "DISEASE", 293, 310], ["samples", "CANCER", 101, 108], ["samples", "CANCER", 254, 261], ["Seeplex", "TEST", 45, 52], ["Clart", "TEST", 73, 78], ["positivity", "TEST", 231, 241], ["a respiratory virus", "PROBLEM", 291, 310], ["NAAT results", "TEST", 338, 350], ["respiratory virus", "OBSERVATION", 293, 310]]], ["Viral detection was coincident between IF/VC and both NAATs in 20 samples out of 36.", [["samples", "ANATOMY", 66, 73], ["IF", "PROTEIN", 39, 41], ["NAATs", "PROTEIN", 54, 59], ["Viral detection", "TEST", 0, 15], ["both NAATs", "TEST", 49, 59]]], ["Coincident results were found between IF/VC and only one NAAT in 12 samples (one by Seeplex 1 and 11 by Clart 1 ).", [["samples", "ANATOMY", 68, 75], ["IF", "PROTEIN", 38, 40], ["one NAAT", "TEST", 53, 61]]], ["Three samples had a positive viral detection by IF/VC but were negative by NAATs.", [["samples", "ANATOMY", 6, 13], ["IF", "PROTEIN", 48, 50], ["NAATs", "PROTEIN", 75, 80], ["Three samples", "TEST", 0, 13], ["a positive viral detection", "PROBLEM", 18, 44], ["VC", "TEST", 51, 53]]], ["Another positive sample was inhibited.", [["sample", "ANATOMY", 17, 23], ["Another positive sample", "PROBLEM", 0, 23]]], ["In three positive samples by IF/VC, additional viruses were detected by both Seeplex 1 and Clart 1 .", [["samples", "ANATOMY", 18, 25], ["IF", "GENE_OR_GENE_PRODUCT", 29, 31], ["IF", "PROTEIN", 29, 31], ["additional viruses", "PROBLEM", 36, 54], ["viruses", "OBSERVATION", 47, 54]]], ["RV were detected in all samples positive only by both NAATs (n \u00bc 10), one of them having an additional virus (AdV).", [["samples", "ANATOMY", 24, 31], ["RV", "ORGAN", 0, 2], ["AdV", "ORGANISM", 110, 113], ["AdV", "SPECIES", 110, 113], ["RV", "TEST", 0, 2], ["an additional virus", "PROBLEM", 89, 108], ["virus", "OBSERVATION", 103, 108]]], ["Overall, 50 significant viruses were detected.", [["50 significant viruses", "PROBLEM", 9, 31], ["50 significant", "OBSERVATION_MODIFIER", 9, 23], ["viruses", "OBSERVATION", 24, 31]]], ["Since EVs were only detected by one NAAT, they were not included in further calculations.", [["EVs", "ANATOMY", 6, 9], ["EVs", "CELL", 6, 9], ["EVs", "TEST", 6, 9], ["further calculations", "TEST", 68, 88]]], ["Considering the remaining significant viruses, the relative sensitivity of IF/VC, Seeplex 1 and Clart 1 was 70% (32/46), 76% (35/46), and 89% (41/46), respectively (Table II) .Multiple Viral DetectionNAATs achieved a high rate of multiple virus detection (37.5%; 30/80), corresponding to 10% (8/80) by Seeplex 1 and 31% (25/80) by Clart 1 .", [["Seeplex 1", "CELL", 82, 91], ["IF", "PROTEIN", 75, 77], ["Seeplex 1", "SPECIES", 302, 311], ["the remaining significant viruses", "PROBLEM", 12, 45], ["VC", "TEST", 78, 80], ["Seeplex", "TEST", 82, 89], ["Clart", "TEST", 96, 101], ["Multiple Viral DetectionNAATs", "PROBLEM", 176, 205], ["multiple virus detection", "TEST", 230, 254], ["Seeplex", "TEST", 302, 309], ["significant", "OBSERVATION_MODIFIER", 26, 37], ["viruses", "OBSERVATION", 38, 45], ["Viral DetectionNAATs", "OBSERVATION", 185, 205]]], ["Regarding viruses identified only by one technique, Clart 1 detected HBoVs in 16 samples and 13 of them (81%) were multiple detections.", [["samples", "ANATOMY", 81, 88], ["HBoVs", "CANCER", 69, 74], ["samples", "CANCER", 81, 88], ["viruses", "PROBLEM", 10, 17], ["HBoVs", "TEST", 69, 74], ["multiple detections", "TEST", 115, 134], ["viruses", "OBSERVATION", 10, 17]]], ["Seeplex 1 detected HCoV-OC43 in five samples corresponding to multiple detections in three cases (60%).", [["samples", "ANATOMY", 37, 44], ["HCoV-OC43", "GENE_OR_GENE_PRODUCT", 19, 28], ["samples", "CANCER", 37, 44], ["HCoV", "DNA", 19, 23], ["OC43", "DNA", 24, 28], ["HCoV-OC43", "SPECIES", 19, 28], ["Seeplex", "TEST", 0, 7], ["OC43", "PROBLEM", 24, 28], ["multiple detections", "TEST", 62, 81], ["OC43", "OBSERVATION", 24, 28]]], ["Following the criterion of positivity previously established, only four samples were considered to have real multiple infections (8.7%; 4/46) (Table III) .Clinical AnalysisRegarding clinical and demographic analysis, no relevant data were obtained.", [["infections", "DISEASE", 118, 128], ["real multiple infections", "PROBLEM", 104, 128], ["demographic analysis", "TEST", 195, 215], ["relevant data", "TEST", 220, 233], ["multiple", "OBSERVATION_MODIFIER", 109, 117], ["infections", "OBSERVATION", 118, 128]]], ["From the total number of samples assessed, 39 and 41 specimens belonged to patients with upper and lower respiratory tract infections (URTI and LRTI), respectively.", [["samples", "ANATOMY", 25, 32], ["specimens", "ANATOMY", 53, 62], ["lower respiratory tract", "ANATOMY", 99, 122], ["respiratory tract infections", "DISEASE", 105, 133], ["URTI", "DISEASE", 135, 139], ["LRTI", "DISEASE", 144, 148], ["samples", "CANCER", 25, 32], ["patients", "ORGANISM", 75, 83], ["upper", "ORGANISM_SUBDIVISION", 89, 94], ["lower", "ORGANISM_SUBDIVISION", 99, 104], ["respiratory tract", "ORGANISM_SUBDIVISION", 105, 122], ["patients", "SPECIES", 75, 83], ["samples", "TEST", 25, 32], ["41 specimens", "TEST", 50, 62], ["upper and lower respiratory tract infections", "PROBLEM", 89, 133], ["total", "OBSERVATION_MODIFIER", 9, 14], ["upper", "ANATOMY_MODIFIER", 89, 94], ["lower", "ANATOMY_MODIFIER", 99, 104], ["respiratory tract", "ANATOMY", 105, 122], ["infections", "OBSERVATION", 123, 133]]], ["The viral distribution did not follow a definite pattern although RSV and AdV were predominantly detected in patients with LRTI and URTI, respectively.", [["LRTI", "DISEASE", 123, 127], ["URTI", "DISEASE", 132, 136], ["RSV", "ORGANISM", 66, 69], ["AdV", "ORGANISM", 74, 77], ["patients", "ORGANISM", 109, 117], ["patients", "SPECIES", 109, 117], ["RSV", "SPECIES", 66, 69], ["AdV", "SPECIES", 74, 77], ["RSV", "PROBLEM", 66, 69], ["LRTI", "PROBLEM", 123, 127], ["URTI", "PROBLEM", 132, 136], ["viral distribution", "OBSERVATION", 4, 22], ["RSV", "OBSERVATION", 66, 69]]], ["No statistically significant association was found between viruses detected and each clinical group.DISCUSSIONThe main finding in the present study was that both NAATs used to detect respiratory viruses yielded different results.", [["respiratory viruses", "DISEASE", 183, 202], ["NAATs", "GENE_OR_GENE_PRODUCT", 162, 167], ["NAATs", "PROTEIN", 162, 167], ["viruses", "PROBLEM", 59, 66], ["the present study", "TEST", 130, 147], ["respiratory viruses", "PROBLEM", 183, 202], ["statistically", "OBSERVATION_MODIFIER", 3, 16], ["significant", "OBSERVATION_MODIFIER", 17, 28], ["viruses", "OBSERVATION", 59, 66], ["main", "OBSERVATION_MODIFIER", 114, 118], ["respiratory viruses", "OBSERVATION", 183, 202]]], ["As expected, NAATs detected more viruses than the conventional techniques.", [["NAATs", "GENE_OR_GENE_PRODUCT", 13, 18], ["NAATs", "PROTEIN", 13, 18], ["NAATs", "PROBLEM", 13, 18]]], ["The question remains, however, as to whether this extra sensitivity provides more reliable information about the etiology of the infection.", [["infection", "DISEASE", 129, 138], ["this extra sensitivity", "PROBLEM", 45, 67], ["the infection", "PROBLEM", 125, 138], ["infection", "OBSERVATION", 129, 138]]], ["This could be due to the different range of viruses covered by each technique.", [["could be due to", "UNCERTAINTY", 5, 20], ["viruses", "OBSERVATION", 44, 51]]], ["Although both NAATs have been investigated before, the methods used as gold standard were different [Roh et al., 2008; Bruijnesteijn van Coppenraet et al., 2010; Frobert et al., 2011; Zhang et al., 2012; Cho et al., 2013; Culebras et al., 2013; Kim et al., 2013; Pillet et al., 2013 ].", [["NAATs", "GENE_OR_GENE_PRODUCT", 14, 19], ["NAATs", "PROTEIN", 14, 19]]], ["An important drawback in comparing NAATs is therefore the lack of a real gold standard.DISCUSSIONBoth conventional and PCR-based methods yielded similar results for RSV and ADV.", [["ADV", "CHEMICAL", 173, 176], ["RSV", "ORGANISM", 165, 168], ["RSV", "SPECIES", 165, 168], ["ADV", "SPECIES", 173, 176], ["conventional and PCR", "TEST", 102, 122], ["RSV", "PROBLEM", 165, 168], ["important", "OBSERVATION_MODIFIER", 3, 12], ["drawback", "OBSERVATION_MODIFIER", 13, 21]]], ["For RSV, IF was more sensitive than VC and equally sensitive to the molecular methods.", [["RSV", "ORGANISM", 4, 7], ["IF", "GENE_OR_GENE_PRODUCT", 9, 11], ["RSV", "SPECIES", 4, 7], ["RSV", "PROBLEM", 4, 7]]], ["For AdV, isolation in cell cultures is usually required because of the poor sensitivity of IF and the number of AdV isolates coincided with those detected by molecular methods.", [["cell cultures", "ANATOMY", 22, 35], ["AdV", "ORGANISM", 4, 7], ["cell cultures", "CELL", 22, 35], ["IF", "GENE_OR_GENE_PRODUCT", 91, 93], ["AdV", "ORGANISM", 112, 115], ["cell cultures", "CELL_LINE", 22, 35], ["IF", "PROTEIN", 91, 93], ["AdV", "SPECIES", 4, 7], ["AdV", "SPECIES", 112, 115], ["AdV", "PROBLEM", 4, 7], ["isolation in cell cultures", "TEST", 9, 35], ["AdV isolates", "TREATMENT", 112, 124]]], ["These findings coincided with the experience of our group over the last two decades and have been reported by other authors [Dunn et al., 2004; Mahony, 2008; Doan et al., 2012; Cho et al., 2013] .DISCUSSIONMolecular techniques have been the key to diagnosing a large range of new viruses incapable of multiplying in VC, such as HCoV and HBoV, and the new species of RV.", [["HCoV", "GENE_OR_GENE_PRODUCT", 328, 332], ["HBoV", "ORGANISM", 337, 341], ["HCoV", "SPECIES", 328, 332], ["HBoV", "SPECIES", 337, 341], ["new viruses", "PROBLEM", 276, 287], ["HBoV", "PROBLEM", 337, 341], ["large", "OBSERVATION_MODIFIER", 261, 266], ["new", "OBSERVATION_MODIFIER", 276, 279], ["viruses", "OBSERVATION", 280, 287], ["HBoV", "OBSERVATION", 337, 341], ["RV", "ANATOMY", 366, 368]]], ["Considering those viruses detected only by PCR, about 72% corresponded to RV, hMPV, HCoV-OC43, PIV-4, FLUCV, and HBoV.", [["HBoV", "DISEASE", 113, 117], ["hMPV", "ORGANISM", 78, 82], ["HCoV-OC43", "ORGANISM", 84, 93], ["PIV-4", "ORGANISM", 95, 100], ["FLUCV", "GENE_OR_GENE_PRODUCT", 102, 107], ["HBoV", "ORGANISM", 113, 117], ["RV", "SPECIES", 74, 76], ["hMPV", "SPECIES", 78, 82], ["HCoV", "SPECIES", 84, 88], ["FLUCV", "SPECIES", 102, 107], ["HBoV", "SPECIES", 113, 117], ["those viruses", "PROBLEM", 12, 25], ["PCR", "TEST", 43, 46], ["RV", "TEST", 74, 76], ["hMPV", "TEST", 78, 82], ["HCoV", "TEST", 84, 88], ["OC43", "TEST", 89, 93], ["PIV", "TEST", 95, 98], ["FLUCV", "TREATMENT", 102, 107], ["HBoV", "PROBLEM", 113, 117], ["viruses", "OBSERVATION", 18, 25], ["RV", "ANATOMY", 74, 76], ["hMPV", "OBSERVATION", 78, 82], ["HBoV", "OBSERVATION", 113, 117]]], ["As in previous studies, both NAATs largely increased the number of RV detected [Freymuth et al., 2006; Li et al., 2007; Mahony et al., 2007; Bruijnesteijn van Coppenraet et al., 2010; Cho et al., 2013] .DISCUSSIONNAATs do not always give a result.", [["NAATs", "GENE_OR_GENE_PRODUCT", 29, 34], ["NAATs", "PROTEIN", 29, 34], ["previous studies", "TEST", 6, 22], ["increased", "OBSERVATION_MODIFIER", 43, 52], ["RV", "ANATOMY", 67, 69]]], ["Inhibition of the amplification reaction is a drawback, mainly because of the specimen itself or the extraction protocol.", [["specimen", "ANATOMY", 78, 86], ["the amplification reaction", "PROBLEM", 14, 40], ["the extraction protocol", "TREATMENT", 97, 120]]], ["Both NAATs tested yielded inhibited results.", [["NAATs", "SIMPLE_CHEMICAL", 5, 10], ["NAATs", "PROTEIN", 5, 10]]], ["The fact that most inhibited samples differed between the two techniques, despite the extract being the same, suggests that the methods were probably the main cause of PCR inhibition.DISCUSSIONThe failure of NAATs to give a result may also be because of the lack of a specific target.", [["samples", "ANATOMY", 29, 36], ["samples", "CANCER", 29, 36], ["NAATs", "SIMPLE_CHEMICAL", 208, 213], ["PCR inhibition", "PROBLEM", 168, 182], ["The failure of NAATs", "PROBLEM", 193, 213], ["failure", "OBSERVATION", 197, 204]]], ["This is not only because the target is not included in the reaction, as in the case of Human herpesvirus 5, but also because of the variability of the respiratory viruses.", [["respiratory viruses", "DISEASE", 151, 170], ["Human herpesvirus 5", "ORGANISM", 87, 106], ["Human", "SPECIES", 87, 92], ["Human herpesvirus", "SPECIES", 87, 104], ["Human herpesvirus", "PROBLEM", 87, 104], ["the respiratory viruses", "PROBLEM", 147, 170], ["not only", "UNCERTAINTY", 8, 16], ["respiratory viruses", "OBSERVATION", 151, 170]]], ["Therefore laboratories, especially those that rely only on NAATs, need to constantly review the viruses included in the assays they use [Ogilvie, 2001] .DISCUSSIONNAATs have created a new scenario in the diagnosis of viral respiratory infections: the high yield of multiple viral detections [Kuypers et al., 2006; Madhi and Klugman, 2006; Leland and Ginocchio, 2007] .", [["respiratory", "ANATOMY", 223, 234], ["viral respiratory infections", "DISEASE", 217, 245], ["laboratories", "TEST", 10, 22], ["the viruses", "PROBLEM", 92, 103], ["viral respiratory infections", "PROBLEM", 217, 245], ["multiple viral detections", "PROBLEM", 265, 290], ["new", "OBSERVATION_MODIFIER", 184, 187], ["viral", "OBSERVATION_MODIFIER", 217, 222], ["respiratory infections", "OBSERVATION", 223, 245]]], ["Compared to Seeplex 1 , the Clart 1 system tripled the number of multiple detections; differences in their design, particularly concerning the primers and the amplification conditions, may contribute to this disparity.", [["the primers", "PROBLEM", 139, 150], ["the amplification conditions", "PROBLEM", 155, 183], ["this disparity", "PROBLEM", 203, 217], ["multiple", "OBSERVATION_MODIFIER", 65, 73], ["detections", "OBSERVATION", 74, 84]]], ["The high rate of multiple detection, which may be explained because of the pediatric population, is in agreement with other authors [Roh et al., 2008; Kim et al., 2009; Bruijnesteijn van Coppenraet et al., 2010; Frobert et al., 2011; Zhang et al., 2012] .DISCUSSIONSo an important remaining question is the clinical relevance of the results obtained by NAATs.", [["high", "OBSERVATION_MODIFIER", 4, 8]]], ["Covering a broad range of etiological agents, these quick techniques may be especially useful in immunosupressed or critically ill patients although their clinical impact is not yet well established [Garbino et al., 2009; Schnell et al., 2012] .", [["critically ill", "DISEASE", 116, 130], ["patients", "ORGANISM", 131, 139], ["patients", "SPECIES", 131, 139], ["etiological agents", "TREATMENT", 26, 44], ["these quick techniques", "TREATMENT", 46, 68]]], ["However, as NAATs detect viral nucleic acids regardless of the presence of viral antigens or infective viruses [Pagarolas and Sune, [Elnifro et al., 2000; Mahony, 2008; Ginocchio and McAdam, 2011; Jansen et al., 2011] .", [["nucleic acids", "CHEMICAL", 31, 44], ["NAATs", "GENE_OR_GENE_PRODUCT", 12, 17], ["NAATs", "PROTEIN", 12, 17], ["viral antigens", "PROTEIN", 75, 89], ["NAATs", "TEST", 12, 17], ["viral nucleic acids", "TEST", 25, 44], ["viral antigens", "PROBLEM", 75, 89], ["infective viruses", "PROBLEM", 93, 110]]], ["Although the viral load may be useful to predict the correlation of a virus and an infectious process it is not well-established for respiratory viral infections [Kuypers et al., 2006; Debiaggi et al., 2012] .", [["respiratory viral infections", "DISEASE", 133, 161], ["the viral load", "TEST", 9, 23], ["a virus", "PROBLEM", 68, 75], ["an infectious process", "PROBLEM", 80, 101], ["respiratory viral infections", "PROBLEM", 133, 161], ["viral load", "OBSERVATION", 13, 23], ["infectious", "OBSERVATION", 83, 93]]], ["The prevalence of specific viruses based on NAATs differs between symptomatic and asymptomatic children [Debiaggi et al., 2012; Buller, 2013] .", [["NAATs", "CANCER", 44, 49], ["children", "ORGANISM", 95, 103], ["children", "SPECIES", 95, 103], ["specific viruses", "PROBLEM", 18, 34], ["viruses", "OBSERVATION", 27, 34]]], ["Some viruses, such as RSV, are usually associated with clinical illness and should be considered as the etiological agent in a patient with respiratory symptoms.", [["respiratory", "ANATOMY", 140, 151], ["respiratory symptoms", "DISEASE", 140, 160], ["RSV", "ORGANISM", 22, 25], ["patient", "ORGANISM", 127, 134], ["RSV", "SPECIES", 22, 25], ["patient", "SPECIES", 127, 134], ["RSV", "SPECIES", 22, 25], ["Some viruses", "PROBLEM", 0, 12], ["RSV", "PROBLEM", 22, 25], ["clinical illness", "PROBLEM", 55, 71], ["respiratory symptoms", "PROBLEM", 140, 160], ["viruses", "OBSERVATION", 5, 12], ["RSV", "OBSERVATION", 22, 25]]], ["In contrast, viruses such as RV, HCoV, and HBoV seem to be frequently found in asymptomatic children [Debiaggi et al., 2012; Meriluoto et al., 2012] although more studies on this issue are required.DISCUSSIONThe management of patients requires reporting results within a clinically relevant time-scale; microbiology laboratories should take this into consideration when choosing a diagnostic test.", [["RV", "GENE_OR_GENE_PRODUCT", 29, 31], ["HCoV", "GENE_OR_GENE_PRODUCT", 33, 37], ["HBoV", "ORGANISM", 43, 47], ["children", "ORGANISM", 92, 100], ["patients", "ORGANISM", 226, 234], ["children", "SPECIES", 92, 100], ["patients", "SPECIES", 226, 234], ["RV", "SPECIES", 29, 31], ["HCoV", "SPECIES", 33, 37], ["HBoV", "SPECIES", 43, 47], ["viruses", "PROBLEM", 13, 20], ["RV", "TEST", 29, 31], ["HBoV", "PROBLEM", 43, 47], ["microbiology laboratories", "TEST", 303, 328], ["a diagnostic test", "TEST", 379, 396], ["viruses", "OBSERVATION", 13, 20], ["RV", "ANATOMY", 29, 31], ["HBoV", "OBSERVATION", 43, 47]]], ["NAATs are faster than culture, which requires two days minimum; both NAATs tested had a turn around time of six and nine hours.", [["NAATs", "SIMPLE_CHEMICAL", 0, 5], ["culture", "TEST", 22, 29], ["faster", "OBSERVATION_MODIFIER", 10, 16]]], ["However, most NAATs are not faster than IF or immunochromatography.", [["NAATs", "SIMPLE_CHEMICAL", 14, 19], ["NAATs", "PROTEIN", 14, 19], ["IF", "PROTEIN", 40, 42], ["immunochromatography", "TEST", 46, 66]]], ["Rapid antigen detection tests of certain respiratory viruses provide a result with very high specificity within 15-30 min [Mandell et al., 2007] .", [["Rapid antigen detection tests", "TEST", 0, 29], ["certain respiratory viruses", "PROBLEM", 33, 60]]], ["In the epidemic situation, the use of these techniques as the first step to detect viruses such as influenza virus or RSV may accelerate results and bring simplicity to the laboratory.", [["influenza", "DISEASE", 99, 108], ["RSV", "DISEASE", 118, 121], ["influenza virus", "ORGANISM", 99, 114], ["RSV", "ORGANISM", 118, 121], ["influenza virus", "SPECIES", 99, 114], ["influenza virus", "SPECIES", 99, 114], ["RSV", "SPECIES", 118, 121], ["these techniques", "TREATMENT", 38, 54], ["viruses", "PROBLEM", 83, 90], ["influenza virus", "PROBLEM", 99, 114], ["RSV", "PROBLEM", 118, 121]]], ["Only the negative results would require further analysis [Buller, 2013] .", [["further analysis", "TEST", 40, 56]]], ["Another important point is that NAATs and antigen detection techniques only detect the specific viruses under investigation; other viruses that may be related to the clinical process will not be detected.DISCUSSIONThe combination of several methods in the diagnosis of viral respiratory infections is still a great option.", [["respiratory", "ANATOMY", 275, 286], ["viral respiratory infections", "DISEASE", 269, 297], ["NAATs", "GENE_OR_GENE_PRODUCT", 32, 37], ["antigen", "GENE_OR_GENE_PRODUCT", 42, 49], ["NAATs", "PROTEIN", 32, 37], ["antigen detection techniques", "TEST", 42, 70], ["other viruses", "PROBLEM", 125, 138], ["the clinical process", "PROBLEM", 162, 182], ["viral respiratory infections", "PROBLEM", 269, 297], ["several", "OBSERVATION_MODIFIER", 233, 240], ["viral", "OBSERVATION_MODIFIER", 269, 274], ["respiratory infections", "OBSERVATION", 275, 297]]], ["However, not all laboratories have the facilities or the personnel required to perform a wide range of techniques, such as antigen detection tests, virus isolation and molecular tests.", [["antigen detection tests", "TEST", 123, 146], ["virus isolation", "TREATMENT", 148, 163], ["molecular tests", "TEST", 168, 183]]], ["NAATs are particularly useful in detecting new viruses and in giving a quick result.", [["NAATs", "SIMPLE_CHEMICAL", 0, 5], ["new viruses", "PROBLEM", 43, 54], ["new", "OBSERVATION_MODIFIER", 43, 46], ["viruses", "OBSERVATION", 47, 54]]], ["However, the interpretation of a molecular test is not always straightforward.", [["a molecular test", "TEST", 31, 47]]], ["The clinical virologist must consider the pros and cons of the technique used and the clinical impact of the result.", [["the technique", "TREATMENT", 59, 72]]]], "PMC7102821": [["Introduction(+)RNA viruses infect almost all eukaryotic organisms, often inducing devastating diseases in humans, animals and plants.", [["humans", "ORGANISM", 106, 112], ["humans", "SPECIES", 106, 112], ["humans", "SPECIES", 106, 112], ["RNA viruses infect", "PROBLEM", 15, 33], ["devastating diseases in humans", "PROBLEM", 82, 112], ["devastating", "OBSERVATION_MODIFIER", 82, 93], ["diseases", "OBSERVATION", 94, 102]]], ["Despite adaptation to diverse hosts, the replication mechanisms of (+)RNA viruses display remarkable conservation.", [["diverse hosts", "TREATMENT", 22, 35], ["RNA viruses", "PROBLEM", 70, 81]]], ["These viruses universally require cellular membranes for assembly of their replication complexes \u2013 containing viral proteins, RNA, and host factors \u2013 to amplify their genome.", [["cellular membranes", "ANATOMY", 34, 52], ["cellular membranes", "CELLULAR_COMPONENT", 34, 52], ["replication complexes", "PROTEIN", 75, 96], ["viral proteins", "PROTEIN", 110, 124], ["RNA", "RNA", 126, 129], ["host factors", "PROTEIN", 135, 147], ["cellular membranes", "TREATMENT", 34, 52], ["viral proteins", "PROBLEM", 110, 124], ["viruses", "OBSERVATION", 6, 13], ["cellular membranes", "OBSERVATION", 34, 52], ["viral proteins", "OBSERVATION", 110, 124]]], ["To convert cellular membranes into replication sites, (+)RNA viruses must have evolved efficient ways of manipulating the highly regulated cellular membrane metabolism.", [["cellular membranes", "ANATOMY", 11, 29], ["cellular membrane", "ANATOMY", 139, 156], ["cellular membranes", "CELLULAR_COMPONENT", 11, 29], ["cellular membrane", "CELLULAR_COMPONENT", 139, 156], ["replication sites", "DNA", 35, 52], ["cellular membranes", "TREATMENT", 11, 29], ["RNA viruses", "PROBLEM", 57, 68], ["cellular membranes", "OBSERVATION", 11, 29], ["cellular membrane metabolism", "OBSERVATION", 139, 167]]], ["The small genome size of these viruses and thus limited repertoire of available resources suggests that they rely on only a few evolutionarily successful strategies shared among different viruses.IntroductionRecently, major advances have been made in understanding of virus\u2013cell interaction of several groups of (+)RNA viruses.", [["virus\u2013cell", "ANATOMY", 268, 278], ["virus\u2013cell", "CELL", 268, 278], ["these viruses", "PROBLEM", 25, 38], ["RNA viruses", "PROBLEM", 315, 326], ["small", "OBSERVATION_MODIFIER", 4, 9], ["genome", "OBSERVATION_MODIFIER", 10, 16], ["size", "OBSERVATION_MODIFIER", 17, 21], ["viruses", "OBSERVATION", 31, 38]]], ["The pioneering research of picornavirus-induced membrane remodeling has been complemented lately by detailed examinations of the biochemistry and morphology of replication organelles of flaviviruses, alphaviruses and nidoviruses.", [["membrane", "ANATOMY", 48, 56], ["organelles", "ANATOMY", 172, 182], ["picornavirus", "ORGANISM", 27, 39], ["membrane", "CELLULAR_COMPONENT", 48, 56], ["nidoviruses", "GENE_OR_GENE_PRODUCT", 217, 228], ["picornavirus-induced membrane remodeling", "TREATMENT", 27, 67], ["detailed examinations", "TEST", 100, 121], ["the biochemistry", "TEST", 125, 141], ["flaviviruses", "PROBLEM", 186, 198], ["alphaviruses", "PROBLEM", 200, 212], ["nidoviruses", "PROBLEM", 217, 228], ["picornavirus", "OBSERVATION", 27, 39], ["membrane remodeling", "OBSERVATION", 48, 67], ["replication organelles", "OBSERVATION", 160, 182], ["flaviviruses", "OBSERVATION", 186, 198]]], ["Many important insights into virus-induced membrane modifications were gained from studies on Flock House virus and Brome Mosaic virus (BMV), which can replicate in yeast, allowing application of yeast genetic tools to elucidate the role of specific host factors.", [["membrane", "ANATOMY", 43, 51], ["membrane", "CELLULAR_COMPONENT", 43, 51], ["Flock House virus", "ORGANISM", 94, 111], ["Brome Mosaic virus", "ORGANISM", 116, 134], ["BMV", "ORGANISM", 136, 139], ["host factors", "PROTEIN", 250, 262], ["Brome Mosaic virus", "SPECIES", 116, 134], ["yeast", "SPECIES", 165, 170], ["yeast", "SPECIES", 196, 201], ["Flock House virus", "SPECIES", 94, 111], ["Brome Mosaic virus", "SPECIES", 116, 134], ["BMV", "SPECIES", 136, 139], ["yeast", "SPECIES", 165, 170], ["yeast", "SPECIES", 196, 201], ["virus-induced membrane modifications", "TREATMENT", 29, 65], ["Flock House virus", "TREATMENT", 94, 111], ["Brome Mosaic virus (BMV", "TREATMENT", 116, 139], ["yeast genetic tools", "PROBLEM", 196, 215]]], ["These studies revealed important similarities in the principles of remodeling cellular membranes and organizing replication sites among diverse (+)RNA viruses.", [["cellular membranes", "ANATOMY", 78, 96], ["cellular membranes", "CELLULAR_COMPONENT", 78, 96], ["replication sites", "DNA", 112, 129], ["These studies", "TEST", 0, 13], ["remodeling cellular membranes", "PROBLEM", 67, 96], ["organizing replication sites", "PROBLEM", 101, 129], ["diverse (+)RNA viruses", "PROBLEM", 136, 158], ["remodeling", "OBSERVATION", 67, 77], ["cellular membranes", "OBSERVATION", 78, 96], ["organizing", "OBSERVATION_MODIFIER", 101, 111], ["replication", "OBSERVATION", 112, 123], ["diverse", "OBSERVATION_MODIFIER", 136, 143], ["RNA viruses", "OBSERVATION", 147, 158]]], ["The development and functioning of these structures require rewiring of cellular pathways into new configurations that are induced and regulated by viral proteins.IntroductionIn this review, we will describe new data on the organization and development of replication structures and focus on the emerging concept that viral membranous replication complexes are bona fide new organelles with unique lipid and protein compositions.Distinct membranous structures may support different steps in the viral life cycle ::: Morphology of membranous replication organellesDifferent combinations of membranous structures can often be simultaneously observed in one infected cell, or they can develop in a defined succession during the course of infection.", [["cellular", "ANATOMY", 72, 80], ["organelles", "ANATOMY", 375, 385], ["membranous structures", "ANATOMY", 438, 459], ["membranous replication organelles", "ANATOMY", 530, 563], ["membranous structures", "ANATOMY", 589, 610], ["cell", "ANATOMY", 664, 668], ["infection", "DISEASE", 735, 744], ["cellular", "CELL", 72, 80], ["organelles", "CELLULAR_COMPONENT", 375, 385], ["lipid", "SIMPLE_CHEMICAL", 398, 403], ["organelles", "CELLULAR_COMPONENT", 553, 563], ["cell", "CELL", 664, 668], ["viral proteins", "PROTEIN", 148, 162], ["viral membranous replication complexes", "PROTEIN", 318, 356], ["cellular pathways", "PROBLEM", 72, 89], ["viral proteins", "PROBLEM", 148, 162], ["replication structures", "PROBLEM", 256, 278], ["viral membranous replication complexes", "PROBLEM", 318, 356], ["Distinct membranous structures", "PROBLEM", 429, 459], ["membranous replication organelles", "PROBLEM", 530, 563], ["membranous structures", "PROBLEM", 589, 610], ["infection", "PROBLEM", 735, 744], ["rewiring", "OBSERVATION", 60, 68], ["cellular pathways", "OBSERVATION", 72, 89], ["new", "OBSERVATION_MODIFIER", 95, 98], ["viral proteins", "OBSERVATION", 148, 162], ["replication", "OBSERVATION", 256, 267], ["viral membranous", "OBSERVATION", 318, 334], ["replication complexes", "OBSERVATION", 335, 356], ["membranous", "OBSERVATION", 438, 448], ["membranous", "OBSERVATION", 530, 540], ["replication organelles", "OBSERVATION", 541, 563], ["membranous", "OBSERVATION", 589, 599], ["infected cell", "OBSERVATION", 655, 668], ["infection", "OBSERVATION", 735, 744]]], ["It is not always clear whether these structures contribute equally to RNA replication or have other specialized functions in the viral life cycle.", [["RNA replication", "TREATMENT", 70, 85]]], ["For enveloped viruses, distinct membrane structures may be expected to be associated with genome replication and virion maturation.", [["membrane structures", "ANATOMY", 32, 51], ["membrane structures", "CELLULAR_COMPONENT", 32, 51], ["genome", "CELLULAR_COMPONENT", 90, 96], ["virion", "CELLULAR_COMPONENT", 113, 119], ["enveloped viruses", "PROBLEM", 4, 21], ["genome replication", "PROBLEM", 90, 108], ["virion maturation", "TREATMENT", 113, 130], ["viruses", "OBSERVATION", 14, 21], ["distinct", "OBSERVATION_MODIFIER", 23, 31], ["membrane structures", "OBSERVATION", 32, 51], ["replication", "OBSERVATION", 97, 108], ["virion maturation", "OBSERVATION", 113, 130]]], ["Indeed, genome replication of HCV is associated with a membranous web believed to originate from ER membranes [7], while RNA encapsidation is linked to the surface of lipid droplets [8, 9].", [["membranous web", "ANATOMY", 55, 69], ["ER membranes", "ANATOMY", 97, 109], ["surface", "ANATOMY", 156, 163], ["lipid droplets", "ANATOMY", 167, 181], ["genome", "CELLULAR_COMPONENT", 8, 14], ["HCV", "ORGANISM", 30, 33], ["ER", "GENE_OR_GENE_PRODUCT", 97, 99], ["surface", "CELLULAR_COMPONENT", 156, 163], ["ER", "PROTEIN", 97, 99], ["HCV", "SPECIES", 30, 33], ["HCV", "PROBLEM", 30, 33], ["a membranous web", "PROBLEM", 53, 69], ["RNA encapsidation", "PROBLEM", 121, 138], ["HCV", "OBSERVATION", 30, 33]]], ["Polyprotein processing, RNA replication and virion maturation each appear to be confined to different membrane compartments in cells infected with arthropod-borne flaviviruses [3\u2022, 10, 11].", [["membrane compartments", "ANATOMY", 102, 123], ["cells", "ANATOMY", 127, 132], ["Polyprotein", "GENE_OR_GENE_PRODUCT", 0, 11], ["membrane compartments", "CELLULAR_COMPONENT", 102, 123], ["cells", "CELL", 127, 132], ["Polyprotein processing", "TREATMENT", 0, 22], ["RNA replication", "TREATMENT", 24, 39], ["virion maturation", "PROBLEM", 44, 61], ["RNA replication", "OBSERVATION", 24, 39], ["virion maturation", "OBSERVATION", 44, 61]]], ["Time-dependent evolution of membrane structures, implicated to reflect distinct stages of virus propagation, has been described for coronaviruses [1\u2022, 12], and recently for enteroviruses (i.e. poliovirus and coxsackievirus).", [["membrane structures", "ANATOMY", 28, 47], ["enteroviruses", "DISEASE", 173, 186], ["membrane", "CELLULAR_COMPONENT", 28, 36], ["coronaviruses", "ORGANISM", 132, 145], ["enteroviruses", "ORGANISM", 173, 186], ["i.e. poliovirus", "ORGANISM", 188, 203], ["coxsackievirus", "ORGANISM", 208, 222], ["membrane structures", "PROBLEM", 28, 47], ["virus propagation", "PROBLEM", 90, 107], ["coronaviruses", "PROBLEM", 132, 145], ["enteroviruses", "PROBLEM", 173, 186], ["poliovirus", "PROBLEM", 193, 203], ["coxsackievirus", "PROBLEM", 208, 222], ["membrane structures", "OBSERVATION", 28, 47], ["distinct stages", "OBSERVATION_MODIFIER", 71, 86], ["virus propagation", "OBSERVATION", 90, 107]]], ["Early in infection enteroviruses replicate their RNA on single membrane convoluted tubular clusters that later in infection are converted into double-membrane vesicles (DMV) and complex multimembrane structures [4\u2022, 5\u2022].", [["membrane convoluted tubular clusters", "ANATOMY", 63, 99], ["double-membrane vesicles", "ANATOMY", 143, 167], ["infection", "DISEASE", 9, 18], ["infection", "DISEASE", 114, 123], ["enteroviruses", "ORGANISM", 19, 32], ["membrane vesicles", "CELLULAR_COMPONENT", 150, 167], ["Early in infection enteroviruses", "PROBLEM", 0, 32], ["single membrane convoluted tubular clusters", "PROBLEM", 56, 99], ["infection", "PROBLEM", 114, 123], ["complex multimembrane structures", "PROBLEM", 178, 210], ["infection", "OBSERVATION", 9, 18], ["tubular clusters", "OBSERVATION", 83, 99], ["infection", "OBSERVATION", 114, 123], ["membrane vesicles", "ANATOMY", 150, 167]]], ["Although DMV may contribute to enterovirus RNA replication, they have also been implicated in non-lytic release of newly formed virions [13].Morphology of replication structures is conserved among large taxa of viruses ::: Morphology of membranous replication organelles(+)RNA viruses can be divided into three superfamilies: picorna-like, alpha-like and flavi-like viruses [14, 15, 16].", [["membranous replication organelles", "ANATOMY", 237, 270], ["DMV", "SIMPLE_CHEMICAL", 9, 12], ["enterovirus", "ORGANISM", 31, 42], ["organelles", "CELLULAR_COMPONENT", 260, 270], ["picorna", "GENE_OR_GENE_PRODUCT", 326, 333], ["alpha", "GENE_OR_GENE_PRODUCT", 340, 345], ["flavi-like viruses", "ORGANISM", 355, 373], ["alpha", "PROTEIN", 340, 345], ["enterovirus", "SPECIES", 31, 42], ["DMV", "PROBLEM", 9, 12], ["enterovirus RNA replication", "PROBLEM", 31, 58], ["newly formed virions", "PROBLEM", 115, 135], ["replication structures", "PROBLEM", 155, 177], ["membranous replication organelles", "PROBLEM", 237, 270], ["RNA viruses", "PROBLEM", 273, 284], ["picorna", "TEST", 326, 333], ["alpha", "TEST", 340, 345], ["flavi-like viruses", "PROBLEM", 355, 373], ["may contribute to", "UNCERTAINTY", 13, 30], ["enterovirus", "OBSERVATION", 31, 42], ["replication", "OBSERVATION", 155, 166], ["large", "OBSERVATION_MODIFIER", 197, 202], ["taxa", "OBSERVATION_MODIFIER", 203, 207], ["viruses", "OBSERVATION", 211, 218], ["membranous replication", "OBSERVATION", 237, 259], ["picorna", "ANATOMY", 326, 333], ["alpha", "ANATOMY", 340, 345], ["flavi", "ANATOMY", 355, 360], ["viruses", "OBSERVATION", 366, 373]]], ["Interestingly, flavi-and alpha-like viruses induce formation of discrete membrane invaginations with negative membrane curvature [3\u2022, 17\u2022, 18, 19], while picorna-like viruses rely on positively curved convoluted tubular\u2013vesicular membrane networks [1\u2022, 4\u2022, 5\u2022, 20, 21, 22, 23].", [["membrane invaginations", "ANATOMY", 73, 95], ["membrane", "ANATOMY", 110, 118], ["tubular\u2013vesicular membrane networks", "ANATOMY", 212, 247], ["flavi", "GENE_OR_GENE_PRODUCT", 15, 20], ["alpha-like viruses", "ORGANISM", 25, 43], ["membrane invaginations", "CELLULAR_COMPONENT", 73, 95], ["membrane", "CELLULAR_COMPONENT", 110, 118], ["picorna", "ORGANISM", 154, 161], ["tubular\u2013vesicular membrane networks", "MULTI-TISSUE_STRUCTURE", 212, 247], ["flavi", "TEST", 15, 20], ["alpha-like viruses", "PROBLEM", 25, 43], ["discrete membrane invaginations", "PROBLEM", 64, 95], ["picorna", "TEST", 154, 161], ["flavi", "ANATOMY", 15, 20], ["discrete", "OBSERVATION_MODIFIER", 64, 72], ["membrane invaginations", "OBSERVATION", 73, 95], ["membrane curvature", "OBSERVATION_MODIFIER", 110, 128], ["viruses", "OBSERVATION", 167, 174], ["tubular\u2013vesicular membrane", "OBSERVATION", 212, 238]]], ["In the invaginations, the replication machinery is located on the inner membrane surface and the replication compartment is connected to the cytoplasm with an opening wide enough to provide a supply of nucleotides and to export synthesized RNA [2\u2022, 3\u2022].", [["invaginations", "ANATOMY", 7, 20], ["inner membrane surface", "ANATOMY", 66, 88], ["cytoplasm", "ANATOMY", 141, 150], ["nucleotides", "CHEMICAL", 202, 213], ["invaginations", "CELLULAR_COMPONENT", 7, 20], ["inner membrane surface", "CELLULAR_COMPONENT", 66, 88], ["cytoplasm", "ORGANISM_SUBSTANCE", 141, 150], ["the replication machinery", "TREATMENT", 22, 47], ["a supply of nucleotides", "TREATMENT", 190, 213], ["inner", "ANATOMY_MODIFIER", 66, 71], ["membrane", "ANATOMY_MODIFIER", 72, 80], ["surface", "OBSERVATION_MODIFIER", 81, 88], ["replication compartment", "OBSERVATION", 97, 120]]], ["In tubulo-vesicular replication structures, the viral replication proteins are localized on the external membranous surface facing the cytoplasm [24].", [["tubulo-vesicular", "ANATOMY", 3, 19], ["membranous surface", "ANATOMY", 105, 123], ["cytoplasm", "ANATOMY", 135, 144], ["membranous surface", "CELLULAR_COMPONENT", 105, 123], ["cytoplasm", "ORGANISM_SUBSTANCE", 135, 144], ["viral replication proteins", "PROTEIN", 48, 74], ["the viral replication proteins", "PROBLEM", 44, 74], ["vesicular replication", "OBSERVATION", 10, 31], ["viral", "OBSERVATION_MODIFIER", 48, 53], ["replication proteins", "OBSERVATION", 54, 74], ["external", "OBSERVATION_MODIFIER", 96, 104], ["membranous", "OBSERVATION_MODIFIER", 105, 115], ["surface", "OBSERVATION_MODIFIER", 116, 123], ["cytoplasm", "OBSERVATION_MODIFIER", 135, 144]]], ["This division may reflect an evolutionary divergence between (+)RNA virus groups and suggest that the mechanisms of membrane remodeling may be significantly different between picorna-like and other (+)RNA viruses (Figure 1).Autophagy ::: (+)RNA viruses rewire cellular pathways to generate replication organellesActivation of at least initial steps of the autophagy pathway is well documented in cells infected with diverse (+)RNA viruses.", [["membrane", "ANATOMY", 116, 124], ["cellular", "ANATOMY", 260, 268], ["organelles", "ANATOMY", 302, 312], ["cells", "ANATOMY", 396, 401], ["membrane", "CELLULAR_COMPONENT", 116, 124], ["::: (+)", "GENE_OR_GENE_PRODUCT", 234, 241], ["cellular", "CELL", 260, 268], ["cells", "CELL", 396, 401], ["an evolutionary divergence between (+)RNA virus groups", "PROBLEM", 26, 80], ["membrane remodeling", "PROBLEM", 116, 135], ["picorna", "TEST", 175, 182], ["other (+)RNA viruses", "PROBLEM", 192, 212], ["Autophagy", "TEST", 224, 233], ["RNA viruses", "PROBLEM", 241, 252], ["the autophagy pathway", "PROBLEM", 352, 373], ["diverse (+)RNA viruses", "PROBLEM", 416, 438], ["may reflect", "UNCERTAINTY", 14, 25], ["evolutionary divergence", "OBSERVATION", 29, 52]]], ["Since a double membrane is a distinctive feature of autophagosomes, it was initially suggested that autophagy-like processes may be responsible for the generation of double membrane replication structures.", [["membrane", "ANATOMY", 15, 23], ["autophagosomes", "ANATOMY", 52, 66], ["membrane", "ANATOMY", 173, 181], ["membrane", "CELLULAR_COMPONENT", 15, 23], ["autophagosomes", "CELLULAR_COMPONENT", 52, 66], ["membrane", "CELLULAR_COMPONENT", 173, 181], ["a double membrane", "PROBLEM", 6, 23], ["autophagosomes", "PROBLEM", 52, 66], ["autophagy", "PROBLEM", 100, 109], ["double membrane replication structures", "TREATMENT", 166, 204], ["double membrane", "OBSERVATION_MODIFIER", 8, 23], ["autophagosomes", "OBSERVATION", 52, 66], ["double membrane", "OBSERVATION", 166, 181]]], ["However conflicting data on the importance of autophagy for replication of coronaviruses [1\u2022, 28, 29, 30, 31] and enteroviruses [32, 33, 34] suggest that DMV are either not essential for replication, or that they bear only superficial resemblance to autophagosomes.", [["autophagosomes", "ANATOMY", 250, 264], ["enteroviruses", "DISEASE", 114, 127], ["coronaviruses", "ORGANISM", 75, 88], ["DMV", "SIMPLE_CHEMICAL", 154, 157], ["autophagosomes", "CELLULAR_COMPONENT", 250, 264], ["coronaviruses", "PROBLEM", 75, 88], ["enteroviruses", "TEST", 114, 127], ["DMV", "PROBLEM", 154, 157]]], ["Recently, an autophagy-independent role of LC3 in tuning the ER-associated degradation (ERAD) pathway was suggested to be important for coronavirus replication, indicating that viruses may selectively utilize autophagy/ERAD pathway components to generate replication membranes [35, 36].", [["membranes", "ANATOMY", 267, 276], ["LC3", "GENE_OR_GENE_PRODUCT", 43, 46], ["ER", "GENE_OR_GENE_PRODUCT", 61, 63], ["ERAD", "GENE_OR_GENE_PRODUCT", 88, 92], ["coronavirus", "ORGANISM", 136, 147], ["ERAD", "GENE_OR_GENE_PRODUCT", 219, 223], ["membranes", "CELLULAR_COMPONENT", 267, 276], ["LC3", "PROTEIN", 43, 46], ["ER", "PROTEIN", 61, 63], ["ERAD", "PROTEIN", 88, 92], ["ERAD", "PROTEIN", 219, 223], ["coronavirus", "SPECIES", 136, 147], ["coronavirus replication", "TREATMENT", 136, 159], ["viruses", "PROBLEM", 177, 184], ["autophagy", "OBSERVATION", 13, 22]]], ["Although an intact autophagy pathway may not be required for bona fide genome replication of (+)RNA viruses, autophagy may be induced upon infection as it plays an important regulatory role in the type I interferon response [37].", [["infection", "DISEASE", 139, 148], ["genome", "CELLULAR_COMPONENT", 71, 77], ["type I interferon", "GENE_OR_GENE_PRODUCT", 197, 214], ["RNA viruses", "PROBLEM", 96, 107], ["autophagy", "PROBLEM", 109, 118], ["infection", "PROBLEM", 139, 148], ["infection", "OBSERVATION", 139, 148]]], ["Indeed, activation of autophagy by HCV and Dengue virus has recently been shown to suppress the cellular capacity to activate this antiviral innate response [38, 39].Secretory pathway ::: (+)RNA viruses rewire cellular pathways to generate replication organellesReplication of most (+)RNA viruses is intimately associated with cellular secretory pathway(-derived) membranes (Figure 2).", [["cellular", "ANATOMY", 96, 104], ["cellular", "ANATOMY", 210, 218], ["organelles", "ANATOMY", 252, 262], ["cellular", "ANATOMY", 327, 335], ["membranes", "ANATOMY", 364, 373], ["Dengue", "DISEASE", 43, 49], ["HCV", "ORGANISM", 35, 38], ["Dengue virus", "ORGANISM", 43, 55], ["cellular", "CELL", 96, 104], ["::: (+)", "GENE_OR_GENE_PRODUCT", 184, 191], ["cellular", "CELL", 210, 218], ["cellular", "CELL", 327, 335], ["membranes", "CELLULAR_COMPONENT", 364, 373], ["Dengue virus", "SPECIES", 43, 55], ["HCV", "SPECIES", 35, 38], ["Dengue virus", "SPECIES", 43, 55], ["autophagy", "PROBLEM", 22, 31], ["HCV", "PROBLEM", 35, 38], ["Dengue virus", "PROBLEM", 43, 55], ["the cellular capacity", "PROBLEM", 92, 113], ["RNA viruses", "PROBLEM", 191, 202], ["RNA viruses", "PROBLEM", 285, 296], ["cellular secretory pathway", "PROBLEM", 327, 353], ["viruses", "OBSERVATION", 289, 296]]], ["Below the roles of some common membrane-remodeling host factors identified to be required for (+)RNA virus replication are discussed.GBF1 ::: (+)RNA viruses rewire cellular pathways to generate replication organellesGBF1, a guanine nucleotide exchange factor for the small GTPase Arf1 and a target of brefeldin A (BFA), coordinates the formation and fusion of transport vesicles in trafficking between ER and early Golgi [40].", [["membrane", "ANATOMY", 31, 39], ["cellular", "ANATOMY", 164, 172], ["vesicles", "ANATOMY", 370, 378], ["ER", "ANATOMY", 402, 404], ["early Golgi", "ANATOMY", 409, 420], ["guanine nucleotide", "CHEMICAL", 224, 242], ["brefeldin A", "CHEMICAL", 301, 312], ["BFA", "CHEMICAL", 314, 317], ["guanine nucleotide", "CHEMICAL", 224, 242], ["brefeldin A", "CHEMICAL", 301, 312], ["BFA", "CHEMICAL", 314, 317], ["membrane", "CELLULAR_COMPONENT", 31, 39], ["GBF1", "GENE_OR_GENE_PRODUCT", 133, 137], ["::: (+)", "GENE_OR_GENE_PRODUCT", 138, 145], ["cellular", "CELL", 164, 172], ["organellesGBF1", "GENE_OR_GENE_PRODUCT", 206, 220], ["Arf1", "GENE_OR_GENE_PRODUCT", 280, 284], ["brefeldin A", "GENE_OR_GENE_PRODUCT", 301, 312], ["BFA", "SIMPLE_CHEMICAL", 314, 317], ["vesicles", "CELLULAR_COMPONENT", 370, 378], ["ER", "GENE_OR_GENE_PRODUCT", 402, 404], ["Golgi", "CELLULAR_COMPONENT", 415, 420], ["GBF1", "PROTEIN", 133, 137], ["replication organellesGBF1", "PROTEIN", 194, 220], ["guanine nucleotide exchange factor", "PROTEIN", 224, 258], ["small GTPase", "PROTEIN", 267, 279], ["Arf1", "PROTEIN", 280, 284], ["brefeldin A", "PROTEIN", 301, 312], ["BFA", "PROTEIN", 314, 317], ["ER", "PROTEIN", 402, 404], ["remodeling host factors", "PROBLEM", 40, 63], ["RNA virus replication", "TREATMENT", 97, 118], ["GBF1", "TEST", 133, 137], ["RNA viruses rewire cellular pathways", "PROBLEM", 145, 181], ["a guanine nucleotide exchange factor", "TREATMENT", 222, 258], ["the small GTPase Arf1", "PROBLEM", 263, 284], ["brefeldin A (BFA", "TREATMENT", 301, 317], ["common membrane", "ANATOMY", 24, 39], ["small", "OBSERVATION_MODIFIER", 267, 272], ["GTPase Arf1", "OBSERVATION", 273, 284]]], ["GBF1 was recognized as an essential factor for replication of enteroviruses [41, 42, 43], but not other picornaviruses such as cardioviruses and aphthoviruses [44, 45].", [["GBF1", "GENE_OR_GENE_PRODUCT", 0, 4], ["enteroviruses", "ORGANISM", 62, 75], ["GBF1", "PROTEIN", 0, 4], ["enteroviruses", "PROBLEM", 62, 75], ["other picornaviruses", "PROBLEM", 98, 118], ["cardioviruses", "PROBLEM", 127, 140], ["aphthoviruses", "TEST", 145, 158], ["picornaviruses", "OBSERVATION", 104, 118]]], ["GBF1 has also been implicated in replication of HCV and mouse hepatitis coronavirus [46, 47].", [["hepatitis coronavirus", "DISEASE", 62, 83], ["GBF1", "GENE_OR_GENE_PRODUCT", 0, 4], ["HCV", "ORGANISM", 48, 51], ["mouse hepatitis coronavirus", "ORGANISM", 56, 83], ["GBF1", "PROTEIN", 0, 4], ["mouse", "SPECIES", 56, 61], ["hepatitis coronavirus", "SPECIES", 62, 83], ["HCV", "SPECIES", 48, 51], ["mouse hepatitis coronavirus", "SPECIES", 56, 83], ["HCV", "PROBLEM", 48, 51], ["mouse hepatitis coronavirus", "PROBLEM", 56, 83], ["HCV", "OBSERVATION", 48, 51]]], ["Several lines of evidence suggest that the role of GBF1 in viral replication is unrelated to its normal function in transport vesicle formation and Arf1 activation.", [["vesicle", "ANATOMY", 126, 133], ["GBF1", "GENE_OR_GENE_PRODUCT", 51, 55], ["vesicle", "CELLULAR_COMPONENT", 126, 133], ["Arf1", "GENE_OR_GENE_PRODUCT", 148, 152], ["GBF1", "PROTEIN", 51, 55], ["Arf1", "PROTEIN", 148, 152], ["the role of GBF1 in viral replication", "PROBLEM", 39, 76], ["Arf1 activation", "PROBLEM", 148, 163], ["lines", "OBSERVATION", 8, 13], ["viral replication", "OBSERVATION", 59, 76], ["Arf1 activation", "OBSERVATION", 148, 163]]], ["Expression of poliovirus and HCV proteins in the presence of BFA resulted in the appearance of new membrane structures that are indistinguishable from those observed without the drug, indicating that GBF1 is more probably involved in the function of replication organelles than in their formation [41, 45].", [["membrane structures", "ANATOMY", 99, 118], ["organelles", "ANATOMY", 262, 272], ["BFA", "CHEMICAL", 61, 64], ["BFA", "CHEMICAL", 61, 64], ["poliovirus", "ORGANISM", 14, 24], ["HCV", "ORGANISM", 29, 32], ["BFA", "SIMPLE_CHEMICAL", 61, 64], ["membrane structures", "CELLULAR_COMPONENT", 99, 118], ["GBF1", "GENE_OR_GENE_PRODUCT", 200, 204], ["organelles", "CELLULAR_COMPONENT", 262, 272], ["poliovirus and HCV proteins", "PROTEIN", 14, 41], ["GBF1", "PROTEIN", 200, 204], ["poliovirus", "SPECIES", 14, 24], ["HCV", "SPECIES", 29, 32], ["poliovirus", "PROBLEM", 14, 24], ["HCV proteins", "PROBLEM", 29, 41], ["BFA", "PROBLEM", 61, 64], ["new membrane structures", "PROBLEM", 95, 118], ["poliovirus", "OBSERVATION", 14, 24], ["HCV proteins", "OBSERVATION", 29, 41], ["BFA", "OBSERVATION_MODIFIER", 61, 64], ["resulted", "OBSERVATION", 65, 73], ["new", "OBSERVATION_MODIFIER", 95, 98], ["membrane structures", "OBSERVATION", 99, 118], ["more probably", "UNCERTAINTY", 208, 221]]], ["Moreover, while activated Arf1 accumulates on enterovirus replication organelles, BFA-resistant poliovirus mutants can efficiently replicate without active Arf1, and siRNA knockdown of Arf1 does not affect coxsackievirus replication [42, 48\u2022].", [["organelles", "ANATOMY", 70, 80], ["BFA", "CHEMICAL", 82, 85], ["BFA", "CHEMICAL", 82, 85], ["Arf1", "GENE_OR_GENE_PRODUCT", 26, 30], ["organelles", "CELLULAR_COMPONENT", 70, 80], ["BFA", "SIMPLE_CHEMICAL", 82, 85], ["poliovirus", "ORGANISM", 96, 106], ["Arf1", "GENE_OR_GENE_PRODUCT", 156, 160], ["Arf1", "GENE_OR_GENE_PRODUCT", 185, 189], ["coxsackievirus", "ORGANISM", 206, 220], ["Arf1", "PROTEIN", 26, 30], ["Arf1", "PROTEIN", 156, 160], ["Arf1", "PROTEIN", 185, 189], ["enterovirus replication organelles", "PROBLEM", 46, 80], ["BFA", "TEST", 82, 85], ["resistant poliovirus mutants", "PROBLEM", 86, 114], ["active Arf1", "PROBLEM", 149, 160], ["siRNA knockdown of Arf1", "PROBLEM", 166, 189]]], ["Lastly, expression of truncated GBF1 deficient in supporting cellular metabolism rescued poliovirus replication in the presence of BFA [48\u2022].Phosphatidylinositol-4-kinase (PI4K) ::: (+)RNA viruses rewire cellular pathways to generate replication organellesReplication membranes of enteroviruses were shown to become enriched in PI4KIII\u03b2, but depleted of coat proteins, yielding unique uncoated phosphatidylinositol-4-phosphate (PI4P) lipid-enriched organelles [49\u2022].", [["cellular", "ANATOMY", 61, 69], ["cellular", "ANATOMY", 204, 212], ["organelles", "ANATOMY", 246, 256], ["membranes", "ANATOMY", 268, 277], ["organelles", "ANATOMY", 449, 459], ["BFA", "CHEMICAL", 131, 134], ["phosphatidylinositol-4-phosphate", "CHEMICAL", 394, 426], ["BFA", "CHEMICAL", 131, 134], ["Phosphatidylinositol", "CHEMICAL", 141, 161], ["phosphatidylinositol-4-phosphate", "CHEMICAL", 394, 426], ["PI4P", "CHEMICAL", 428, 432], ["GBF1", "GENE_OR_GENE_PRODUCT", 32, 36], ["cellular", "CELL", 61, 69], ["poliovirus", "ORGANISM", 89, 99], ["BFA", "SIMPLE_CHEMICAL", 131, 134], ["Phosphatidylinositol-4-kinase", "GENE_OR_GENE_PRODUCT", 141, 170], ["PI4K", "GENE_OR_GENE_PRODUCT", 172, 176], ["::", "GENE_OR_GENE_PRODUCT", 178, 180], ["cellular", "CELL", 204, 212], ["membranes", "CELLULAR_COMPONENT", 268, 277], ["enteroviruses", "ORGANISM", 281, 294], ["PI4KIII\u03b2", "GENE_OR_GENE_PRODUCT", 328, 336], ["phosphatidylinositol-4-phosphate", "SIMPLE_CHEMICAL", 394, 426], ["PI4P", "SIMPLE_CHEMICAL", 428, 432], ["lipid", "SIMPLE_CHEMICAL", 434, 439], ["organelles", "CELLULAR_COMPONENT", 449, 459], ["GBF1", "PROTEIN", 32, 36], ["Phosphatidylinositol-4-kinase", "PROTEIN", 141, 170], ["PI4K", "PROTEIN", 172, 176], ["PI4KIII\u03b2", "PROTEIN", 328, 336], ["coat proteins", "PROTEIN", 354, 367], ["poliovirus", "SPECIES", 89, 99], ["truncated GBF1 deficient", "PROBLEM", 22, 46], ["poliovirus replication", "TREATMENT", 89, 111], ["Phosphatidylinositol", "TEST", 141, 161], ["RNA viruses", "TREATMENT", 185, 196], ["Replication membranes of enteroviruses", "PROBLEM", 256, 294], ["coat proteins", "PROBLEM", 354, 367], ["unique uncoated phosphatidylinositol", "TEST", 378, 414], ["phosphate", "TEST", 417, 426], ["lipid", "TEST", 434, 439], ["GBF1 deficient", "OBSERVATION", 32, 46], ["metabolism rescued", "OBSERVATION", 70, 88], ["poliovirus replication", "OBSERVATION", 89, 111]]], ["It was proposed that recruitment of PI4KIII\u03b2 to replication organelles depends on the interaction of viral protein 3A with GBF1 as well as on the Arf1 activation function of GBF1 [45, 49\u2022].", [["organelles", "ANATOMY", 60, 70], ["PI4KIII\u03b2", "GENE_OR_GENE_PRODUCT", 36, 44], ["viral protein 3A", "GENE_OR_GENE_PRODUCT", 101, 117], ["GBF1", "GENE_OR_GENE_PRODUCT", 123, 127], ["Arf1", "GENE_OR_GENE_PRODUCT", 146, 150], ["GBF1", "GENE_OR_GENE_PRODUCT", 174, 178], ["PI4KIII\u03b2", "PROTEIN", 36, 44], ["viral protein 3A", "PROTEIN", 101, 117], ["GBF1", "PROTEIN", 123, 127], ["Arf1", "PROTEIN", 146, 150], ["GBF1", "PROTEIN", 174, 178], ["PI4KIII", "TREATMENT", 36, 43], ["replication organelles", "PROBLEM", 48, 70], ["viral protein 3A", "PROBLEM", 101, 117], ["GBF1", "TREATMENT", 123, 127], ["GBF1", "TEST", 174, 178]]], ["However, the observations that Arf1 as well as strong 3A\u2013GBF1 interaction may be dispensable for enterovirus replication [42] (G. Belov, F. van Kuppeveld, unpublished data) argue that this model may be an oversimplification of the actual processes (Figure 3).", [["Arf1", "GENE_OR_GENE_PRODUCT", 31, 35], ["3A\u2013", "GENE_OR_GENE_PRODUCT", 54, 57], ["GBF1", "GENE_OR_GENE_PRODUCT", 57, 61], ["enterovirus", "ORGANISM", 97, 108], ["Arf1", "PROTEIN", 31, 35], ["GBF1", "PROTEIN", 57, 61], ["enterovirus replication", "PROBLEM", 97, 120]]], ["Another PI4K, PI4KIII\u03b1, is recruited to replication sites of HCV by viral protein NS5A [50, 51\u2022].", [["PI4K", "GENE_OR_GENE_PRODUCT", 8, 12], ["PI4KIII\u03b1", "GENE_OR_GENE_PRODUCT", 14, 22], ["HCV", "ORGANISM", 61, 64], ["NS5A", "GENE_OR_GENE_PRODUCT", 82, 86], ["PI4K", "PROTEIN", 8, 12], ["PI4KIII\u03b1", "PROTEIN", 14, 22], ["replication sites", "DNA", 40, 57], ["viral protein", "PROTEIN", 68, 81], ["NS5A", "PROTEIN", 82, 86], ["HCV", "SPECIES", 61, 64], ["Another PI4K", "TEST", 0, 12], ["HCV", "PROBLEM", 61, 64], ["viral protein NS5A", "TEST", 68, 86]]], ["Inhibition of PI4K activity potently blocks replication of enteroviruses and HCV, showing that PI4P is an important component of their replication membranes [49\u2022, 52, 53].", [["membranes", "ANATOMY", 147, 156], ["PI4K", "GENE_OR_GENE_PRODUCT", 14, 18], ["enteroviruses", "ORGANISM", 59, 72], ["HCV", "ORGANISM", 77, 80], ["PI4P", "GENE_OR_GENE_PRODUCT", 95, 99], ["membranes", "CELLULAR_COMPONENT", 147, 156], ["PI4K", "PROTEIN", 14, 18], ["PI4P", "PROTEIN", 95, 99], ["HCV", "SPECIES", 77, 80], ["Inhibition of PI4K activity", "TREATMENT", 0, 27], ["enteroviruses", "PROBLEM", 59, 72], ["HCV", "PROBLEM", 77, 80], ["enteroviruses", "OBSERVATION", 59, 72], ["replication membranes", "OBSERVATION", 135, 156]]], ["As is the case for GBF1, PI4Ks are not required for the replication of all (+)RNA viruses and even viruses from one family may demonstrate different requirements for PI4Ks [51\u2022, 54] (F. van Kuppeveld, unpublished data).", [["GBF1", "GENE_OR_GENE_PRODUCT", 19, 23], ["PI4Ks", "GENE_OR_GENE_PRODUCT", 25, 30], ["GBF1", "PROTEIN", 19, 23], ["PI4Ks", "PROTEIN", 25, 30], ["GBF1", "TEST", 19, 23], ["PI4Ks", "TEST", 25, 30], ["RNA viruses", "PROBLEM", 78, 89], ["PI4Ks", "TEST", 166, 171]]], ["The role of PI4P, the product of PI4K activity, is likely to mediate recruitment and/or activation of viral proteins and host factors on replication organelles (e.g. PI4P-binding cellular proteins such as oxysterol binding proteins and ceramide transport protein), where they may support RNA replication directly or indirectly by remodeling membranes (Figure 3).", [["organelles", "ANATOMY", 149, 159], ["cellular", "ANATOMY", 179, 187], ["membranes", "ANATOMY", 341, 350], ["ceramide", "CHEMICAL", 236, 244], ["oxysterol", "CHEMICAL", 205, 214], ["ceramide", "CHEMICAL", 236, 244], ["PI4P", "GENE_OR_GENE_PRODUCT", 12, 16], ["PI4K", "GENE_OR_GENE_PRODUCT", 33, 37], ["organelles", "CELLULAR_COMPONENT", 149, 159], ["PI4P-binding cellular proteins", "GENE_OR_GENE_PRODUCT", 166, 196], ["oxysterol binding proteins", "GENE_OR_GENE_PRODUCT", 205, 231], ["ceramide transport protein", "GENE_OR_GENE_PRODUCT", 236, 262], ["membranes", "CELLULAR_COMPONENT", 341, 350], ["PI4P", "PROTEIN", 12, 16], ["PI4K", "PROTEIN", 33, 37], ["viral proteins", "PROTEIN", 102, 116], ["host factors", "PROTEIN", 121, 133], ["PI4P-binding cellular proteins", "PROTEIN", 166, 196], ["oxysterol binding proteins", "PROTEIN", 205, 231], ["ceramide transport protein", "PROTEIN", 236, 262], ["PI4P", "TREATMENT", 12, 16], ["viral proteins", "PROBLEM", 102, 116], ["host factors", "PROBLEM", 121, 133], ["replication organelles", "PROBLEM", 137, 159], ["PI4P-binding cellular proteins", "TREATMENT", 166, 196], ["oxysterol binding proteins", "TREATMENT", 205, 231], ["ceramide transport protein", "TREATMENT", 236, 262], ["RNA replication", "PROBLEM", 288, 303], ["likely to", "UNCERTAINTY", 51, 60], ["recruitment", "OBSERVATION", 69, 80], ["RNA replication", "OBSERVATION", 288, 303]]], ["Poliovirus polymerase 3D has been shown to preferentially bind PI4P in a biochemical assay, but the relevance of this observation for replication in vivo remains to be elaborated [49\u2022].", [["Poliovirus polymerase 3D", "GENE_OR_GENE_PRODUCT", 0, 24], ["PI4P", "GENE_OR_GENE_PRODUCT", 63, 67], ["Poliovirus polymerase 3D", "PROTEIN", 0, 24], ["PI4P", "PROTEIN", 63, 67], ["Poliovirus", "SPECIES", 0, 10], ["Poliovirus polymerase 3D", "PROBLEM", 0, 24], ["a biochemical assay", "TEST", 71, 90], ["this observation", "TEST", 113, 129], ["replication", "TREATMENT", 134, 145]]], ["For HCV, the absence of PI4KIII\u03b1 activity induced a dramatic change in the ultrastructural morphology of the membranous replication complex, suggesting a role of PI4P in recruiting specific membrane-shaping proteins [51\u2022].Phosphatidylinositol-4-kinase (PI4K) ::: (+)RNA viruses rewire cellular pathways to generate replication organellesTaken together, these data suggest that (+)RNA viruses do not rely on a functional secretory pathway, but rather dismantle it and stitch together separate elements in new configurations that serve to support viral genome replication.", [["membrane", "ANATOMY", 190, 198], ["cellular", "ANATOMY", 285, 293], ["organelles", "ANATOMY", 327, 337], ["Phosphatidylinositol", "CHEMICAL", 222, 242], ["HCV", "ORGANISM", 4, 7], ["PI4KIII\u03b1", "GENE_OR_GENE_PRODUCT", 24, 32], ["membranous", "CELLULAR_COMPONENT", 109, 119], ["PI4P", "GENE_OR_GENE_PRODUCT", 162, 166], ["membrane", "CELLULAR_COMPONENT", 190, 198], ["Phosphatidylinositol-4-kinase", "GENE_OR_GENE_PRODUCT", 222, 251], ["PI4K", "GENE_OR_GENE_PRODUCT", 253, 257], ["::", "GENE_OR_GENE_PRODUCT", 259, 261], ["cellular", "CELL", 285, 293], ["PI4KIII\u03b1", "PROTEIN", 24, 32], ["membranous replication complex", "PROTEIN", 109, 139], ["PI4P", "PROTEIN", 162, 166], ["membrane-shaping proteins", "PROTEIN", 190, 215], ["Phosphatidylinositol-4-kinase", "PROTEIN", 222, 251], ["PI4K", "PROTEIN", 253, 257], ["HCV", "SPECIES", 4, 7], ["HCV", "PROBLEM", 4, 7], ["PI4KIII\u03b1 activity", "PROBLEM", 24, 41], ["a dramatic change", "PROBLEM", 50, 67], ["PI4P", "TREATMENT", 162, 166], ["Phosphatidylinositol", "TEST", 222, 242], ["RNA viruses", "TREATMENT", 266, 277], ["these data", "TEST", 353, 363], ["RNA viruses", "PROBLEM", 380, 391], ["stitch", "TREATMENT", 467, 473], ["viral genome replication", "TREATMENT", 545, 569], ["dramatic", "OBSERVATION_MODIFIER", 52, 60], ["change", "OBSERVATION_MODIFIER", 61, 67], ["ultrastructural morphology", "OBSERVATION_MODIFIER", 75, 101], ["membranous replication", "OBSERVATION", 109, 131], ["new", "OBSERVATION_MODIFIER", 504, 507]]], ["Despite the critical role of GBF1 and PI4K in replication, enteroviruses can become resistant to inhibitors targeting these factors, suggesting built-in redundancy of essential virus\u2013cell interactions [55, 56].", [["virus\u2013cell", "ANATOMY", 177, 187], ["GBF1", "GENE_OR_GENE_PRODUCT", 29, 33], ["PI4K", "GENE_OR_GENE_PRODUCT", 38, 42], ["enteroviruses", "ORGANISM", 59, 72], ["virus\u2013cell", "GENE_OR_GENE_PRODUCT", 177, 187], ["GBF1", "PROTEIN", 29, 33], ["PI4K", "PROTEIN", 38, 42], ["GBF1", "TREATMENT", 29, 33], ["PI4K", "TREATMENT", 38, 42], ["replication", "TREATMENT", 46, 57], ["enteroviruses", "PROBLEM", 59, 72], ["inhibitors", "TREATMENT", 97, 107], ["these factors", "PROBLEM", 118, 131]]], ["Other studies have shown that replication of some (+)RNA viruses can be redirected to alternative intracellular membranes, suggesting a remarkable plasticity of the viral replication machinery regarding the availability of at least some cellular factors [57, 58, 59\u2022].", [["intracellular membranes", "ANATOMY", 98, 121], ["cellular", "ANATOMY", 237, 245], ["intracellular membranes", "CELLULAR_COMPONENT", 98, 121], ["cellular", "CELL", 237, 245], ["cellular factors", "PROTEIN", 237, 253], ["Other studies", "TEST", 0, 13], ["some (+)RNA viruses", "PROBLEM", 45, 64], ["viral replication", "OBSERVATION", 165, 182]]], ["The multiple compensatory mechanisms may be important for replication in different cell types, where availability of cellular components may vary.", [["cell", "ANATOMY", 83, 87], ["cellular", "ANATOMY", 117, 125], ["cell", "CELL", 83, 87], ["cellular", "CELL", 117, 125], ["The multiple compensatory mechanisms", "PROBLEM", 0, 36], ["multiple", "OBSERVATION_MODIFIER", 4, 12], ["compensatory", "OBSERVATION", 13, 25], ["may be important for", "UNCERTAINTY", 37, 57], ["different cell types", "OBSERVATION", 73, 93], ["cellular components", "OBSERVATION", 117, 136]]], ["This may serve as an essential source of evolutionary elasticity, and allow adaptation to changing conditions, including chemotherapeutic interventions.Lipid synthesis pathways ::: (+)RNA viruses rewire cellular pathways to generate replication organellesThe remarkable conservation of the overall design of the membranous replication complexes among distant (+)RNA viruses suggests shared basic mechanisms of their formation.", [["cellular", "ANATOMY", 203, 211], ["organelles", "ANATOMY", 245, 255], ["Lipid", "SIMPLE_CHEMICAL", 152, 157], ["cellular", "CELL", 203, 211], ["organelles", "CELLULAR_COMPONENT", 245, 255], ["membranous", "GENE_OR_GENE_PRODUCT", 312, 322], ["membranous replication complexes", "PROTEIN", 312, 344], ["evolutionary elasticity", "PROBLEM", 41, 64], ["changing conditions", "TREATMENT", 90, 109], ["chemotherapeutic interventions", "TREATMENT", 121, 151], ["Lipid synthesis pathways", "TEST", 152, 176], ["RNA viruses rewire cellular pathways", "PROBLEM", 184, 220], ["the membranous replication complexes", "PROBLEM", 308, 344], ["distant (+)RNA viruses", "PROBLEM", 351, 373], ["evolutionary elasticity", "OBSERVATION", 41, 64], ["membranous", "OBSERVATION_MODIFIER", 312, 322], ["replication", "OBSERVATION", 323, 334]]], ["Currently known elements of the autophagy and/or secretory pathways cannot fit the bill, since even related viruses display significant variability in requirements for these factors.", [["the autophagy", "PROBLEM", 28, 41], ["secretory pathways", "PROBLEM", 49, 67], ["even related viruses", "PROBLEM", 95, 115], ["these factors", "PROBLEM", 168, 181], ["viruses", "OBSERVATION", 108, 115], ["significant", "OBSERVATION_MODIFIER", 124, 135], ["variability", "OBSERVATION", 136, 147]]], ["The only universal feature of the (+)RNA virus infection that emerges over the years of research seems to be the obligatory modulation of cellular lipid biosynthesis pathways.", [["cellular", "ANATOMY", 138, 146], ["infection", "DISEASE", 47, 56], ["cellular", "CELL", 138, 146], ["lipid", "SIMPLE_CHEMICAL", 147, 152], ["the (+)RNA virus infection", "PROBLEM", 30, 56], ["lipid biosynthesis", "OBSERVATION", 147, 165]]], ["Picornavirus (picorna-like superfamily) infection is long known to significantly enhance cellular phospholipid synthesis [60, 61, 62].", [["cellular", "ANATOMY", 89, 97], ["infection", "DISEASE", 40, 49], ["Picornavirus", "GENE_OR_GENE_PRODUCT", 0, 12], ["picorna-like superfamily", "GENE_OR_GENE_PRODUCT", 14, 38], ["cellular", "CELL", 89, 97], ["phospholipid", "SIMPLE_CHEMICAL", 98, 110], ["Picornavirus (picorna-like superfamily", "PROTEIN", 0, 38], ["Picornavirus", "PROBLEM", 0, 12], ["infection", "PROBLEM", 40, 49], ["cellular phospholipid synthesis", "TEST", 89, 120], ["infection", "OBSERVATION", 40, 49]]], ["Investigation of BMV (alpha-like superfamily) replication in yeast system showed that formation of replication structures strongly depends on the metabolism of fatty acids and other lipids [63, 64].", [["fatty acids", "CHEMICAL", 160, 171], ["fatty acids", "CHEMICAL", 160, 171], ["BMV", "ORGANISM", 17, 20], ["alpha-like superfamily", "GENE_OR_GENE_PRODUCT", 22, 44], ["fatty acids", "SIMPLE_CHEMICAL", 160, 171], ["lipids", "SIMPLE_CHEMICAL", 182, 188], ["BMV (alpha-like superfamily", "PROTEIN", 17, 44], ["yeast", "SPECIES", 61, 66], ["BMV", "SPECIES", 17, 20], ["yeast", "SPECIES", 61, 66], ["BMV", "TEST", 17, 20], ["replication in yeast system", "PROBLEM", 46, 73], ["replication structures", "PROBLEM", 99, 121], ["fatty acids", "TEST", 160, 171], ["other lipids", "TEST", 176, 188], ["BMV", "OBSERVATION", 17, 20], ["replication", "OBSERVATION", 99, 110]]], ["Recently, new high-throughput lipidomics techniques allowed resolution of profound changes in the lipid spectrum upon Dengue virus (flavi-like superfamily) infection [65\u2022].", [["infection", "DISEASE", 156, 165], ["Dengue virus", "ORGANISM", 118, 130], ["flavi-like superfamily", "ORGANISM", 132, 154], ["Dengue virus", "SPECIES", 118, 130], ["Dengue virus", "SPECIES", 118, 130], ["new high-throughput lipidomics techniques", "PROBLEM", 10, 51], ["profound changes in the lipid spectrum", "PROBLEM", 74, 112], ["Dengue virus", "PROBLEM", 118, 130], ["infection", "PROBLEM", 156, 165], ["new", "OBSERVATION_MODIFIER", 10, 13], ["high", "OBSERVATION_MODIFIER", 14, 18], ["profound", "OBSERVATION_MODIFIER", 74, 82], ["changes", "OBSERVATION", 83, 90]]], ["Replication of many viruses has been proposed to depend on the activity of cellular fatty acid synthase (FAS).", [["cellular", "ANATOMY", 75, 83], ["fatty acid", "CHEMICAL", 84, 94], ["fatty acid", "CHEMICAL", 84, 94], ["cellular fatty acid synthase", "GENE_OR_GENE_PRODUCT", 75, 103], ["FAS", "GENE_OR_GENE_PRODUCT", 105, 108], ["cellular fatty acid synthase", "PROTEIN", 75, 103], ["FAS", "PROTEIN", 105, 108], ["many viruses", "PROBLEM", 15, 27], ["cellular fatty acid synthase", "TREATMENT", 75, 103], ["many", "OBSERVATION_MODIFIER", 15, 19], ["viruses", "OBSERVATION", 20, 27]]], ["Expression of FAS is activated in HCV-infected cells [66] and the enzyme is recruited to the replication membranes of Dengue virus [67].", [["cells", "ANATOMY", 47, 52], ["membranes", "ANATOMY", 105, 114], ["HCV-infected", "DISEASE", 34, 46], ["Dengue", "DISEASE", 118, 124], ["FAS", "GENE_OR_GENE_PRODUCT", 14, 17], ["HCV", "ORGANISM", 34, 37], ["cells", "CELL", 47, 52], ["membranes", "CELLULAR_COMPONENT", 105, 114], ["Dengue virus", "ORGANISM", 118, 130], ["FAS", "PROTEIN", 14, 17], ["Dengue virus", "SPECIES", 118, 130], ["HCV", "SPECIES", 34, 37], ["Dengue virus", "SPECIES", 118, 130], ["HCV", "PROBLEM", 34, 37], ["infected cells", "PROBLEM", 38, 52], ["the enzyme", "TEST", 62, 72], ["Dengue virus", "PROBLEM", 118, 130], ["infected cells", "OBSERVATION", 38, 52], ["replication membranes", "OBSERVATION", 93, 114]]], ["The apparently universal up-regulation of lipid metabolism by (+)RNA viruses raises interesting questions: Are the local changes in structural lipid composition the major driving force for formation of the membranous replication sites?", [["membranous", "ANATOMY", 206, 216], ["lipid", "SIMPLE_CHEMICAL", 42, 47], ["lipid", "SIMPLE_CHEMICAL", 143, 148], ["membranous replication sites", "DNA", 206, 234], ["lipid metabolism", "PROBLEM", 42, 58], ["RNA viruses", "PROBLEM", 65, 76], ["the local changes", "PROBLEM", 111, 128], ["the membranous replication sites", "PROBLEM", 202, 234], ["local", "OBSERVATION_MODIFIER", 115, 120], ["lipid composition", "OBSERVATION", 143, 160], ["membranous", "OBSERVATION_MODIFIER", 206, 216], ["replication", "OBSERVATION", 217, 228]]], ["Are these sites further stabilized by interaction with viral and/or cellular proteins?", [["cellular", "ANATOMY", 68, 76], ["cellular", "CELL", 68, 76], ["viral and/or cellular proteins", "PROTEIN", 55, 85], ["viral and/or cellular proteins", "PROBLEM", 55, 85]]], ["Do (+)RNA viruses remodel pre-existing cellular membranes, as we generally assume, or do they actually build replication membranes de novo and thus can they be truly called \u201cnovel replication organelles\u201d?Concluding remarksWe are only beginning to understand the complex details of biogenesis of viral replication organelles and their role in infection of (+)RNA viruses, and many questions still need to be resolved.", [["cellular membranes", "ANATOMY", 39, 57], ["membranes", "ANATOMY", 121, 130], ["organelles", "ANATOMY", 192, 202], ["organelles", "ANATOMY", 313, 323], ["infection", "DISEASE", 342, 351], ["cellular membranes", "CELLULAR_COMPONENT", 39, 57], ["membranes", "CELLULAR_COMPONENT", 121, 130], ["organelles", "CELLULAR_COMPONENT", 192, 202], ["organelles", "CELLULAR_COMPONENT", 313, 323], ["RNA viruses remodel pre-existing cellular membranes", "PROBLEM", 6, 57], ["viral replication organelles", "PROBLEM", 295, 323], ["infection of (+)RNA viruses", "PROBLEM", 342, 369], ["cellular membranes", "OBSERVATION", 39, 57], ["viral replication", "OBSERVATION", 295, 312], ["infection", "OBSERVATION", 342, 351]]], ["The shared morphology of replication structures and the apparently universal requirement for active lipid synthesis strongly suggest that key steps of their formation are shared among distantly related viruses. (+)RNA viruses actively change cellular membranes, rather than rely on pre-existing membranes.", [["cellular membranes", "ANATOMY", 242, 260], ["membranes", "ANATOMY", 295, 304], ["lipid", "SIMPLE_CHEMICAL", 100, 105], ["cellular membranes", "CELLULAR_COMPONENT", 242, 260], ["membranes", "CELLULAR_COMPONENT", 295, 304], ["replication structures", "PROBLEM", 25, 47], ["active lipid synthesis", "PROBLEM", 93, 115], ["RNA viruses actively change cellular membranes", "PROBLEM", 214, 260], ["pre-existing membranes", "PROBLEM", 282, 304], ["morphology", "OBSERVATION_MODIFIER", 11, 21], ["replication structures", "OBSERVATION", 25, 47], ["RNA", "ANATOMY", 214, 217], ["viruses", "OBSERVATION", 218, 225], ["change", "OBSERVATION_MODIFIER", 235, 241], ["cellular membranes", "OBSERVATION", 242, 260], ["membranes", "OBSERVATION", 295, 304]]], ["They relocate key cellular regulators of membrane metabolism, and modulate their activities to create new pathways of membrane remodeling.", [["cellular", "ANATOMY", 18, 26], ["membrane", "ANATOMY", 41, 49], ["membrane", "ANATOMY", 118, 126], ["cellular", "CELL", 18, 26], ["membrane", "CELLULAR_COMPONENT", 41, 49], ["membrane", "CELLULAR_COMPONENT", 118, 126], ["membrane remodeling", "PROBLEM", 118, 137], ["membrane remodeling", "OBSERVATION", 118, 137]]], ["Redundant networks of crucial virus\u2013cell interactions that allow the generation of a favorable replication microenvironment may exist, thereby providing viruses the opportunity to adapt to and evolve under changing conditions.", [["virus\u2013cell", "ANATOMY", 30, 40], ["virus\u2013cell", "CELL", 30, 40], ["crucial virus\u2013cell interactions", "TREATMENT", 22, 53], ["crucial virus\u2013cell", "OBSERVATION", 22, 40]]], ["Understanding how viral proteins hijack regulatory mechanisms of membrane metabolism will undoubtedly bring new perspective to many areas of cell biology and will be indispensable for the development of a new generation of anti-viral control strategies.References and recommended readingPapers of particular interest, published within the period of review, have been highlighted as:\u2022 of special interest", [["membrane", "ANATOMY", 65, 73], ["cell", "ANATOMY", 141, 145], ["membrane", "CELLULAR_COMPONENT", 65, 73], ["cell", "CELL", 141, 145], ["viral proteins", "PROTEIN", 18, 32], ["membrane metabolism", "PROBLEM", 65, 84], ["anti-viral control strategies", "TREATMENT", 223, 252], ["new", "OBSERVATION_MODIFIER", 205, 208], ["anti-viral control", "OBSERVATION", 223, 241]]]], "03ca8647a9d984270ae2ab7d34a12f70546a068d": [["IntroductionR espiratory tract infection is a leading cause of morbidity and mortality for children.", [["espiratory tract infection", "DISEASE", 14, 40], ["children", "ORGANISM", 91, 99], ["children", "SPECIES", 91, 99], ["IntroductionR espiratory tract infection", "PROBLEM", 0, 40], ["morbidity", "PROBLEM", 63, 72], ["tract", "OBSERVATION_MODIFIER", 25, 30], ["infection", "OBSERVATION", 31, 40], ["morbidity", "OBSERVATION", 63, 72]]], ["[1] Viruses are the major causative agents for childhood acute respiratory tract illness.", [["respiratory tract", "ANATOMY", 63, 80], ["acute respiratory tract illness", "DISEASE", 57, 88], ["tract", "ORGANISM_SUBDIVISION", 75, 80], ["Viruses", "PROBLEM", 4, 11], ["childhood acute respiratory tract illness", "PROBLEM", 47, 88], ["acute", "OBSERVATION_MODIFIER", 57, 62], ["respiratory tract", "OBSERVATION", 63, 80]]], ["[2] In 2005, human bocavirus (HBoV) was discovered in the respiratory samples from Swedish children with respiratory tract infection caused by other unknown agents.", [["respiratory samples", "ANATOMY", 58, 77], ["respiratory tract", "ANATOMY", 105, 122], ["respiratory tract infection", "DISEASE", 105, 132], ["human", "ORGANISM", 13, 18], ["bocavirus", "GENE_OR_GENE_PRODUCT", 19, 28], ["HBoV", "ORGANISM", 30, 34], ["children", "ORGANISM", 91, 99], ["tract", "ORGANISM_SUBDIVISION", 117, 122], ["human", "SPECIES", 13, 18], ["children", "SPECIES", 91, 99], ["human bocavirus", "SPECIES", 13, 28], ["HBoV", "SPECIES", 30, 34], ["human bocavirus (HBoV", "TREATMENT", 13, 34], ["respiratory tract infection", "PROBLEM", 105, 132], ["respiratory", "ANATOMY", 58, 69], ["respiratory tract", "ANATOMY", 105, 122], ["infection", "OBSERVATION", 123, 132]]], ["[3] Based on the genetic sequence of HBoV, it is classifi ed as bocavirus genus and belongs to the family of parvoviridae.", [["HBoV", "DISEASE", 37, 41], ["HBoV", "ORGANISM", 37, 41], ["parvoviridae", "CANCER", 109, 121], ["HBoV", "PROBLEM", 37, 41], ["parvoviridae", "TREATMENT", 109, 121]]], ["To date, HBoV has been found to circulate worldwide.", [["HBoV", "ORGANISM", 9, 13], ["HBoV", "SPECIES", 9, 13], ["HBoV", "PROBLEM", 9, 13]]], ["Serological studies have revealed that antibody seroconversion to HBoV is common in the early childhood.", [["HBoV", "DISEASE", 66, 70], ["HBoV", "ORGANISM", 66, 70], ["HBoV", "SPECIES", 66, 70], ["Serological studies", "TEST", 0, 19], ["antibody seroconversion", "PROBLEM", 39, 62], ["HBoV", "PROBLEM", 66, 70], ["early", "OBSERVATION_MODIFIER", 88, 93], ["childhood", "OBSERVATION", 94, 103]]], ["[24] [25] [26] The pathogenic role of HBoV has not yet been proved by classical Koch's postulates because neither an in vitro culture of HBoV nor an animal mode of infection can be established.", [["HBoV", "DISEASE", 38, 42], ["infection", "DISEASE", 164, 173], ["HBoV", "ORGANISM", 38, 42], ["HBoV", "ORGANISM", 137, 141], ["HBoV", "SPECIES", 38, 42], ["HBoV", "SPECIES", 137, 141], ["HBoV", "PROBLEM", 38, 42], ["an in vitro culture", "TEST", 114, 133], ["HBoV", "PROBLEM", 137, 141], ["infection", "PROBLEM", 164, 173], ["infection", "OBSERVATION", 164, 173]]], ["Two recent studies from Allander and coworkers [23, 27] suggested that HBoV signifi cantly correlates with acute wheezing, and that HBoV-related respiratory infection can elicit B cell immune response.IntroductionShanghai is a metropolitan city with a temperate climate where acute respiratory tract infection (ARTI) is endemic throughout the year.", [["respiratory", "ANATOMY", 145, 156], ["B cell", "ANATOMY", 178, 184], ["respiratory tract", "ANATOMY", 282, 299], ["HBoV signifi", "DISEASE", 71, 83], ["wheezing", "DISEASE", 113, 121], ["respiratory infection", "DISEASE", 145, 166], ["acute respiratory tract infection", "DISEASE", 276, 309], ["ARTI", "DISEASE", 311, 315], ["HBoV", "ORGANISM", 71, 75], ["HBoV", "ORGANISM", 132, 136], ["B cell", "CELL", 178, 184], ["tract", "ORGANISM_SUBDIVISION", 294, 299], ["HBoV signifi", "SPECIES", 71, 83], ["HBoV", "SPECIES", 132, 136], ["ARTI", "SPECIES", 311, 315], ["Two recent studies", "TEST", 0, 18], ["HBoV", "PROBLEM", 71, 75], ["acute wheezing", "PROBLEM", 107, 121], ["HBoV", "PROBLEM", 132, 136], ["respiratory infection", "PROBLEM", 145, 166], ["a temperate climate", "TREATMENT", 250, 269], ["acute respiratory tract infection", "PROBLEM", 276, 309], ["acute", "OBSERVATION_MODIFIER", 107, 112], ["wheezing", "OBSERVATION", 113, 121], ["respiratory", "ANATOMY", 145, 156], ["infection", "OBSERVATION", 157, 166], ["acute", "OBSERVATION_MODIFIER", 276, 281], ["respiratory tract", "ANATOMY", 282, 299], ["infection", "OBSERVATION", 300, 309], ["endemic", "OBSERVATION_MODIFIER", 320, 327]]], ["Usually respiratory virus season spans the winter and early spring annually and seven common respiratory viruses account for at least 24% of ARTI.", [["respiratory viruses", "DISEASE", 93, 112], ["ARTI", "DISEASE", 141, 145], ["ARTI", "CANCER", 141, 145], ["Usually respiratory virus season", "PROBLEM", 0, 32], ["seven common respiratory viruses", "PROBLEM", 80, 112], ["ARTI", "PROBLEM", 141, 145], ["respiratory virus", "OBSERVATION", 8, 25], ["respiratory viruses", "OBSERVATION", 93, 112], ["ARTI", "OBSERVATION", 141, 145]]], ["[28] HBoV, a newly identifi ed Mei Zeng, Qi-Rong Zhu, Xiao-Hong Wang, Hui Yu, Jun Shen Shanghai, ChinaHuman bocavirus in children with respiratory tract infection in Shanghai: a retrospective studyWorld Journal of PediatricsOriginal articlevirus, has been reported to be prevalent in the pediatric populations and is potentially associated with respiratory tract disease.", [["respiratory tract", "ANATOMY", 135, 152], ["respiratory tract", "ANATOMY", 345, 362], ["ChinaHuman bocavirus", "DISEASE", 97, 117], ["respiratory tract infection", "DISEASE", 135, 162], ["PediatricsOriginal articlevirus", "DISEASE", 214, 245], ["respiratory tract disease", "DISEASE", 345, 370], ["HBoV", "ORGANISM", 5, 9], ["ChinaHuman bocavirus", "ORGANISM", 97, 117], ["children", "ORGANISM", 121, 129], ["tract", "ORGANISM_SUBDIVISION", 357, 362], ["children", "SPECIES", 121, 129], ["HBoV", "PROBLEM", 5, 9], ["respiratory tract infection", "PROBLEM", 135, 162], ["respiratory tract disease", "PROBLEM", 345, 370], ["respiratory tract", "ANATOMY", 135, 152], ["potentially associated with", "UNCERTAINTY", 317, 344], ["respiratory tract", "OBSERVATION", 345, 362]]], ["Since epidemiology of respiratory viruses displays geographic and temporal characteristics, we investigated HBoV-associated respiratory tract infection among hospitalized children in Shanghai.Patients and samplesWe retrospectively studied HBoV infection between November 2006 and January 2007.", [["respiratory tract", "ANATOMY", 124, 141], ["respiratory viruses", "DISEASE", 22, 41], ["respiratory tract infection", "DISEASE", 124, 151], ["HBoV infection", "DISEASE", 239, 253], ["HBoV", "ORGANISM", 108, 112], ["tract", "ORGANISM_SUBDIVISION", 136, 141], ["children", "ORGANISM", 171, 179], ["Patients", "ORGANISM", 192, 200], ["HBoV", "ORGANISM", 239, 243], ["children", "SPECIES", 171, 179], ["Patients", "SPECIES", 192, 200], ["HBoV", "SPECIES", 239, 243], ["respiratory viruses", "PROBLEM", 22, 41], ["HBoV", "PROBLEM", 108, 112], ["respiratory tract infection", "PROBLEM", 124, 151], ["HBoV infection", "PROBLEM", 239, 253], ["respiratory viruses", "OBSERVATION", 22, 41], ["geographic", "OBSERVATION_MODIFIER", 51, 61], ["temporal", "OBSERVATION_MODIFIER", 66, 74], ["HBoV", "OBSERVATION", 108, 112], ["respiratory tract", "ANATOMY", 124, 141], ["infection", "OBSERVATION", 142, 151]]], ["Altogether 351 nasopharyngeal aspirates (NPAs) collected from 349 hospitalized children with ARTI were tested for HBoV.", [["nasopharyngeal aspirates", "ANATOMY", 15, 39], ["NPAs", "ANATOMY", 41, 45], ["ARTI", "DISEASE", 93, 97], ["HBoV", "DISEASE", 114, 118], ["nasopharyngeal aspirates", "MULTI-TISSUE_STRUCTURE", 15, 39], ["NPAs", "CANCER", 41, 45], ["children", "ORGANISM", 79, 87], ["HBoV", "ORGANISM", 114, 118], ["children", "SPECIES", 79, 87], ["HBoV", "SPECIES", 114, 118], ["nasopharyngeal aspirates", "TEST", 15, 39], ["ARTI", "TREATMENT", 93, 97], ["HBoV", "PROBLEM", 114, 118], ["nasopharyngeal", "ANATOMY", 15, 29], ["aspirates", "OBSERVATION", 30, 39]]], ["One sample was taken from each patient except two children from whom two samples were collected and tested at admission and during the occurrence of nosocomial infection.", [["sample", "ANATOMY", 4, 10], ["samples", "ANATOMY", 73, 80], ["nosocomial infection", "DISEASE", 149, 169], ["patient", "ORGANISM", 31, 38], ["children", "ORGANISM", 50, 58], ["patient", "SPECIES", 31, 38], ["children", "SPECIES", 50, 58], ["nosocomial infection", "PROBLEM", 149, 169], ["nosocomial", "OBSERVATION_MODIFIER", 149, 159], ["infection", "OBSERVATION", 160, 169]]], ["For children with communityacquired (CA) infection, samples were obtained within 48 hours after admission.", [["samples", "ANATOMY", 52, 59], ["communityacquired (CA) infection", "DISEASE", 18, 50], ["children", "ORGANISM", 4, 12], ["children", "SPECIES", 4, 12], ["communityacquired (CA) infection", "PROBLEM", 18, 50]]], ["For children with hospitalacquired (HA) infection, samples were collected within 2 days to 7 days after the occurrence of presumed nosocomial infection.", [["samples", "ANATOMY", 51, 58], ["hospitalacquired (HA) infection", "DISEASE", 18, 49], ["nosocomial infection", "DISEASE", 131, 151], ["children", "ORGANISM", 4, 12], ["children", "SPECIES", 4, 12], ["hospitalacquired (HA) infection", "PROBLEM", 18, 49], ["nosocomial infection", "PROBLEM", 131, 151], ["infection", "OBSERVATION", 40, 49], ["presumed", "UNCERTAINTY", 122, 130], ["nosocomial", "OBSERVATION_MODIFIER", 131, 141], ["infection", "OBSERVATION", 142, 151]]], ["Nosocomial ARTI was defi ned by the criteria that respiratory infection-associated symptoms such as cough, fever, and wheezing appeared 48 hours after hospitalization, and these symptoms could not be interpreted by primary infection.Patients and samplesNasopharyngeal aspirates were collected in a sterile container with 3 ml of sterile physiological saline, then transported to the virology laboratory for immediate processing.", [["respiratory", "ANATOMY", 50, 61], ["Nasopharyngeal aspirates", "ANATOMY", 253, 277], ["ARTI", "DISEASE", 11, 15], ["respiratory infection", "DISEASE", 50, 71], ["cough", "DISEASE", 100, 105], ["fever", "DISEASE", 107, 112], ["wheezing", "DISEASE", 118, 126], ["primary infection", "DISEASE", 215, 232], ["Patients", "ORGANISM", 233, 241], ["Nasopharyngeal aspirates", "MULTI-TISSUE_STRUCTURE", 253, 277], ["saline", "SIMPLE_CHEMICAL", 351, 357], ["Patients", "SPECIES", 233, 241], ["Nosocomial ARTI", "PROBLEM", 0, 15], ["respiratory infection", "PROBLEM", 50, 71], ["associated symptoms", "PROBLEM", 72, 91], ["cough", "PROBLEM", 100, 105], ["fever", "PROBLEM", 107, 112], ["wheezing", "PROBLEM", 118, 126], ["these symptoms", "PROBLEM", 172, 186], ["primary infection", "PROBLEM", 215, 232], ["Nasopharyngeal aspirates", "TEST", 253, 277], ["a sterile container", "TREATMENT", 296, 315], ["sterile physiological saline", "TREATMENT", 329, 357], ["respiratory", "ANATOMY", 50, 61], ["infection", "OBSERVATION", 62, 71], ["infection", "OBSERVATION", 223, 232], ["Nasopharyngeal", "ANATOMY", 253, 267], ["aspirates", "OBSERVATION", 268, 277]]], ["Each sample was pipetted and homogenized, and then 1 ml of the sample was removed into a sterile eppendorf tube and kept at -70\u00b0C for further HBoV DNA detection by polymerase chain reaction (PCR).", [["sample", "ANATOMY", 5, 11], ["sample", "ANATOMY", 63, 69], ["HBoV", "ORGANISM", 142, 146], ["DNA", "CELLULAR_COMPONENT", 147, 150], ["HBoV", "SPECIES", 142, 146], ["a sterile eppendorf tube", "TREATMENT", 87, 111], ["further HBoV DNA detection", "TREATMENT", 134, 160], ["polymerase chain reaction", "PROBLEM", 164, 189], ["PCR", "TEST", 191, 194]]], ["The remaining sample was used for the routine test of respiratory syncytial virus (RSV), infl uenza virus (IV) A and B, parainfl uenza virus (PIV) type 1-3, and adenovirus (ADV) by direct immunofl uorescence assay (Respiratory Panel IFA Kit, Chemicon) according to the manufacturer's instructions.Patients and samplesClinical symptoms and laboratory data of hospitalized children were reviewed from their medical records.", [["sample", "ANATOMY", 14, 20], ["samples", "ANATOMY", 310, 317], ["respiratory syncytial virus", "DISEASE", 54, 81], ["respiratory syncytial virus", "ORGANISM", 54, 81], ["RSV", "ORGANISM", 83, 86], ["infl uenza virus (IV) A", "ORGANISM", 89, 112], ["B", "ORGANISM", 117, 118], ["parainfl uenza virus", "ORGANISM", 120, 140], ["(PIV) type 1-3", "GENE_OR_GENE_PRODUCT", 141, 155], ["adenovirus", "ORGANISM", 161, 171], ["Patients", "ORGANISM", 297, 305], ["children", "ORGANISM", 371, 379], ["respiratory syncytial virus", "SPECIES", 54, 81], ["uenza virus", "SPECIES", 94, 105], ["parainfl uenza virus", "SPECIES", 120, 140], ["Patients", "SPECIES", 297, 305], ["children", "SPECIES", 371, 379], ["respiratory syncytial virus", "SPECIES", 54, 81], ["RSV", "SPECIES", 83, 86], ["infl uenza virus", "SPECIES", 89, 105], ["parainfl uenza virus", "SPECIES", 120, 140], ["PIV", "SPECIES", 142, 145], ["adenovirus", "SPECIES", 161, 171], ["ADV", "SPECIES", 173, 176], ["the routine test", "TEST", 34, 50], ["respiratory syncytial virus", "PROBLEM", 54, 81], ["RSV", "TEST", 83, 86], ["A and B, parainfl uenza virus", "TEST", 111, 140], ["adenovirus", "PROBLEM", 161, 171], ["Respiratory Panel", "TEST", 215, 232], ["Clinical symptoms", "PROBLEM", 317, 334], ["respiratory syncytial", "ANATOMY", 54, 75]]], ["The fi nal diagnosis of these children conformed to the diagnosis on discharge.", [["children", "ORGANISM", 30, 38], ["children", "SPECIES", 30, 38]]], ["Diagnosis of pneumonia was confi rmed by chest X-ray showing consolidation, patchy or interstitial infi ltrates in the lungs.", [["interstitial", "ANATOMY", 86, 98], ["lungs", "ANATOMY", 119, 124], ["pneumonia", "DISEASE", 13, 22], ["lungs", "ORGAN", 119, 124], ["pneumonia", "PROBLEM", 13, 22], ["confi", "PROBLEM", 27, 32], ["chest X-ray", "TEST", 41, 52], ["consolidation", "PROBLEM", 61, 74], ["patchy or interstitial infi ltrates in the lungs", "PROBLEM", 76, 124], ["pneumonia", "OBSERVATION", 13, 22], ["chest", "ANATOMY", 41, 46], ["consolidation", "OBSERVATION", 61, 74], ["patchy", "OBSERVATION_MODIFIER", 76, 82], ["interstitial", "ANATOMY_MODIFIER", 86, 98], ["infi ltrates", "OBSERVATION", 99, 111], ["lungs", "ANATOMY", 119, 124]]], ["For patients, if moist rale was revealed on auscultation but chest X-ray did not show infi ltrates, bronchitis or bronchiolitis was diagnosed.", [["bronchitis", "DISEASE", 100, 110], ["bronchiolitis", "DISEASE", 114, 127], ["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["auscultation", "TEST", 44, 56], ["chest X-ray", "TEST", 61, 72], ["infi ltrates", "PROBLEM", 86, 98], ["bronchitis", "PROBLEM", 100, 110], ["bronchiolitis", "PROBLEM", 114, 127], ["chest", "ANATOMY", 61, 66], ["bronchitis", "OBSERVATION", 100, 110], ["bronchiolitis", "OBSERVATION", 114, 127]]], ["Bronchial asthma was defi ned on the basis of the guidelines of the Subspecialty Group of Respiratory Diseases of Chinese Pediatric Society.", [["Bronchial", "ANATOMY", 0, 9], ["Bronchial asthma", "DISEASE", 0, 16], ["Respiratory Diseases", "DISEASE", 90, 110], ["Bronchial asthma", "PROBLEM", 0, 16], ["asthma", "OBSERVATION", 10, 16], ["Respiratory Diseases", "OBSERVATION", 90, 110]]], ["[29] Our study was approved by the Ethics Committee of Fudan Children's Hospital,Patients and sampleswhich does not require patients' consent for laboratory analysis of routinely collected clinical specimens.Detection of HBoVThe specimens were thawed and pipetted repeatedly and then centrifuged at 1500g for 5 minutes.", [["specimens", "ANATOMY", 198, 207], ["HBoVThe specimens", "ANATOMY", 221, 238], ["Patients", "ORGANISM", 81, 89], ["patients", "ORGANISM", 124, 132], ["HBoVThe specimens", "CANCER", 221, 238], ["Children", "SPECIES", 61, 69], ["Patients", "SPECIES", 81, 89], ["patients", "SPECIES", 124, 132], ["Our study", "TEST", 5, 14], ["laboratory analysis", "TEST", 146, 165], ["clinical specimens", "TEST", 189, 207], ["HBoVThe specimens", "TEST", 221, 238]]], ["200 \u03bcl supernatant was used for DNA nucleic acid extraction with MinElute DNA Virus Spin Kit (Sangon, Shanghai) according to the manufacturer's procedures.", [["supernatant", "ANATOMY", 7, 18], ["DNA", "CELLULAR_COMPONENT", 32, 35], ["DNA nucleic acid extraction", "TREATMENT", 32, 59], ["MinElute DNA Virus", "TREATMENT", 65, 83], ["the manufacturer's procedures", "TREATMENT", 125, 154]]], ["One set of primers 188F 5'-GAC CTC TGT AAG TAC TAT TAC-3' and 542R 5'-CTC TGT GTT GAC TGA ATA CAG-3' was used to screen a 354-bp fragment of the putative NP-1 gene.", [["NP-1", "GENE_OR_GENE_PRODUCT", 154, 158], ["354-bp fragment", "DNA", 122, 137], ["putative NP-1 gene", "DNA", 145, 163], ["primers", "TEST", 11, 18], ["GAC CTC", "TEST", 27, 34], ["TGT", "TEST", 35, 38], ["AAG", "TEST", 39, 42], ["TAC", "TEST", 51, 54], ["TGT GTT GAC TGA ATA CAG", "TREATMENT", 74, 97]]], ["[3] If positive PCR product was visualized, positive template was amplifi ed with another set of primers VP1/VP2F 5'-GCA AAC CCA TCA CTC TCA ATG C-3' and VP1/VP2F 5'-GCT CTC TCC TCC CAG TGA CAT-3' to produce a 404-bp fragment of the putative VP1 and VP2 genes.", [["CAT-3", "GENE_OR_GENE_PRODUCT", 190, 195], ["VP1", "GENE_OR_GENE_PRODUCT", 242, 245], ["VP2", "GENE_OR_GENE_PRODUCT", 250, 253], ["VP1", "DNA", 105, 108], ["VP1", "DNA", 154, 157], ["404-bp fragment", "DNA", 210, 225], ["putative VP1 and VP2 genes", "DNA", 233, 259], ["positive PCR product", "PROBLEM", 7, 27], ["primers", "TEST", 97, 104], ["VP1", "TEST", 105, 108], ["VP2F", "TEST", 109, 113], ["GCA", "TEST", 117, 120], ["AAC", "TEST", 121, 124], ["CCA", "TEST", 125, 128], ["TCA", "TEST", 129, 132], ["CTC", "TEST", 133, 136], ["TCA", "TEST", 137, 140], ["ATG", "TEST", 141, 144], ["C", "TEST", 145, 146], ["VP1", "TEST", 154, 157], ["VP2F", "TEST", 158, 162], ["GCT CTC", "TEST", 166, 173], ["TCC", "TEST", 174, 177], ["a 404-bp fragment", "PROBLEM", 208, 225], ["VP2 genes", "OBSERVATION", 250, 259]]], ["[6] HBoV infection was ascertained on condition that both target PCR fragmentsBocavirus respiratory infectionOriginal article were positive.", [["HBoV infection", "DISEASE", 4, 18], ["HBoV", "ORGANISM", 4, 8], ["PCR fragments", "DNA", 65, 78], ["HBoV infection", "PROBLEM", 4, 18], ["target PCR fragments", "PROBLEM", 58, 78], ["Bocavirus respiratory infectionOriginal article", "PROBLEM", 78, 125], ["infection", "OBSERVATION", 9, 18], ["respiratory", "ANATOMY", 88, 99], ["infectionOriginal article", "OBSERVATION", 100, 125]]], ["5 \u03bcl of extracted DNA templates were added into 50 \u03bcl master PCR reaction mixture containing 20 pmol each primer, 0.2 mmol/L dNTP, 2.5 U Taq DNA polymerase (Sangon, Shanghai), 2.5 mmol/L MgCl 2 , and 1 \u00d7 PCR buffer.", [["NTP", "CHEMICAL", 126, 129], ["NTP", "CHEMICAL", 126, 129], ["DNA", "CELLULAR_COMPONENT", 18, 21], ["DNA", "CELLULAR_COMPONENT", 141, 144], ["extracted DNA templates", "TREATMENT", 8, 31], ["NTP", "TREATMENT", 126, 129], ["2.5 U Taq DNA polymerase", "TREATMENT", 131, 155]]], ["PCR amplifi cation thermocycles were performed at 95\u00b0C for 15 minutes followed by 35 cycles of PCR with denature at 94\u00b0C for 1 minute, annealing at 54\u00b0C for 1 minute, extension at 72\u00b0C for 1 minute, and a fi nal 10-minute cycle at 72\u00b0C. A negative control consisting of sterile water and a positive control of HBoV capsid were included in each PCR run.", [["HBoV", "ORGANISM", 310, 314], ["HBoV", "SPECIES", 310, 314], ["PCR amplifi cation thermocycles", "TREATMENT", 0, 31], ["PCR", "TEST", 95, 98], ["denature", "TREATMENT", 104, 112], ["extension", "TEST", 167, 176], ["a fi nal", "TEST", 203, 211], ["sterile water", "TREATMENT", 270, 283], ["HBoV capsid", "PROBLEM", 310, 321], ["negative", "OBSERVATION", 239, 247]]], ["5 \u03bcl PCR product was mixed with 5 \u03bcl of loading buffer and subsequently separated on an ethidium bromide stained 1.5% agarose gel.", [["ethidium bromide", "CHEMICAL", 88, 104], ["ethidium bromide", "CHEMICAL", 88, 104], ["ethidium bromide", "SIMPLE_CHEMICAL", 88, 104], ["agarose", "SIMPLE_CHEMICAL", 118, 125], ["5 \u03bcl PCR product", "TREATMENT", 0, 16], ["loading buffer", "TREATMENT", 40, 54], ["an ethidium bromide", "TREATMENT", 85, 104], ["1.5% agarose gel", "TREATMENT", 113, 129]]], ["Gels were run for 20 minutes at 100 V in 0.5 \u00d7 TBE buffer and photographed under UV light with a digital camera.Frequencies of detection of HBoV and 7 common virusesThe demographic and clinical characteristics of patients are shown in Table 1 .", [["HBoV", "DISEASE", 140, 144], ["Gels", "SIMPLE_CHEMICAL", 0, 4], ["HBoV", "ORGANISM", 140, 144], ["patients", "ORGANISM", 213, 221], ["patients", "SPECIES", 213, 221], ["HBoV", "SPECIES", 140, 144], ["TBE buffer", "TREATMENT", 47, 57], ["HBoV", "PROBLEM", 140, 144], ["HBoV", "OBSERVATION", 140, 144]]], ["Among 351 nasopharyngeal aspirate samples obtained between 1 day and 25 days after onset of illness, 16 (4.6%) were ascertained to be HBoV positive through PCR assay and 3 (18.8%) were dual infection including 2 coinfection with RSV and 1 with PIV-3.", [["nasopharyngeal aspirate samples", "ANATOMY", 10, 41], ["illness", "DISEASE", 92, 99], ["infection", "DISEASE", 190, 199], ["coinfection", "DISEASE", 212, 223], ["RSV", "DISEASE", 229, 232], ["nasopharyngeal aspirate samples", "CANCER", 10, 41], ["HBoV", "ORGANISM", 134, 138], ["RSV", "ORGANISM", 229, 232], ["PIV-3", "GENE_OR_GENE_PRODUCT", 244, 249], ["HBoV", "SPECIES", 134, 138], ["RSV", "SPECIES", 229, 232], ["nasopharyngeal aspirate samples", "TEST", 10, 41], ["illness", "PROBLEM", 92, 99], ["HBoV", "TEST", 134, 138], ["PCR assay", "TEST", 156, 165], ["dual infection", "PROBLEM", 185, 199], ["2 coinfection", "PROBLEM", 210, 223], ["RSV", "PROBLEM", 229, 232], ["PIV", "TREATMENT", 244, 247], ["infection", "OBSERVATION", 190, 199]]], ["In 16 HBoV-positive samples, 15 were obtained within 7 days after occurrence of respiratory illness and 1 was obtained at 14 days after onset of symptoms.", [["samples", "ANATOMY", 20, 27], ["respiratory", "ANATOMY", 80, 91], ["respiratory illness", "DISEASE", 80, 99], ["HBoV", "ORGANISM", 6, 10], ["HBoV", "SPECIES", 6, 10], ["HBoV", "TEST", 6, 10], ["respiratory illness", "PROBLEM", 80, 99], ["symptoms", "PROBLEM", 145, 153], ["respiratory illness", "OBSERVATION", 80, 99]]], ["In addition, routine immunofl uorescence assay detected RSV in 116 (33.0%), IV in 11 (3.1%), PIV-3 in 11 (3.1%), ADV in 9 (2.6%), PIV-1 in 3 (0.9%), PIV-2 in 2 (0.9%), and RSV coinfection with ADV in 1 (0.3%).", [["RSV coinfection", "DISEASE", 172, 187], ["ADV", "CHEMICAL", 193, 196], ["RSV", "ORGANISM", 56, 59], ["PIV-3", "GENE_OR_GENE_PRODUCT", 93, 98], ["PIV-1", "GENE_OR_GENE_PRODUCT", 130, 135], ["RSV", "ORGANISM", 172, 175], ["RSV", "SPECIES", 56, 59], ["PIV-3", "SPECIES", 93, 98], ["ADV", "SPECIES", 113, 116], ["PIV-1", "SPECIES", 130, 135], ["PIV-2", "SPECIES", 149, 154], ["RSV", "SPECIES", 172, 175], ["ADV", "SPECIES", 193, 196], ["routine immunofl uorescence assay", "TEST", 13, 46], ["RSV", "TEST", 56, 59], ["IV", "TEST", 76, 78], ["PIV", "TEST", 93, 96], ["ADV", "TEST", 113, 116], ["PIV", "TEST", 130, 133], ["PIV", "TEST", 149, 152], ["RSV coinfection", "PROBLEM", 172, 187], ["ADV", "TREATMENT", 193, 196], ["PIV", "ANATOMY", 149, 152], ["RSV", "ANATOMY", 172, 175], ["coinfection", "OBSERVATION", 176, 187]]], ["Obviously, HBoV was the second most prevalent virus in this study after RSV.Frequencies of detection of HBoV and 7 common virusesAmong 351 NPA samples, 92 were collected in November 2006 and HBoV was detected in 6 (6.5%); 113 samples were collected in December 2006 and HBoV was detected in 6 (5.3%); 146 samples were collected in January 2007 and HBoV was detected in 4 (2.7%).", [["NPA samples", "ANATOMY", 139, 150], ["samples", "ANATOMY", 226, 233], ["samples", "ANATOMY", 305, 312], ["HBoV", "DISEASE", 104, 108], ["HBoV", "ORGANISM", 11, 15], ["RSV", "ORGANISM", 72, 75], ["HBoV", "ORGANISM", 104, 108], ["NPA samples", "CANCER", 139, 150], ["HBoV", "ORGANISM", 191, 195], ["samples", "CANCER", 226, 233], ["HBoV", "ORGANISM", 270, 274], ["samples", "CANCER", 305, 312], ["HBoV", "ORGANISM", 348, 352], ["HBoV", "SPECIES", 11, 15], ["RSV", "SPECIES", 72, 75], ["HBoV", "SPECIES", 104, 108], ["HBoV", "SPECIES", 191, 195], ["HBoV", "SPECIES", 270, 274], ["HBoV", "SPECIES", 348, 352], ["HBoV", "PROBLEM", 11, 15], ["this study", "TEST", 55, 65], ["RSV", "PROBLEM", 72, 75], ["HBoV", "PROBLEM", 104, 108], ["NPA samples", "TEST", 139, 150], ["HBoV", "TEST", 191, 195], ["HBoV", "TEST", 270, 274], ["samples", "TEST", 305, 312], ["HBoV", "TEST", 348, 352], ["HBoV", "OBSERVATION", 11, 15], ["HBoV", "OBSERVATION", 104, 108]]], ["Apparently there was a declining trend by month.Frequencies of detection of HBoV and 7 common virusesClinical fi ndings of HBoV-positive children HBoV was found in 8 (14.8%) of 54 patients with bronchitis, in 2 (12.5%) of 16 patients with asthma attack, and in 6 (2.3%) of 266 patients with pneumonia.", [["HBoV", "DISEASE", 76, 80], ["HBoV-positive", "DISEASE", 123, 136], ["HBoV", "DISEASE", 146, 150], ["bronchitis", "DISEASE", 194, 204], ["asthma", "DISEASE", 239, 245], ["pneumonia", "DISEASE", 291, 300], ["HBoV", "ORGANISM", 76, 80], ["HBoV", "ORGANISM", 123, 127], ["children", "ORGANISM", 137, 145], ["HBoV", "ORGANISM", 146, 150], ["patients", "ORGANISM", 180, 188], ["patients", "ORGANISM", 225, 233], ["patients", "ORGANISM", 277, 285], ["children", "SPECIES", 137, 145], ["patients", "SPECIES", 180, 188], ["patients", "SPECIES", 225, 233], ["patients", "SPECIES", 277, 285], ["HBoV", "SPECIES", 76, 80], ["HBoV", "SPECIES", 146, 150], ["HBoV", "PROBLEM", 76, 80], ["HBoV", "TEST", 123, 127], ["positive children HBoV", "PROBLEM", 128, 150], ["bronchitis", "PROBLEM", 194, 204], ["asthma attack", "PROBLEM", 239, 252], ["pneumonia", "PROBLEM", 291, 300], ["declining", "OBSERVATION_MODIFIER", 23, 32], ["trend", "OBSERVATION_MODIFIER", 33, 38], ["HBoV", "OBSERVATION", 76, 80], ["HBoV", "OBSERVATION", 123, 127], ["bronchitis", "OBSERVATION", 194, 204], ["asthma", "OBSERVATION", 239, 245], ["pneumonia", "OBSERVATION", 291, 300]]], ["HBoV was detected in 10 (6.8%) of 148 children with acute wheezing and all 10 HBoV-positive children with wheezing were due to CA infection rather than HA infection.", [["HBoV", "DISEASE", 0, 4], ["wheezing", "DISEASE", 58, 66], ["HBoV-positive", "DISEASE", 78, 91], ["wheezing", "DISEASE", 106, 114], ["infection", "DISEASE", 130, 139], ["HA infection", "DISEASE", 152, 164], ["HBoV", "ORGANISM", 0, 4], ["children", "ORGANISM", 38, 46], ["HBoV", "ORGANISM", 78, 82], ["children", "ORGANISM", 92, 100], ["CA", "GENE_OR_GENE_PRODUCT", 127, 129], ["children", "SPECIES", 38, 46], ["children", "SPECIES", 92, 100], ["HBoV", "SPECIES", 0, 4], ["HBoV", "PROBLEM", 0, 4], ["acute wheezing", "PROBLEM", 52, 66], ["wheezing", "PROBLEM", 106, 114], ["CA infection", "PROBLEM", 127, 139], ["HA infection", "PROBLEM", 152, 164], ["acute", "OBSERVATION_MODIFIER", 52, 57], ["wheezing", "OBSERVATION", 58, 66], ["infection", "OBSERVATION", 130, 139], ["infection", "OBSERVATION", 155, 164]]], ["Among 16 HBoV-positive children, 11 were CA infection and 5 were HA infection; 6 children were diagnosed with CA pneumonia (4 with sole infection and 2 coinfected with RSV and PIV-3, respectively), 3 with CA bronchitis (2 with sole infection and 1 coinfected with RSV), 2 with bronchial asthma exacerbation, and 5 with HA bronchitis without other seven viruses co-detected.Frequencies of detection of HBoV and 7 common virusesThe HBoV-positive children were 1.7 to 43 months of age (mean: 13.7 months; median: 13 months).", [["HBoV-positive", "DISEASE", 9, 22], ["infection", "DISEASE", 44, 53], ["HA infection", "DISEASE", 65, 77], ["pneumonia", "DISEASE", 113, 122], ["infection", "DISEASE", 136, 145], ["CA bronchitis", "DISEASE", 205, 218], ["sole infection", "DISEASE", 227, 241], ["RSV", "DISEASE", 264, 267], ["bronchial asthma exacerbation", "DISEASE", 277, 306], ["HA bronchitis", "DISEASE", 319, 332], ["HBoV", "DISEASE", 401, 405], ["HBoV", "ORGANISM", 9, 13], ["children", "ORGANISM", 23, 31], ["CA", "GENE_OR_GENE_PRODUCT", 41, 43], ["children", "ORGANISM", 81, 89], ["RSV", "ORGANISM", 168, 171], ["RSV", "ORGANISM", 264, 267], ["HBoV", "ORGANISM", 401, 405], ["HBoV", "ORGANISM", 430, 434], ["children", "ORGANISM", 444, 452], ["children", "SPECIES", 23, 31], ["children", "SPECIES", 81, 89], ["children", "SPECIES", 444, 452], ["RSV", "SPECIES", 168, 171], ["RSV", "SPECIES", 264, 267], ["HBoV", "SPECIES", 401, 405], ["HBoV", "TEST", 9, 13], ["CA infection", "PROBLEM", 41, 53], ["HA infection", "PROBLEM", 65, 77], ["CA pneumonia", "PROBLEM", 110, 122], ["sole infection", "PROBLEM", 131, 145], ["RSV and PIV", "TREATMENT", 168, 179], ["CA bronchitis", "PROBLEM", 205, 218], ["sole infection", "PROBLEM", 227, 241], ["RSV", "PROBLEM", 264, 267], ["bronchial asthma exacerbation", "PROBLEM", 277, 306], ["HA bronchitis", "PROBLEM", 319, 332], ["other seven viruses co-detected", "PROBLEM", 341, 372], ["HBoV", "PROBLEM", 401, 405], ["pneumonia", "OBSERVATION", 113, 122], ["bronchitis", "OBSERVATION", 208, 218], ["infection", "OBSERVATION", 232, 241], ["bronchial", "ANATOMY", 277, 286], ["asthma", "OBSERVATION", 287, 293], ["bronchitis", "OBSERVATION", 322, 332], ["viruses", "OBSERVATION", 353, 360], ["HBoV", "OBSERVATION", 401, 405]]], ["Five (31.3%) of 16 cases were <6 months old, 7 (43.8%) <12 months old, 13 (81.3%) <24 months old, 15 (93.8%) <36 months old, and all (100%) were younger than 48 months old.Frequencies of detection of HBoV and 7 common virusesAll (100%) of the HBoV-positive children had a cough, 68.8% (11/16) had wheezing, and 62.5% (10/16) were febrile.", [["HBoV-positive", "DISEASE", 243, 256], ["cough", "DISEASE", 272, 277], ["wheezing", "DISEASE", 297, 305], ["febrile", "DISEASE", 330, 337], ["HBoV", "ORGANISM", 200, 204], ["HBoV", "ORGANISM", 243, 247], ["children", "ORGANISM", 257, 265], ["children", "SPECIES", 257, 265], ["HBoV", "SPECIES", 200, 204], ["HBoV", "PROBLEM", 200, 204], ["7 common viruses", "PROBLEM", 209, 225], ["the HBoV", "TEST", 239, 247], ["a cough", "PROBLEM", 270, 277], ["wheezing", "PROBLEM", 297, 305], ["febrile", "PROBLEM", 330, 337], ["HBoV", "OBSERVATION", 200, 204]]], ["14 children were tested with white blood cell (WBC) and C-reaction protein (CRP) in peripheral blood.", [["white blood cell", "ANATOMY", 29, 45], ["WBC", "ANATOMY", 47, 50], ["peripheral blood", "ANATOMY", 84, 100], ["children", "ORGANISM", 3, 11], ["white blood cell", "CELL", 29, 45], ["WBC", "CELL", 47, 50], ["C-reaction protein", "GENE_OR_GENE_PRODUCT", 56, 74], ["CRP", "GENE_OR_GENE_PRODUCT", 76, 79], ["peripheral blood", "ORGANISM_SUBSTANCE", 84, 100], ["white blood cell", "CELL_TYPE", 29, 45], ["WBC", "CELL_TYPE", 47, 50], ["C-reaction protein", "PROTEIN", 56, 74], ["CRP", "PROTEIN", 76, 79], ["children", "SPECIES", 3, 11], ["white blood cell", "TEST", 29, 45], ["WBC", "TEST", 47, 50], ["C-reaction protein", "TEST", 56, 74], ["CRP", "TEST", 76, 79], ["peripheral blood", "TEST", 84, 100], ["peripheral", "ANATOMY_MODIFIER", 84, 94], ["blood", "ANATOMY", 95, 100]]], ["WBC was in the range of 4.6\u00d710 9 /L and 25.5\u00d7 10 9 /L and most patients had normal WBC.", [["WBC", "ANATOMY", 0, 3], ["WBC", "ANATOMY", 83, 86], ["WBC", "CELL", 0, 3], ["patients", "ORGANISM", 63, 71], ["WBC", "CELL_TYPE", 0, 3], ["WBC", "CELL_TYPE", 83, 86], ["patients", "SPECIES", 63, 71], ["WBC", "TEST", 0, 3], ["normal WBC", "OBSERVATION", 76, 86]]], ["CRP ranged from <8 mg/L to 30 mg/L. Chest radiography revealed patchy or interstitial infi ltrates in HBoV-positive patients with pneumonia (Table 2 ).DiscussionHBoV has been frequently found to circulate among children from the community while HBoV-related nosocomial infection has rarely been reported.", [["interstitial", "ANATOMY", 73, 85], ["HBoV-positive", "DISEASE", 102, 115], ["pneumonia", "DISEASE", 130, 139], ["DiscussionHBoV", "CHEMICAL", 151, 165], ["HBoV", "DISEASE", 245, 249], ["nosocomial infection", "DISEASE", 258, 278], ["CRP", "GENE_OR_GENE_PRODUCT", 0, 3], ["HBoV", "ORGANISM", 102, 106], ["patients", "ORGANISM", 116, 124], ["children", "ORGANISM", 211, 219], ["HBoV", "ORGANISM", 245, 249], ["CRP", "PROTEIN", 0, 3], ["patients", "SPECIES", 116, 124], ["children", "SPECIES", 211, 219], ["CRP", "TEST", 0, 3], ["Chest radiography", "TEST", 36, 53], ["patchy or interstitial infi ltrates", "PROBLEM", 63, 98], ["HBoV", "PROBLEM", 102, 106], ["pneumonia", "PROBLEM", 130, 139], ["HBoV", "PROBLEM", 245, 249], ["nosocomial infection", "PROBLEM", 258, 278], ["Chest", "ANATOMY", 36, 41], ["patchy", "OBSERVATION_MODIFIER", 63, 69], ["interstitial", "ANATOMY_MODIFIER", 73, 85], ["HBoV", "OBSERVATION", 102, 106], ["positive", "OBSERVATION_MODIFIER", 107, 115], ["pneumonia", "OBSERVATION", 130, 139], ["nosocomial", "OBSERVATION_MODIFIER", 258, 268], ["infection", "OBSERVATION", 269, 278]]], ["In this study, we found HBoV is a common viral agent in the respiratory samples from symptomatic children.", [["respiratory samples", "ANATOMY", 60, 79], ["HBoV", "ORGANISM", 24, 28], ["children", "ORGANISM", 97, 105], ["children", "SPECIES", 97, 105], ["HBoV", "SPECIES", 24, 28], ["this study", "TEST", 3, 13], ["HBoV", "PROBLEM", 24, 28], ["HBoV", "OBSERVATION", 24, 28], ["respiratory", "ANATOMY", 60, 71]]], ["Kesebir et al [11] reported HBoV was detected in 3 (14%) of 22 infants with presumed nosocomial respiratory infection.", [["respiratory", "ANATOMY", 96, 107], ["HBoV", "DISEASE", 28, 32], ["nosocomial respiratory infection", "DISEASE", 85, 117], ["HBoV", "ORGANISM", 28, 32], ["infants", "ORGANISM", 63, 70], ["infants", "SPECIES", 63, 70], ["HBoV", "SPECIES", 28, 32], ["HBoV", "TEST", 28, 32], ["nosocomial respiratory infection", "PROBLEM", 85, 117], ["presumed", "UNCERTAINTY", 76, 84], ["nosocomial", "OBSERVATION_MODIFIER", 85, 95], ["respiratory", "ANATOMY", 96, 107], ["infection", "OBSERVATION", 108, 117]]], ["Similarly, our present study found HBoV was detected in 5 (19.2%) of 26 inpatients who developed nosocomial ARTI.", [["ARTI", "DISEASE", 108, 112], ["HBoV", "ORGANISM", 35, 39], ["inpatients", "ORGANISM", 72, 82], ["HBoV", "SPECIES", 35, 39], ["our present study", "TEST", 11, 28], ["HBoV", "TEST", 35, 39], ["nosocomial ARTI", "PROBLEM", 97, 112], ["HBoV", "OBSERVATION", 35, 39], ["nosocomial ARTI", "OBSERVATION", 97, 112]]], ["In 5 HBoV-positive children with nosocomial infection, 7 common viruses were not detected coincidently.", [["HBoV-positive", "DISEASE", 5, 18], ["nosocomial infection", "DISEASE", 33, 53], ["HBoV", "ORGANISM", 5, 9], ["children", "ORGANISM", 19, 27], ["children", "SPECIES", 19, 27], ["nosocomial infection", "PROBLEM", 33, 53], ["7 common viruses", "PROBLEM", 55, 71], ["positive children", "OBSERVATION_MODIFIER", 10, 27], ["nosocomial", "OBSERVATION_MODIFIER", 33, 43], ["infection", "OBSERVATION", 44, 53]]], ["Particularly 2 HBoV positive patients had HBoV detected only in their second samples collected during the episode of nosocomial infection; however, their fi rst controlled samples obtained at admission were HBoV negative.", [["samples", "ANATOMY", 77, 84], ["samples", "ANATOMY", 172, 179], ["nosocomial infection", "DISEASE", 117, 137], ["HBoV", "ORGANISM", 15, 19], ["patients", "ORGANISM", 29, 37], ["HBoV", "ORGANISM", 42, 46], ["HBoV", "ORGANISM", 207, 211], ["patients", "SPECIES", 29, 37], ["HBoV", "SPECIES", 42, 46], ["HBoV", "PROBLEM", 42, 46], ["nosocomial infection", "PROBLEM", 117, 137], ["HBoV", "TEST", 207, 211], ["nosocomial", "OBSERVATION_MODIFIER", 117, 127], ["infection", "OBSERVATION", 128, 137]]], ["Hence, it is reasonable to suggest that HBoV is very likely to play a pathogenic role in patients with nosocomial ARTI.DiscussionIn our study, HBoV was positive in 4.6% of nasopharyngeal aspirates from hospitalized children with ARTI.", [["nasopharyngeal aspirates", "ANATOMY", 172, 196], ["HBoV", "DISEASE", 40, 44], ["ARTI", "DISEASE", 114, 118], ["ARTI", "DISEASE", 229, 233], ["HBoV", "ORGANISM", 40, 44], ["patients", "ORGANISM", 89, 97], ["HBoV", "ORGANISM", 143, 147], ["nasopharyngeal aspirates", "MULTI-TISSUE_STRUCTURE", 172, 196], ["children", "ORGANISM", 215, 223], ["patients", "SPECIES", 89, 97], ["children", "SPECIES", 215, 223], ["HBoV", "SPECIES", 40, 44], ["HBoV", "SPECIES", 143, 147], ["HBoV", "PROBLEM", 40, 44], ["nosocomial ARTI", "PROBLEM", 103, 118], ["our study", "TEST", 132, 141], ["HBoV", "TEST", 143, 147], ["nasopharyngeal aspirates", "PROBLEM", 172, 196], ["ARTI", "PROBLEM", 229, 233], ["HBoV", "OBSERVATION", 40, 44], ["nasopharyngeal", "ANATOMY", 172, 186], ["aspirates", "OBSERVATION", 187, 196]]], ["The proportion of positive HBoV ranged from 1.5% to 19.3% in respiratory samples from symptomatic patients.", [["respiratory samples", "ANATOMY", 61, 80], ["HBoV", "ORGANISM", 27, 31], ["patients", "ORGANISM", 98, 106], ["patients", "SPECIES", 98, 106], ["HBoV", "SPECIES", 27, 31], ["positive HBoV", "PROBLEM", 18, 31], ["positive", "OBSERVATION_MODIFIER", 18, 26], ["HBoV", "OBSERVATION", 27, 31]]], ["[6, 30] Obviously, the incidence of HBoV infection varied with region and time.", [["HBoV infection", "DISEASE", 36, 50], ["HBoV", "ORGANISM", 36, 40], ["HBoV", "SPECIES", 36, 40], ["HBoV infection", "PROBLEM", 36, 50], ["HBoV", "OBSERVATION", 36, 40], ["infection", "OBSERVATION", 41, 50]]], ["Among the viruses detected in this study, HBoV was the second most common virus after RSV.", [["HBoV", "ORGANISM", 42, 46], ["RSV", "ORGANISM", 86, 89], ["HBoV", "SPECIES", 42, 46], ["RSV", "SPECIES", 86, 89], ["the viruses", "PROBLEM", 6, 17], ["this study", "TEST", 30, 40], ["HBoV", "PROBLEM", 42, 46], ["RSV", "PROBLEM", 86, 89], ["viruses", "OBSERVATION", 10, 17]]], ["This fi nding is consistent with that reported by Weissbrich and Catalano-Pons who used the same protocol of virus detection in their studies.", [["virus detection", "TEST", 109, 124], ["consistent with", "UNCERTAINTY", 17, 32]]], ["[8, 31] Nevertheless, we can not conclude that HBoV is more prevalent than IV, PIV and ADV because World Journal of PediatricsOriginal articlethe sensitivity of methods for viral diagnosis is different and PCR is more sensitive than immunofl uorescence assay.", [["HBoV", "DISEASE", 47, 51], ["HBoV", "ORGANISM", 47, 51], ["HBoV", "SPECIES", 47, 51], ["PIV", "SPECIES", 79, 82], ["ADV", "SPECIES", 87, 90], ["HBoV", "PROBLEM", 47, 51], ["IV", "TREATMENT", 75, 77], ["PIV", "TREATMENT", 79, 82], ["ADV", "TREATMENT", 87, 90], ["viral diagnosis", "TEST", 173, 188], ["PCR", "TEST", 206, 209]]], ["[32] Previous studies reported that HBoV coinfection with other respiratory viruses was common with a frequency of 18% to 90%.", [["HBoV coinfection", "DISEASE", 36, 52], ["respiratory viruses", "DISEASE", 64, 83], ["HBoV", "ORGANISM", 36, 40], ["Previous studies", "TEST", 5, 21], ["HBoV coinfection", "PROBLEM", 36, 52], ["other respiratory viruses", "PROBLEM", 58, 83], ["HBoV coinfection", "OBSERVATION", 36, 52], ["respiratory", "ANATOMY", 64, 75], ["viruses", "OBSERVATION", 76, 83]]], ["[3, 15] In this study, 16.7% of HBoV-positive samples were coinfected with RSV and PIV-3, which is lower than the previous report.", [["samples", "ANATOMY", 46, 53], ["HBoV", "ORGANISM", 32, 36], ["RSV", "ORGANISM", 75, 78], ["HBoV", "SPECIES", 32, 36], ["RSV", "SPECIES", 75, 78], ["this study", "TEST", 11, 21], ["HBoV", "TEST", 32, 36], ["RSV", "TREATMENT", 75, 78], ["PIV", "TREATMENT", 83, 86], ["lower", "OBSERVATION_MODIFIER", 99, 104]]], ["The difference of enrolled subjects, study period, geographic area, disease spectrum, and diagnostic assay may lead to varied results.", [["disease spectrum", "TEST", 68, 84], ["diagnostic assay", "TEST", 90, 106]]], ["Our study may underestimate the overall HBoV coinfection.", [["HBoV coinfection", "DISEASE", 40, 56], ["HBoV", "ORGANISM", 40, 44], ["Our study", "TEST", 0, 9], ["the overall HBoV coinfection", "PROBLEM", 28, 56], ["overall", "OBSERVATION_MODIFIER", 32, 39], ["HBoV coinfection", "OBSERVATION", 40, 56]]], ["A few known respiratory viruses such as human metapneumovirus and rhinovirus were not tested in our study.", [["respiratory viruses", "DISEASE", 12, 31], ["human metapneumovirus and rhinovirus", "DISEASE", 40, 76], ["human", "ORGANISM", 40, 45], ["metapneumovirus", "ORGANISM", 46, 61], ["rhinovirus", "ORGANISM", 66, 76], ["human", "SPECIES", 40, 45], ["metapneumovirus", "SPECIES", 46, 61], ["human metapneumovirus", "SPECIES", 40, 61], ["A few known respiratory viruses", "PROBLEM", 0, 31], ["human metapneumovirus", "PROBLEM", 40, 61], ["rhinovirus", "PROBLEM", 66, 76], ["our study", "TEST", 96, 105], ["few", "OBSERVATION_MODIFIER", 2, 5], ["respiratory viruses", "OBSERVATION", 12, 31], ["metapneumovirus", "OBSERVATION", 46, 61], ["rhinovirus", "OBSERVATION", 66, 76]]], ["On the other hand, less sensitive immunofl uorescence assay was used to screen seven common viruses.Original articleSeasonal variation of HBoV prevalence has been shown.", [["HBoV", "DISEASE", 138, 142], ["HBoV", "ORGANISM", 138, 142], ["HBoV", "SPECIES", 138, 142], ["HBoV prevalence", "PROBLEM", 138, 153], ["articleSeasonal variation", "OBSERVATION", 109, 134], ["HBoV prevalence", "OBSERVATION", 138, 153]]], ["A higher prevalence of HBoV infection Table 2 .", [["HBoV infection", "DISEASE", 23, 37], ["HBoV", "ORGANISM", 23, 27], ["HBoV", "SPECIES", 23, 27], ["HBoV infection Table", "PROBLEM", 23, 43], ["higher", "OBSERVATION_MODIFIER", 2, 8], ["HBoV infection", "OBSERVATION", 23, 37]]], ["Demographic and clinical characteristics of 16 HBoV-positive children All described clinical data were extracted from the medical records. \"+\": presence, \"-\": absence. *: HBoV-related HA illness; \u2020: For patients with CA pneumonia and CA bronchitis, chest X-ray was taken before or after admission; for inpatients diagnosed with nosocomial respiratory tract infection, chest X-ray was repeated if the fi rst report indicated pneumonia. \u2021: These two patients were presented to intensive care for treatment; \u00a7: This patient was admitted to intensive care center and fi nally died from respiratory failure and cardiac failure due to severe congenital heart disease (ventricular septal defect and aortic stenosis) and pneumonia; ||: These two patients had two nasopharyngeal aspirates obtained.", [["respiratory tract", "ANATOMY", 339, 356], ["respiratory", "ANATOMY", 582, 593], ["cardiac", "ANATOMY", 606, 613], ["heart", "ANATOMY", 647, 652], ["ventricular septal", "ANATOMY", 662, 680], ["aortic", "ANATOMY", 692, 698], ["nasopharyngeal aspirates", "ANATOMY", 755, 779], ["HBoV-positive", "DISEASE", 47, 60], ["HA illness", "DISEASE", 184, 194], ["pneumonia", "DISEASE", 220, 229], ["bronchitis", "DISEASE", 237, 247], ["nosocomial respiratory tract infection", "DISEASE", 328, 366], ["pneumonia", "DISEASE", 424, 433], ["respiratory failure", "DISEASE", 582, 601], ["cardiac failure", "DISEASE", 606, 621], ["congenital heart disease", "DISEASE", 636, 660], ["ventricular septal defect and aortic stenosis", "DISEASE", 662, 707], ["pneumonia", "DISEASE", 713, 722], ["HBoV", "ORGANISM", 47, 51], ["children", "ORGANISM", 61, 69], ["HBoV", "ORGANISM", 171, 175], ["patients", "ORGANISM", 203, 211], ["tract", "ORGANISM_SUBDIVISION", 351, 356], ["patients", "ORGANISM", 448, 456], ["patient", "ORGANISM", 513, 520], ["cardiac", "ORGAN", 606, 613], ["heart", "ORGAN", 647, 652], ["ventricular septal", "MULTI-TISSUE_STRUCTURE", 662, 680], ["aortic", "MULTI-TISSUE_STRUCTURE", 692, 698], ["patients", "ORGANISM", 738, 746], ["nasopharyngeal aspirates", "MULTI-TISSUE_STRUCTURE", 755, 779], ["children", "SPECIES", 61, 69], ["patients", "SPECIES", 203, 211], ["patients", "SPECIES", 448, 456], ["patient", "SPECIES", 513, 520], ["patients", "SPECIES", 738, 746], ["HBoV", "TEST", 47, 51], ["HBoV", "PROBLEM", 171, 175], ["CA pneumonia", "PROBLEM", 217, 229], ["CA bronchitis", "PROBLEM", 234, 247], ["chest X-ray", "TEST", 249, 260], ["nosocomial respiratory tract infection", "PROBLEM", 328, 366], ["chest X-ray", "TEST", 368, 379], ["pneumonia", "PROBLEM", 424, 433], ["treatment", "TREATMENT", 494, 503], ["respiratory failure", "PROBLEM", 582, 601], ["cardiac failure", "PROBLEM", 606, 621], ["severe congenital heart disease", "PROBLEM", 629, 660], ["ventricular septal defect", "PROBLEM", 662, 687], ["aortic stenosis)", "PROBLEM", 692, 708], ["pneumonia", "PROBLEM", 713, 722], ["two nasopharyngeal aspirates", "TEST", 751, 779], ["HBoV", "OBSERVATION", 171, 175], ["pneumonia", "OBSERVATION", 220, 229], ["bronchitis", "OBSERVATION", 237, 247], ["chest", "ANATOMY", 249, 254], ["respiratory tract", "ANATOMY", 339, 356], ["chest", "ANATOMY", 368, 373], ["pneumonia", "OBSERVATION", 424, 433], ["respiratory failure", "OBSERVATION", 582, 601], ["cardiac", "ANATOMY", 606, 613], ["failure", "OBSERVATION", 614, 621], ["severe", "OBSERVATION_MODIFIER", 629, 635], ["congenital", "OBSERVATION", 636, 646], ["heart", "ANATOMY", 647, 652], ["disease", "OBSERVATION", 653, 660], ["ventricular septal", "ANATOMY", 662, 680], ["defect", "OBSERVATION", 681, 687], ["aortic", "ANATOMY", 692, 698], ["stenosis", "OBSERVATION", 699, 707], ["pneumonia", "OBSERVATION", 713, 722], ["nasopharyngeal", "ANATOMY", 755, 769], ["aspirates", "OBSERVATION", 770, 779]]], ["The fi rst samples from both were HBoV-negative at admission and the second samples from both were HBoV-positive after occurrence of nosocomial infection.CaseNo.", [["rst samples", "ANATOMY", 7, 18], ["samples", "ANATOMY", 76, 83], ["nosocomial infection", "DISEASE", 133, 153], ["fi rst samples", "CANCER", 4, 18], ["HBoV", "ORGANISM", 34, 38], ["HBoV", "ORGANISM", 99, 103], ["HBoV", "SPECIES", 99, 103], ["The fi rst samples", "TEST", 0, 18], ["HBoV", "TEST", 34, 38], ["the second samples", "TEST", 65, 83], ["HBoV", "TEST", 99, 103], ["nosocomial infection", "PROBLEM", 133, 153], ["nosocomial", "OBSERVATION_MODIFIER", 133, 143], ["infection", "OBSERVATION", 144, 153]]], ["[3, 8, 9, 11, 12, 14, 16, 20, 33] Two studies from Italy and Canada did not observe seasonal activity of HBoV.", [["HBoV", "DISEASE", 105, 109], ["8, 9, 11, 12, 14, 16, 20, 33]", "SIMPLE_CHEMICAL", 4, 33], ["HBoV", "ORGANISM", 105, 109], ["HBoV", "SPECIES", 105, 109], ["Two studies", "TEST", 34, 45], ["HBoV", "PROBLEM", 105, 109], ["HBoV", "OBSERVATION", 105, 109]]], ["[6, 19] Because our study spanned only a winter season in Shanghai, we cannot describe the seasonality of HBoV in Shanghai.", [["HBoV", "DISEASE", 106, 110], ["HBoV", "ORGANISM", 106, 110], ["HBoV", "SPECIES", 106, 110], ["our study", "TEST", 16, 25], ["HBoV", "PROBLEM", 106, 110], ["HBoV", "OBSERVATION", 106, 110]]], ["HBoV can be found in respiratory samples from pediatric and adult patients, but mainly in children.", [["respiratory samples", "ANATOMY", 21, 40], ["HBoV", "ORGANISM", 0, 4], ["respiratory samples", "CANCER", 21, 40], ["patients", "ORGANISM", 66, 74], ["children", "ORGANISM", 90, 98], ["patients", "SPECIES", 66, 74], ["children", "SPECIES", 90, 98], ["HBoV", "SPECIES", 0, 4], ["HBoV", "PROBLEM", 0, 4]]], ["[6, 16, 19, 34] Most HBoV-infected patients are younger than 5 years old.", [["HBoV-infected", "DISEASE", 21, 34], ["[6, 16, 19, 34", "SIMPLE_CHEMICAL", 0, 14], ["HBoV", "ORGANISM", 21, 25], ["patients", "ORGANISM", 35, 43], ["patients", "SPECIES", 35, 43], ["infected", "OBSERVATION", 26, 34]]], ["[6, 16, 20, 21, 35] In this study, HBoV-positive inpatients were younger than 4 years, as reported previously.", [["HBoV", "ORGANISM", 35, 39], ["inpatients", "ORGANISM", 49, 59], ["this study", "TEST", 23, 33], ["HBoV", "TEST", 35, 39]]], ["Studies from Japan and America revealed that the HBoV-seropositive rate increases with age after 6 months and most children have been exposed to HBoV before school-age.", [["HBoV", "DISEASE", 145, 149], ["HBoV", "ORGANISM", 49, 53], ["children", "ORGANISM", 115, 123], ["HBoV", "ORGANISM", 145, 149], ["children", "SPECIES", 115, 123], ["HBoV", "SPECIES", 145, 149], ["the HBoV", "TEST", 45, 53], ["HBoV", "OBSERVATION", 49, 53]]], ["[24, 25] We speculate that infants and young children are most susceptible to HBoV infection, but none of the neonates with pneumonia in our study was found to be HBoV-positive.", [["HBoV infection", "DISEASE", 78, 92], ["pneumonia", "DISEASE", 124, 133], ["infants", "ORGANISM", 27, 34], ["children", "ORGANISM", 45, 53], ["HBoV", "ORGANISM", 78, 82], ["neonates", "ORGANISM", 110, 118], ["HBoV", "ORGANISM", 163, 167], ["infants", "SPECIES", 27, 34], ["children", "SPECIES", 45, 53], ["HBoV", "SPECIES", 78, 82], ["HBoV infection", "PROBLEM", 78, 92], ["the neonates", "PROBLEM", 106, 118], ["pneumonia", "PROBLEM", 124, 133], ["our study", "TEST", 137, 146], ["HBoV", "TEST", 163, 167], ["infection", "OBSERVATION", 83, 92], ["pneumonia", "OBSERVATION", 124, 133], ["positive", "OBSERVATION", 168, 176]]], ["Kahn et al [25] found 91.8% of serum specimens from infants in the fi rst month of life were HBoV seropositive.", [["serum specimens", "ANATOMY", 31, 46], ["serum specimens", "ORGANISM_SUBSTANCE", 31, 46], ["infants", "ORGANISM", 52, 59], ["HBoV", "ORGANISM", 93, 97], ["infants", "SPECIES", 52, 59], ["HBoV", "SPECIES", 93, 97], ["serum specimens", "TEST", 31, 46], ["HBoV seropositive", "PROBLEM", 93, 110]]], ["Maternal IgG could aid to prevent neonates from acquiring HBoV infection.Type of infectionHBoV has been detected in children with upper and lower respiratory tract infections and acute wheezing.", [["lower respiratory tract", "ANATOMY", 140, 163], ["HBoV infection", "DISEASE", 58, 72], ["respiratory tract infections", "DISEASE", 146, 174], ["wheezing", "DISEASE", 185, 193], ["IgG", "GENE_OR_GENE_PRODUCT", 9, 12], ["neonates", "ORGANISM", 34, 42], ["HBoV", "ORGANISM", 58, 62], ["children", "ORGANISM", 116, 124], ["upper", "ORGANISM_SUBDIVISION", 130, 135], ["tract", "ORGANISM_SUBDIVISION", 158, 163], ["IgG", "PROTEIN", 9, 12], ["children", "SPECIES", 116, 124], ["HBoV", "SPECIES", 58, 62], ["Maternal IgG", "TREATMENT", 0, 12], ["neonates", "PROBLEM", 34, 42], ["acquiring HBoV infection", "PROBLEM", 48, 72], ["Type of infectionHBoV", "PROBLEM", 73, 94], ["upper and lower respiratory tract infections", "PROBLEM", 130, 174], ["acute wheezing", "PROBLEM", 179, 193], ["infection", "OBSERVATION", 63, 72], ["upper", "ANATOMY_MODIFIER", 130, 135], ["lower", "ANATOMY_MODIFIER", 140, 145], ["respiratory tract", "ANATOMY", 146, 163], ["infections", "OBSERVATION", 164, 174], ["acute", "OBSERVATION_MODIFIER", 179, 184], ["wheezing", "OBSERVATION", 185, 193]]], ["[10, 16, [20] [21] 23, 33, 35, 36] Since a few children had upper respiratory tract infection in our study cohort, we only observed that HBoV is associated with lower respiratory tract infection.", [["upper respiratory tract", "ANATOMY", 60, 83], ["respiratory tract", "ANATOMY", 167, 184], ["respiratory tract infection", "DISEASE", 66, 93], ["HBoV", "DISEASE", 137, 141], ["respiratory tract infection", "DISEASE", 167, 194], ["children", "ORGANISM", 47, 55], ["upper respiratory", "ORGANISM_SUBDIVISION", 60, 77], ["tract", "ORGANISM_SUBDIVISION", 78, 83], ["HBoV", "ORGANISM", 137, 141], ["respiratory tract", "ORGANISM_SUBDIVISION", 167, 184], ["children", "SPECIES", 47, 55], ["HBoV", "SPECIES", 137, 141], ["upper respiratory tract infection", "PROBLEM", 60, 93], ["HBoV", "PROBLEM", 137, 141], ["lower respiratory tract infection", "PROBLEM", 161, 194], ["upper", "ANATOMY_MODIFIER", 60, 65], ["respiratory tract", "ANATOMY", 66, 83], ["infection", "OBSERVATION", 84, 93], ["HBoV", "OBSERVATION", 137, 141], ["lower", "ANATOMY_MODIFIER", 161, 166], ["respiratory tract", "ANATOMY", 167, 184], ["infection", "OBSERVATION", 185, 194]]], ["Most of HBoV-positive children with CA infection suffered from acute wheezing, whereas all HBoV-positive children with nosocomial ARTI did not present wheezing.", [["HBoV-positive", "DISEASE", 8, 21], ["CA infection", "DISEASE", 36, 48], ["wheezing", "DISEASE", 69, 77], ["HBoV-positive", "DISEASE", 91, 104], ["ARTI", "DISEASE", 130, 134], ["wheezing", "DISEASE", 151, 159], ["HBoV", "ORGANISM", 8, 12], ["children", "ORGANISM", 22, 30], ["CA", "GENE_OR_GENE_PRODUCT", 36, 38], ["HBoV", "ORGANISM", 91, 95], ["children", "ORGANISM", 105, 113], ["children", "SPECIES", 22, 30], ["children", "SPECIES", 105, 113], ["HBoV", "SPECIES", 91, 95], ["HBoV", "PROBLEM", 8, 12], ["CA infection", "PROBLEM", 36, 48], ["acute wheezing", "PROBLEM", 63, 77], ["nosocomial ARTI", "PROBLEM", 119, 134], ["wheezing", "PROBLEM", 151, 159], ["positive children", "OBSERVATION_MODIFIER", 13, 30], ["infection", "OBSERVATION", 39, 48], ["acute", "OBSERVATION_MODIFIER", 63, 68], ["wheezing", "OBSERVATION", 69, 77], ["wheezing", "OBSERVATION", 151, 159]]], ["Whether other viruses especially rhinovirus we had not tested were co-pathogenic for our patients with acute wheezing deserves further investigation.", [["wheezing", "DISEASE", 109, 117], ["rhinovirus", "ORGANISM", 33, 43], ["patients", "ORGANISM", 89, 97], ["patients", "SPECIES", 89, 97], ["other viruses", "PROBLEM", 8, 21], ["rhinovirus", "PROBLEM", 33, 43], ["acute wheezing", "PROBLEM", 103, 117], ["further investigation", "TEST", 127, 148], ["viruses", "OBSERVATION", 14, 21], ["acute", "OBSERVATION_MODIFIER", 103, 108], ["wheezing", "OBSERVATION", 109, 117]]], ["Allander and colleagues [23] reported that HBoV was prevalent in 19% of children with acute wheezing but only 5% of the children had HBoV detected alone.", [["HBoV", "DISEASE", 43, 47], ["wheezing", "DISEASE", 92, 100], ["HBoV", "DISEASE", 133, 137], ["HBoV", "ORGANISM", 43, 47], ["children", "ORGANISM", 72, 80], ["children", "ORGANISM", 120, 128], ["HBoV", "ORGANISM", 133, 137], ["children", "SPECIES", 72, 80], ["children", "SPECIES", 120, 128], ["HBoV", "SPECIES", 43, 47], ["HBoV", "SPECIES", 133, 137], ["HBoV", "PROBLEM", 43, 47], ["acute wheezing", "PROBLEM", 86, 100], ["HBoV", "PROBLEM", 133, 137], ["acute", "OBSERVATION_MODIFIER", 86, 91], ["wheezing", "OBSERVATION", 92, 100]]], ["We are not sure that HBoV is a major virus triggering acute wheezing for our children.Type of infectionThe role of HBoV in respiratory tract diseases is still controversial.", [["respiratory tract", "ANATOMY", 123, 140], ["HBoV", "DISEASE", 21, 25], ["wheezing", "DISEASE", 60, 68], ["infection", "DISEASE", 94, 103], ["HBoV", "DISEASE", 115, 119], ["respiratory tract diseases", "DISEASE", 123, 149], ["HBoV", "ORGANISM", 21, 25], ["children", "ORGANISM", 77, 85], ["HBoV", "ORGANISM", 115, 119], ["respiratory tract", "ORGANISM_SUBDIVISION", 123, 140], ["children", "SPECIES", 77, 85], ["HBoV", "SPECIES", 21, 25], ["HBoV", "PROBLEM", 21, 25], ["acute wheezing", "PROBLEM", 54, 68], ["Type of infection", "PROBLEM", 86, 103], ["HBoV in respiratory tract diseases", "PROBLEM", 115, 149], ["acute", "OBSERVATION_MODIFIER", 54, 59], ["wheezing", "OBSERVATION", 60, 68], ["infection", "OBSERVATION", 94, 103], ["HBoV", "OBSERVATION", 115, 119], ["respiratory tract", "ANATOMY", 123, 140]]], ["Some studies compared HBoV detection in symptomatic children and asymptomatic controls to demonstrate its pathogenic signifi cance.", [["HBoV", "ORGANISM", 22, 26], ["children", "ORGANISM", 52, 60], ["children", "SPECIES", 52, 60], ["HBoV", "SPECIES", 22, 26], ["Some studies", "TEST", 0, 12], ["HBoV detection", "TEST", 22, 36], ["asymptomatic controls", "PROBLEM", 65, 86], ["its pathogenic signifi cance", "PROBLEM", 102, 130]]], ["The existing literatures reported the frequency of HBoV detection in asymptomatic children was 0%-5%, which was signifi cantly lower than that in symptomatic children.", [["HBoV", "DISEASE", 51, 55], ["HBoV", "ORGANISM", 51, 55], ["children", "ORGANISM", 82, 90], ["children", "ORGANISM", 158, 166], ["children", "SPECIES", 82, 90], ["children", "SPECIES", 158, 166], ["HBoV", "SPECIES", 51, 55], ["HBoV detection", "TEST", 51, 65], ["HBoV", "OBSERVATION", 51, 55]]], ["[3, 11, 16, 19, 21] These fi ndings, however, is challenged by a recent study from Canada which reported that HBoV was detected in 13.8% of symptomatic children and 43% of asymptomatic children.", [["HBoV", "DISEASE", 110, 114], ["[3, 11, 16, 19, 21]", "SIMPLE_CHEMICAL", 0, 19], ["HBoV", "ORGANISM", 110, 114], ["children", "ORGANISM", 152, 160], ["children", "ORGANISM", 185, 193], ["children", "SPECIES", 152, 160], ["children", "SPECIES", 185, 193], ["HBoV", "SPECIES", 110, 114], ["a recent study", "TEST", 63, 77], ["HBoV", "PROBLEM", 110, 114], ["HBoV", "OBSERVATION", 110, 114]]], ["[34] It is necessary to understand persistent HBoV shedding or asymptomatic carriage in the respiratory tract for rationally explaining the clinical implication of HBoV.Type of infectionIn conclusion, our study suggests that HBoV circulating in Shanghai might play a pathogenic role in young children with ARTI in the community and hospital settings.", [["respiratory tract", "ANATOMY", 92, 109], ["HBoV", "DISEASE", 164, 168], ["infection", "DISEASE", 177, 186], ["ARTI", "DISEASE", 306, 310], ["HBoV", "ORGANISM", 46, 50], ["respiratory tract", "ORGANISM_SUBDIVISION", 92, 109], ["HBoV", "ORGANISM", 164, 168], ["HBoV", "ORGANISM", 225, 229], ["Shanghai", "ORGANISM", 245, 253], ["children", "ORGANISM", 292, 300], ["children", "SPECIES", 292, 300], ["HBoV", "SPECIES", 164, 168], ["HBoV", "SPECIES", 225, 229], ["persistent HBoV shedding", "PROBLEM", 35, 59], ["asymptomatic carriage in the respiratory tract", "PROBLEM", 63, 109], ["HBoV", "PROBLEM", 164, 168], ["Type of infection", "PROBLEM", 169, 186], ["our study", "TEST", 201, 210], ["HBoV", "PROBLEM", 225, 229], ["respiratory tract", "ANATOMY", 92, 109], ["HBoV", "OBSERVATION", 164, 168], ["infection", "OBSERVATION", 177, 186], ["HBoV", "OBSERVATION", 225, 229]]]], "PMC7273087": [], "PMC7304373": [["EinleitungDie Corona-Pandemie ist eine Gefahr f\u00fcr die Gesundheit und das Leben der Menschheit, deren problematische Folgen sich in allen gesellschaftlichen Bereichen und im Alltag niederschlagen.", [["EinleitungDie Corona-Pandemie ist eine Gefahr f\u00fcr die Gesundheit und das Leben der Menschheit, deren problematische Folgen sich in allen gesellschaftlichen Bereichen und im Alltag niederschlagen", "SPECIES", 0, 194]]], ["Die rasante, weltweite Ausbreitung des Corona-Virus ist allem Anschein nach auch der Globalisierung der letzten Jahrzehnte geschuldet: Unternehmen haben ihre Arbeit global verteilt und arbeiten international eng verflochten zusammen, der wachsende Tourismus hat mittlerweile den gesamten Globus im Blick.", [["Die rasante, weltweite Ausbreitung des Corona-Virus ist allem Anschein nach auch der Globalisierung der letzten Jahrzehnte geschuldet: Unternehmen haben ihre Arbeit global verteilt und arbeiten international eng verflochten zusammen, der wachsende Tourismus hat mittlerweile den gesamten Globus im Blick", "SPECIES", 0, 303], ["Ausbreitung des Corona-Virus ist allem", "TREATMENT", 23, 61]]], ["Diese soll durch umfangreiche staatliche Finanzhilfen gest\u00fctzt werden, aber dennoch gilt eine Rezession als sicher und eine Weltwirtschaftskrise als wahrscheinlich.", [["Diese soll durch umfangreiche staatliche Finanzhilfen gest\u00fctzt werden, aber dennoch gilt eine Rezession als sicher und eine Weltwirtschaftskrise als wahrscheinlich", "SPECIES", 0, 163], ["aber dennoch gilt eine Rezession", "TREATMENT", 71, 103]]], ["Allerdings sind die entwickelten Wirtschaftsgesellschaften nicht nur mit einer Naturkatastrophe und ihren Auswirkungen konfrontiert, sondern diese ist in weitere, schon l\u00e4nger schwelende Krisen eingebettet wie dem Austritt GB aus der EU, dem Handelskrieg zwischen den USA und China, dem immer wieder aufflammenden handelspolitischen Streit der USA mit Europa sowie last not least mit dem Klimawandel.", [["schon l\u00e4nger schwelende Krisen eingebettet wie dem Austritt GB aus der EU, dem Handelskrieg zwischen den USA und China, dem immer wieder aufflammenden handelspolitischen Streit der USA mit Europa sowie", "SPECIES", 163, 364]]], ["Ferner durchlaufen die Industriebranchen mit der Digitalisierung und der Forderung nach umweltvertr\u00e4glichen Produkten und einer entsprechenden Fertigung einen fundamentalen Transformationsprozess.", [["Ferner durchlaufen die Industriebranchen mit der Digitalisierung und der Forderung nach umweltvertr\u00e4glichen Produkten und einer entsprechenden Fertigung einen fundamentalen", "SPECIES", 0, 172]]], ["F\u00fcr Deutschland kommt au\u00dfer diesen Verwerfungen noch eine weitere Herausforderung hinzu, n\u00e4mlich als \u201eExportweltmeister\u201c international auf M\u00e4rkten \u00fcberaus machtvoll pr\u00e4sent zu sein \u2013 eine durchaus ambivalente Meisterschaft, wie der Bundesverband der deutschen Industrie (BDI) angesichts der Pandemie j\u00fcngst feststellte: \u201eEs werde deutlich, \u201awie verletzlich die exportorientierte und international arbeitsteilig organisierte Wirtschaft ist\u2018\u201c (zitiert nach: Busse 2020, S. 1).", [["F\u00fcr Deutschland kommt au\u00dfer diesen Verwerfungen noch eine weitere Herausforderung hinzu, n\u00e4mlich als \u201eExportweltmeister\u201c international auf M\u00e4rkten \u00fcberaus machtvoll pr\u00e4sent zu sein \u2013 eine durchaus ambivalente Meisterschaft, wie der Bundesverband der deutschen Industrie (BDI) angesichts der Pandemie j\u00fcngst feststellte: \u201eEs werde deutlich, \u201awie verletzlich die exportorientierte und international arbeitsteilig organisierte Wirtschaft ist\u2018\u201c (zitiert nach: Busse 2020, S. 1", "SPECIES", 0, 472], ["international auf M\u00e4rkten \u00fcberaus machtvoll", "TREATMENT", 121, 164]]], ["Hinzu kommt, dass eine Weltwirtschaftskrise die deutschen Unternehmen besonders treffen w\u00fcrde, da deren G\u00fcter und Dienstleistungen nicht mehr im gewohnten Umfang aus dem Ausland nachgefragt w\u00fcrden.", [["aus dem", "OBSERVATION", 162, 169]]], ["Diese nachteilige Aussicht w\u00fcrde sich weiter zuspitzen, falls die europ\u00e4ischen Nachbarl\u00e4nder, die Hauptabnehmer deutscher Exporte, die Krise nicht \u00fcberwinden (k\u00f6nnen).EinleitungIn den letzten drei Jahrzehnten hat sich ein Organisations- und Arbeitsmodell durchgesetzt, das von den privaten und \u00f6ffentlichen Akteuren in der Produktion, in den Dienstleistungen und in der Verwaltung zum Leitbild erkoren wurde.", [["den letzten drei Jahrzehnten hat sich ein Organisations- und Arbeitsmodell durchgesetzt, das von den privaten und \u00f6ffentlichen Akteuren in der Produktion, in den Dienstleistungen und in der Verwaltung zum Leitbild erkoren wurde", "SPECIES", 180, 407], ["den", "ANATOMY", 180, 183]]], ["Das Modell firmiert unter dem Namen lean production bzw. lean administration.", [["lean", "ORGANISM_SUBDIVISION", 57, 61], ["lean administration", "TREATMENT", 57, 76]]], ["Diese zum Ideal stilisierte Organisation ist durch die Corona-Pandemie in eine Krise gest\u00fcrzt.", [["Diese zum Ideal stilisierte Organisation ist durch die Corona-Pandemie in eine Krise gest\u00fcrzt", "SPECIES", 0, 93], ["Diese zum", "TREATMENT", 0, 9]]], ["Zu erinnern ist daran, dass dieses System angesichts augenf\u00e4lliger Dysfunktionen in den letzten Jahren bereits ver\u00e4ndert wurde.EinleitungDas Thema entfalte ich in drei Schritten: Zun\u00e4chst wird das Lean-Konzept vorgestellt, sodann werden diverse Dysfunktionen und m\u00f6gliche Korrekturen diskutiert und abschlie\u00dfend f\u00fcr ein erweitertes Verst\u00e4ndnis von Rationalisierung geworben.Lean production/lean administration\u00a0\u2013 ein Rationalisierungsmodell f\u00fcr das 21.\u00a0Jahrhundert?Im Zuge der Durchsetzung moderner Gesellschaften wurde Rationalisierung zu einem zentralen Thema.", [["Zun\u00e4chst wird das Lean-Konzept vorgestellt, sodann werden diverse Dysfunktionen und m\u00f6gliche Korrekturen diskutiert und abschlie\u00dfend f\u00fcr ein erweitertes Verst\u00e4ndnis von Rationalisierung geworben", "SPECIES", 179, 373], ["Zu erinnern ist daran", "TREATMENT", 0, 21], ["ich", "PROBLEM", 156, 159], ["lean administration", "TREATMENT", 390, 409], ["Im Zuge der Durchsetzung moderner Gesellschaften wurde", "TREATMENT", 464, 518], ["ich", "OBSERVATION", 156, 159]]], ["Mit der Industrialisierung und der zunehmenden Gr\u00fcndung von Unternehmen bestimmten technisch-organisatorische Rationalisierungen die Praxis des Managements.", [["organisatorische Rationalisierungen die Praxis des Managements", "TREATMENT", 93, 155]]], ["Mit Blick auf deren Folgen zeigt sich die Ambivalenz dieser Ma\u00dfnahmen: W\u00e4hrend die Arbeitgeber die gestiegene Effizienz und Wirtschaftlichkeit sowie geringere Kosten begr\u00fc\u00dfen und sich mithin ihre Gewinnerwartungen erh\u00f6hen, anerkennen die Arbeitskr\u00e4fte zwar die effizientere Arbeitsgestaltung mit reduzierter Beanspruchung, gleichzeitig aber nimmt diese durch eine Intensivierung der Arbeit zu, die zu Verschlei\u00df und sogar Erwerbslosigkeit f\u00fchren kann, sofern die Rationalisierung nicht mit einem Wirtschaftswachstum bzw. einem Nachfrageschub einhergeht.", [["Mit Blick auf deren Folgen zeigt sich die Ambivalenz dieser Ma\u00dfnahmen: W\u00e4hrend die Arbeitgeber die gestiegene Effizienz und Wirtschaftlichkeit sowie geringere Kosten begr\u00fc\u00dfen und sich mithin ihre Gewinnerwartungen erh\u00f6hen, anerkennen die Arbeitskr\u00e4fte zwar die effizientere Arbeitsgestaltung mit reduzierter Beanspruchung, gleichzeitig aber nimmt diese durch eine Intensivierung der Arbeit zu, die zu Verschlei\u00df und sogar Erwerbslosigkeit f\u00fchren kann, sofern die Rationalisierung nicht mit einem Wirtschaftswachstum bzw", "SPECIES", 0, 519], ["Mit Blick auf deren Folgen zeigt sich", "TREATMENT", 0, 37], ["Effizienz", "TREATMENT", 110, 119]]], ["Management und Gesellschaft \u2013 kennzeichnet das unternehmerische Rationalisierungshandeln, wiewohl auch eine teilweise \u00dcbereinstimmung der Interessen nicht auszuschlie\u00dfen ist.Lean production/lean administration\u00a0\u2013 ein Rationalisierungsmodell f\u00fcr das 21.\u00a0Jahrhundert?Diese Ambivalenz kennzeichnet auch die j\u00fcngeren Ans\u00e4tze, wobei bei aller Kritik festzuhalten ist, dass sowohl die Wissenschaftliche Betriebsf\u00fchrung bzw. der Taylorismus als auch das aktuelle, ebenfalls global einflussreiche Modell lean production Grundlage der Massenproduktion sind, die es erm\u00f6glicht, weltweit G\u00fcter anzubieten, die von den Menschen bzw. den Konsumenten f\u00fcr attraktiv und begehrenswert erachtet werden.", [["Diese Ambivalenz kennzeichnet auch die j\u00fcngeren Ans\u00e4tze, wobei bei aller Kritik festzuhalten ist, dass sowohl die Wissenschaftliche Betriebsf\u00fchrung bzw", "SPECIES", 264, 415], ["Taylorismus als auch das aktuelle, ebenfalls global einflussreiche Modell lean production Grundlage der Massenproduktion sind, die es erm\u00f6glicht, weltweit G\u00fcter anzubieten, die von den Menschen bzw", "SPECIES", 421, 618], ["lean administration", "TREATMENT", 190, 209], ["Diese Ambivalenz kennzeichnet", "TREATMENT", 264, 293]]], ["Darauf muss die Produktion eingehen und ein differenziertes Angebot, etwa beim Erscheinungsbild der Waren, offerieren, ohne dass die Vorteile der Massenproduktion, n\u00e4mlich gemeinsame grundlegende Komponenten, beispielsweise technischer Natur, aus dem Blick geraten.Lean production/lean administration\u00a0\u2013 ein Rationalisierungsmodell f\u00fcr das 21.\u00a0Jahrhundert?Beide Ans\u00e4tze z\u00e4hlen zu den Rationalisierungskonzepten, die die Organisations- und Arbeitsgestaltung ma\u00dfgeblich pr\u00e4gten und pr\u00e4gen.", [["Beide Ans\u00e4tze z\u00e4hlen zu den Rationalisierungskonzepten, die die Organisations- und Arbeitsgestaltung ma\u00dfgeblich pr\u00e4gten und pr\u00e4gen", "SPECIES", 355, 485], ["lean administration", "TREATMENT", 281, 300], ["aus dem", "OBSERVATION", 243, 250]]], ["Typisch f\u00fcr sie ist, dass sie mit dem Anspruch eines one best way auftreten, sie erscheinen mithin als alternativlos mit Blick auf das wirtschaftliche Optimum.", [["dass sie mit dem Anspruch eines", "TREATMENT", 21, 52]]], ["Schlie\u00dflich waren und sind f\u00fcr beide Ans\u00e4tze Produktionsunternehmen wie die Automobilbranche erste Experimentier- und Einsatzfelder, allerdings weitete und weitet sich die Umsetzung weltweit auf alle Sektoren und Branchen aus, die private Lebenswelt bleibt ebenfalls davon nicht unber\u00fchrt.", [["Schlie\u00dflich waren und sind f\u00fcr beide Ans\u00e4tze Produktionsunternehmen wie die Automobilbranche erste Experimentier- und Einsatzfelder, allerdings weitete und weitet sich die Umsetzung weltweit auf alle Sektoren und Branchen aus", "SPECIES", 0, 225]]], ["Es kann nicht erstaunen, dass sich die Rationalisierungskonzepte im Verlauf eines Jahrhunderts grundlegend gewandelt haben.", [["dass sich die Rationalisierungskonzepte", "TREATMENT", 25, 64]]], ["Handelte es sich fr\u00fcher um punktuelle, durchaus verbundene Rationalisierungen, so beabsichtigen die diesbez\u00fcglichen Anstrengungen heutzutage, vor allem befeuert durch die Informationstechnologie wie dem Internet, einen ganzheitlichen, systemischen Zugriff, der betriebliche und au\u00dferbetriebliche Dimensionen gleicherma\u00dfen zu erfassen versucht.", [["systemischen Zugriff", "TREATMENT", 235, 255]]], ["Schlie\u00dflich haben international vergleichende Untersuchungen, die in den letzten Jahrzehnten forciert wurden, offengelegt, dass die Umsetzung von Arbeits- und Organisationsmodellen nicht gem\u00e4\u00df dem idealtypischen Konstrukt erfolgt, sondern von spezifischen nationalen, sozio-kulturellen Besonderheiten wie etwa dem Berufsbildungssystem und dem System der industriellen Beziehungen gepr\u00e4gt wird (vgl.", [["den letzten Jahrzehnten forciert wurden, offengelegt, dass die Umsetzung von Arbeits- und Organisationsmodellen nicht gem\u00e4\u00df dem idealtypischen Konstrukt erfolgt, sondern von spezifischen nationalen, sozio-kulturellen Besonderheiten wie etwa dem Berufsbildungssystem und dem System der industriellen Beziehungen gepr\u00e4gt wird", "SPECIES", 69, 392]]], ["Demzufolge gilt Gestaltung als ein pfadabh\u00e4ngiger Prozess.Lean production/lean administration\u00a0\u2013 ein Rationalisierungsmodell f\u00fcr das 21.\u00a0Jahrhundert?Lean Production, das in den Grundz\u00fcgen von dem Japaner Taiichi Ohno (1978/1993) entwickelt und als Toyota-Produktionssystem bekannt wurde, errang Anfang der neunziger Jahre des vergangenen Jahrhunderts weltweit Popularit\u00e4t.", [["Demzufolge gilt Gestaltung als ein pfadabh\u00e4ngiger Prozess", "SPECIES", 0, 57], ["den Grundz\u00fcgen von dem Japaner Taiichi Ohno (1978/1993) entwickelt und als Toyota-Produktionssystem bekannt wurde", "SPECIES", 172, 285], ["Demzufolge gilt", "TREATMENT", 0, 15], ["lean administration", "TREATMENT", 74, 93]]], ["Womack et al. 1990/1994) und avancierte zu einem globalen Bestseller.", [["einem globalen Bestseller", "CELL", 43, 68]]], ["Der programmatische Titel erinnert an die erste, von Henry Ford und Frederick Taylor initiierte Umw\u00e4lzung im Automobilbau.", [["Titel erinnert an die erste, von Henry Ford und Frederick Taylor initiierte Umw\u00e4lzung im Automobilbau", "SPECIES", 20, 121]]], ["Lean Production wurde zum Leitbild von Unternehmensberatern und Rationalisierungsexperten und versprach eine ultimative L\u00f6sung wirtschaftlicher Probleme. \u201eDie Euphorie (\u2026) l\u00f6ste in den westlichen Industriegesellschaften eine der gr\u00f6\u00dften Rationalisierungswellen der Nachkriegszeit aus\u201c (Neuhaus 2013, S. 17).", [["Lean Production wurde zum Leitbild von Unternehmensberatern und Rationalisierungsexperten und versprach eine ultimative L\u00f6sung wirtschaftlicher", "SPECIES", 0, 143]]], ["Die Protagonisten aus dem MIT stellten in Aussicht: \u201eAm Ende (\u2026) wird die schlanke Produktion die Massenproduktion und die verbliebenen Vertreter der handwerklichen Fertigung in allen Bereichen industrieller Bet\u00e4tigung ersetzen, um das weltweite Standardproduktionssystem des einundzwanzigsten Jahrhunderts zu werden.", [["Die Protagonisten aus dem MIT stellten in Aussicht: \u201eAm Ende (\u2026) wird die schlanke Produktion die Massenproduktion und die verbliebenen Vertreter der handwerklichen Fertigung in allen Bereichen industrieller Bet\u00e4tigung ersetzen, um das weltweite Standardproduktionssystem des einundzwanzigsten Jahrhunderts zu werden", "SPECIES", 0, 316]]], ["Diese Welt wird v\u00f6llig anders und sehr viel besser sein\u201c (Womack et al. 1994, S. 291 f.).Lean production/lean administration\u00a0\u2013 ein Rationalisierungsmodell f\u00fcr das 21.\u00a0Jahrhundert?Die globale Ausstrahlung ist zweifellos auch der Tatsache geschuldet, dass sich das System in das weltweit vorherrschende Wirtschaftsmodell problemlos einf\u00fcgte.", [["Diese Welt wird v\u00f6llig anders und sehr viel besser sein\u201c (Womack et al. 1994, S. 291 f.", "SPECIES", 0, 87], ["lean administration", "TREATMENT", 105, 124]]], ["Mit dem Niedergang der realsozialistischen Wirtschaftsgesellschaften avancierte n\u00e4mlich das neoklassische bzw. neoliberale Modell, das in den USA und GB bereits seit Ende der siebziger Jahre die Agenda bestimmte, zum universellen Vorbild wirtschaftlichen Handelns.", [["Mit dem", "PROBLEM", 0, 7]]], ["Die schlanke Fabrik sollte erm\u00f6glichen, die Kosten zu minimieren und den Gewinn zu maximieren.", [["Die schlanke Fabrik sollte erm\u00f6glichen, die Kosten zu minimieren und den Gewinn zu maximieren", "SPECIES", 0, 93]]], ["Mittlerweile versuchen Akteure, diesen Prinzipien bei der organisatorischen Gestaltung allgemeine Geltung zu verschaffen.", [["Prinzipien bei der organisatorischen Gestaltung allgemeine Geltung zu verschaffen", "SPECIES", 39, 120]]], ["Nach betriebswirtschaftlichen Kriterien wurden beispielsweise \u00f6ffentliche Dienstleistungen, die die Grundbed\u00fcrfnisse der B\u00fcrgerInnen stillen sollen, bewertet, und so kam es auch hier zur Verschlankung.", [["Nach betriebswirtschaftlichen Kriterien wurden beispielsweise \u00f6ffentliche Dienstleistungen, die die Grundbed\u00fcrfnisse der B\u00fcrgerInnen stillen sollen, bewertet, und so kam es auch hier zur Verschlankung", "SPECIES", 0, 200]]], ["In den Bereichen Wohnen, Infrastruktur, Sicherheit, Gesundheit und Bildung kam es ferner zu Privatisierungen und im Zuge dessen wurde ebenfalls Personal eingespart und Ressourcen abgebaut, was f\u00fcr die verbliebenen Besch\u00e4ftigten un\u00fcbersehbar eine Arbeitsintensivierung impliziert(e).Lean production/lean administration\u00a0\u2013 ein Rationalisierungsmodell f\u00fcr das 21.\u00a0Jahrhundert?Was bedeutet lean production in der betrieblichen Realit\u00e4t?", [["Gesundheit und Bildung kam es ferner zu Privatisierungen und im Zuge dessen wurde ebenfalls Personal eingespart und Ressourcen abgebaut", "SPECIES", 52, 187], ["lean administration", "TREATMENT", 298, 317]]], ["Sie erfordert auch weit weniger als die H\u00e4lfte des notwendigen Lagerbestands, f\u00fchrt zu viel weniger Fehlern\u201c (ebd., S. 19).", [["Sie erfordert auch weit weniger als die H\u00e4lfte des notwendigen Lagerbestands, f\u00fchrt zu viel weniger Fehlern\u201c (ebd., S. 19", "SPECIES", 0, 121]]], ["Die Ziele solcher Unternehmen seien \u201ekontinuierlich sinkende Preise, Null Fehler, keine Lagerbest\u00e4nde und beliebige Produktvielfalt\u201c (ebd., S. 20).Lean production/lean administration\u00a0\u2013 ein Rationalisierungsmodell f\u00fcr das 21.\u00a0Jahrhundert?Im Kontext der Entwicklung schlanker Unternehmen wurden und werden verschiedene Methoden eingesetzt: (1.)", [["Die Ziele solcher Unternehmen seien \u201ekontinuierlich sinkende Preise, Null Fehler, keine Lagerbest\u00e4nde und beliebige Produktvielfalt\u201c (ebd., S. 20", "SPECIES", 0, 145], ["lean administration", "TREATMENT", 163, 182]]], ["Die Produktion wird durchg\u00e4ngig nach dem Prinzip just-in-time organisiert, d. h. die Nachfrage bestimmt die Produktion, der Stand der Produktion bestimmt den Zeitpunkt der Lieferung von Vorprodukten, so dass sich eine kostspielige Lagerhaltung er\u00fcbrigt.Lean production/lean administration\u00a0\u2013 ein Rationalisierungsmodell f\u00fcr das 21.\u00a0Jahrhundert?Schon im Verlauf der Umsetzung dieses Systems seit den neunziger Jahren zeigten sich Probleme, die den Erfolg in Frage stellten.", [["Die Produktion wird durchg\u00e4ngig nach dem Prinzip just-in-time organisiert, d. h. die Nachfrage bestimmt die Produktion, der Stand der Produktion bestimmt den Zeitpunkt der Lieferung von Vorprodukten, so dass sich eine kostspielige Lagerhaltung er\u00fcbrigt", "SPECIES", 0, 252], ["lean administration", "TREATMENT", 269, 288]]], ["In der Corono-Pandemie erreichen diese Fehlrationalisierungen ein Ausma\u00df, das den Kampf gegen die Krise schw\u00e4cht, bisweilen sogar verhindert und mithin deren Ausweitung sogar beg\u00fcnstigen kann.Dysfunktionale Folgen der Lean-Modelle und Wege aus dem DilemmaIn der derzeitigen Katastrophe zeigen sich die dysfunktionalen Folgen von lean production und lean administration in aller Sch\u00e4rfe.", [["Modelle und Wege aus dem DilemmaIn der derzeitigen Katastrophe zeigen sich", "TREATMENT", 223, 297]]], ["Dennoch verbietet es sich, Probleme bei der Bew\u00e4ltigung der Krise sozusagen monokausal, allein mit solchen Dysfunktionen erkl\u00e4ren zu wollen.", [["Dennoch verbietet es sich, Probleme bei der Bew\u00e4ltigung der Krise sozusagen monokausal, allein mit solchen Dysfunktionen erkl\u00e4ren zu wollen", "SPECIES", 0, 139]]], ["Im Unterschied zu fr\u00fcheren Wirtschaftskrisen haben wir es mit einem Angebots- und einem Nachfrageschock gleichzeitig zu tun, die Rezessionen national wie international ausl\u00f6sen, wobei deren Tiefe und Dauer nicht zu prognostizieren sind.", [["Im Unterschied zu fr\u00fcheren Wirtschaftskrisen haben wir es mit einem Angebots- und einem Nachfrageschock gleichzeitig zu tun, die Rezessionen national wie international ausl\u00f6sen, wobei deren Tiefe und Dauer nicht zu prognostizieren", "SPECIES", 0, 230]]], ["China ist nach den EU-L\u00e4ndern der wohl wichtigste Handelspartner f\u00fcr die deutsche Industrie.", [["China ist nach den EU-L\u00e4ndern der wohl wichtigste Handelspartner f\u00fcr die deutsche", "SPECIES", 0, 81]]], ["Die Wochenzeitung \u201eDie Zeit\u201c, die eine Umfrage unter den Dax-Unternehmen durchf\u00fchrte, konnte zeigen: \u201eFast alle der 30 Konzerne sind in irgendeiner Art vom Ausbruch des Coronavirus betroffen (\u2026).", [["Die Wochenzeitung \u201eDie Zeit\u201c, die eine Umfrage unter den Dax-Unternehmen durchf\u00fchrte, konnte zeigen: \u201eFast alle der 30 Konzerne sind in irgendeiner Art vom Ausbruch des Coronavirus betroffen", "SPECIES", 0, 190]]], ["Diese Katastrophe, in der es um Leben und Tod geht, hat die politischen Akteure alarmiert und veranlasst, das wirtschaftliche und gesellschaftliche Leben durch einen Shutdown still zu legen.", [["der es um Leben und Tod geht, hat die politischen Akteure alarmiert und veranlasst, das wirtschaftliche und gesellschaftliche Leben durch einen Shutdown still zu legen", "SPECIES", 22, 189]]], ["Die Ma\u00dfnahmen unterscheiden sich von Land zu Land, mal sind sie allumfassend und streng, mal weniger total und lockerer.", [["Die Ma\u00dfnahmen unterscheiden sich von Land zu Land, mal sind sie allumfassend und streng, mal weniger", "SPECIES", 0, 100]]], ["Mit dieser Anordnung verbindet sich die Hoffnung, die Pandemie zu verlangsamen und so das Gesundheitssystem funktionst\u00fcchtig zu halten.", [["Mit dieser Anordnung verbindet sich die Hoffnung, die Pandemie zu verlangsamen und so das Gesundheitssystem funktionst\u00fcchtig zu halten", "SPECIES", 0, 134]]], ["Die Menschen sind gehalten, ihre Wohnungen nicht zu verlassen und den Kontakt zu anderen zu meiden.", [["ihre Wohnungen nicht zu verlassen und den Kontakt zu anderen zu meiden", "SPECIES", 28, 98]]], ["Regelverst\u00f6\u00dfe werden staatlicherseits geahndet.", [["Regelverst\u00f6\u00dfe werden staatlicherseits geahndet", "SPECIES", 0, 46]]], ["Durch diese Ma\u00dfnahmen gingen die Ansteckungs- und Todeszahlen nach unten, sodass schrittweise das Erwerbs- und Alltagsleben wieder in Gang kommen kann.", [["Durch diese Ma\u00dfnahmen gingen die Ansteckungs- und Todeszahlen nach unten, sodass schrittweise das Erwerbs- und Alltagsleben wieder in Gang kommen kann", "SPECIES", 0, 150]]], ["Dar\u00fcber hinaus hat der Deutsche Bundestag in einer noch nie dagewesenen H\u00f6he Hilfsprogramme f\u00fcr Solo-Selbstst\u00e4ndige, Unternehmen und ArbeitnehmerInnen verabschiedet, um den wirtschaftlichen Niedergang zu bremsen.", [["Dar\u00fcber hinaus hat der Deutsche Bundestag in einer noch nie dagewesenen H\u00f6he Hilfsprogramme f\u00fcr Solo-Selbstst\u00e4ndige, Unternehmen und ArbeitnehmerInnen verabschiedet, um den wirtschaftlichen Niedergang zu bremsen", "SPECIES", 0, 211]]], ["Der Kampf gegen das Virus, der das Wirtschaftswachstum blockiert, wird, wenn er in absehbarer Zeit durch die Entwicklung eines Impfstoffs hoffentlich gewonnen ist, durch ein Engagement f\u00fcr den Wiederaufbau der Volkswirtschaft ersetzt werden m\u00fcssen.", [["Virus", "ORGANISM", 20, 25], ["Der Kampf gegen das Virus, der das Wirtschaftswachstum blockiert, wird, wenn er in absehbarer Zeit durch die Entwicklung eines Impfstoffs hoffentlich gewonnen ist, durch ein Engagement f\u00fcr den Wiederaufbau der Volkswirtschaft ersetzt werden m\u00fcssen", "SPECIES", 0, 247]]], ["Anzumerken ist, dass \u2013 wie bereits oben erw\u00e4hnt \u2013 der Umgang der einzelnen L\u00e4nder mit der Pandemie h\u00f6chst unterschiedlich ist, zumal die Wirtschaftskraft divergiert, generell das Erfahrungswissen \u2013 abgesehen von medizinischen Experten \u2013 \u00e4u\u00dferst gering ist und das Handeln der Akteure durch spezifische politische Konstellationen und sozio-kulturelle Besonderheiten mitbestimmt wird.Dysfunktionale Folgen der Lean-Modelle und Wege aus dem DilemmaDie dysfunktionalen Folgen der Verschlankung zeigen sich auf vielf\u00e4ltige Weise: Als Folge des Personalabbaus, durchaus auf unterschiedliche Ursachen zur\u00fcck zu f\u00fchren, wurden die Unternehmen bzw.", [["dass \u2013 wie bereits oben erw\u00e4hnt \u2013 der Umgang der einzelnen L\u00e4nder mit der Pandemie h\u00f6chst unterschiedlich ist, zumal die Wirtschaftskraft divergiert, generell das Erfahrungswissen \u2013 abgesehen von medizinischen Experten \u2013 \u00e4u\u00dferst gering ist und das Handeln der Akteure durch spezifische politische Konstellationen und sozio-kulturelle Besonderheiten mitbestimmt wird", "SPECIES", 16, 381], ["Folgen der Lean-Modelle und Wege aus dem DilemmaDie dysfunktionalen Folgen der Verschlankung zeigen sich auf vielf\u00e4ltige Weise: Als Folge des Personalabbaus, durchaus auf unterschiedliche Ursachen zur\u00fcck zu f\u00fchren, wurden die Unternehmen bzw", "SPECIES", 397, 638], ["Modelle und Wege aus dem DilemmaDie dysfunktionalen", "TREATMENT", 413, 464], ["Als Folge des Personalabbaus", "TREATMENT", 525, 553]]], ["Organisationen schlank bis zur \u201eMagersucht\u201c, sodass Besch\u00e4ftigung wieder aufgebaut werden musste.", [["Organisationen", "TEST", 0, 14]]], ["Im Gesundheitssystem, auf das noch genauer einzugehen ist, ist der Personalmangel, vor allem bei den Pflegekr\u00e4ften, ein Gutteil auf die prek\u00e4ren Arbeitsbedingungen zur\u00fcckzuf\u00fchren: Das Defizit bedeutet f\u00fcr die verbliebenen Besch\u00e4ftigten eine Arbeitsintensivierung verbunden mit erheblichen \u00dcberstunden bei einem gleichzeitig geringen Entgelt, was weitere K\u00fcndigungen und sogar fr\u00fchzeitigen Verschlei\u00df mit Ausscheiden aus dem Beruf beg\u00fcnstigt sowie die Gewinnung von Nachwuchskr\u00e4ften erschwert.Dysfunktionale Folgen der Lean-Modelle und Wege aus dem DilemmaAuch die anderen, bereits vorgestellten Methoden erweisen sich als dysfunktional: Outsourcing, das national wie international aus Kostengr\u00fcnden erfolgt(e), vernachl\u00e4ssigte anfangs die Produktqualit\u00e4t.", [["Im Gesundheitssystem, auf das noch genauer einzugehen ist, ist der Personalmangel, vor allem bei den Pflegekr\u00e4ften, ein Gutteil auf die prek\u00e4ren Arbeitsbedingungen zur\u00fcckzuf\u00fchren: Das Defizit bedeutet f\u00fcr die verbliebenen Besch\u00e4ftigten eine Arbeitsintensivierung verbunden mit erheblichen \u00dcberstunden bei einem gleichzeitig geringen Entgelt, was weitere K\u00fcndigungen und sogar fr\u00fchzeitigen Verschlei\u00df mit Ausscheiden aus dem Beruf beg\u00fcnstigt sowie die Gewinnung von Nachwuchskr\u00e4ften erschwert", "SPECIES", 0, 491], ["Folgen der Lean-Modelle und Wege aus dem DilemmaAuch die anderen, bereits vorgestellten Methoden erweisen sich als dysfunktional: Outsourcing, das national wie international aus Kostengr\u00fcnden erfolgt", "SPECIES", 507, 706]]], ["Sie erreicht(e) vielfach nicht das erforderliche Niveau, sodass Schulungen notwendig sind, um einen Null-Fehler-Standard zu erreichen.", [["sodass Schulungen notwendig sind, um einen Null-Fehler-Standard zu erreichen", "SPECIES", 57, 133]]], ["Aber eine Umkehr des Trends auf breiter Front wird es kaum geben, denn die internationale Arbeitsteilung hat sich st\u00e4ndig ausgeweitet und vertieft, zumal die \u00e4u\u00dferst geringen Transportkosten, etwa mit Containerschiffen, ein zu vernachl\u00e4ssigender Faktor sind.", [["Trends auf breiter Front wird es kaum geben, denn die internationale Arbeitsteilung hat sich st\u00e4ndig ausgeweitet und vertieft, zumal die \u00e4u\u00dferst geringen Transportkosten, etwa mit Containerschiffen, ein zu vernachl\u00e4ssigender Faktor sind", "SPECIES", 21, 257]]], ["\u00dcberdies m\u00fcssen nationale Unternehmen auch international pr\u00e4sent sein, um ihre Marktchancen global besser nutzen zu k\u00f6nnen.", [["\u00dcberdies m\u00fcssen nationale Unternehmen auch international pr\u00e4sent sein, um ihre Marktchancen global besser nutzen zu k\u00f6nnen", "SPECIES", 0, 122]]], ["Vermutlich gilt auch f\u00fcr die Zukunft: Outsourcing erfolgt weiterhin aus Kostengr\u00fcnden, sodass die kosteng\u00fcnstigste Beschaffung von (Teil)Produkten avisiert wird.", [["Vermutlich gilt auch f\u00fcr die Zukunft: Outsourcing erfolgt weiterhin aus Kostengr\u00fcnden, sodass die kosteng\u00fcnstigste Beschaffung von (Teil)Produkten avisiert wird", "SPECIES", 0, 160]]], ["Eine nach dem Prinzip just-in-time organisierte Fertigung erweist sich ebenfalls als st\u00f6ranf\u00e4llig, etwa durch schlechtes Wetter, Staus auf den Stra\u00dfen, Streiks in den ausl\u00e4ndischen Zulieferbetrieben, so dass in gewissem Umfang wieder Lager aufgebaut werden mussten und m\u00fcssen.Dysfunktionale Folgen der Lean-Modelle und Wege aus dem DilemmaBlicken wir nun auf das Gesundheitssystem in der Bundesrepublik, wobei sich vergleichbare Tendenzen auch in anderen L\u00e4ndern zeigen: Zwar haben WissenschaftlerInnen schon vor Jahren vor einer Pandemie gewarnt und Vorr\u00e4te an Betten sowie zus\u00e4tzliche Ausr\u00fcstung in Krankenh\u00e4usern, Pflegeheimen, ambulanten Pflegediensten, Arztpraxen angemahnt, aber dazu ist es zumindest nicht in ausreichendem Ma\u00dfe gekommen (vgl.", [["Folgen der Lean-Modelle und Wege aus dem DilemmaBlicken wir nun auf das Gesundheitssystem in der Bundesrepublik, wobei sich vergleichbare Tendenzen auch in anderen L\u00e4ndern zeigen: Zwar haben WissenschaftlerInnen schon vor Jahren vor einer Pandemie gewarnt und Vorr\u00e4te an Betten sowie zus\u00e4tzliche", "SPECIES", 291, 586], ["Zwar", "TREATMENT", 471, 475], ["Pflegeheimen", "TREATMENT", 617, 629], ["ambulanten Pflegediensten", "TREATMENT", 631, 656], ["Arztpraxen", "TREATMENT", 658, 668]]], ["Durch outsourcing wurde die Bundesrepublik \u2013 einst \u201edie Apotheke der Welt\u201c \u2013 im Gesundheitssystem abh\u00e4ngig von Indien und China, und zwar vor allem bei Arzneimitteln und Wirkstoffen, aber auch bei Schutzmaterial f\u00fcr die Besch\u00e4ftigten (vgl.", [["Bundesrepublik \u2013 einst \u201edie Apotheke der Welt\u201c \u2013 im Gesundheitssystem abh\u00e4ngig von Indien und China, und zwar vor allem bei Arzneimitteln und Wirkstoffen, aber auch bei Schutzmaterial f\u00fcr die Besch\u00e4ftigten", "SPECIES", 28, 233]]], ["Die defizit\u00e4re Entwicklung hat zwar mit dem Versagen von Schl\u00fcsselpersonen zu tun, aber es gibt daf\u00fcr tiefere, n\u00e4mlich die skizzierten systemischen Ursachen, die das Handeln der Verantwortlichen leiten: Mit der neoklassischen bzw. neoliberalen Wirtschaftspolitik r\u00fcckt der Markt als Probleml\u00f6ser zu Lasten staatlichen Handelns in den Fokus, und infolge dessen orientieren sich die Akteure im Bereich \u00f6ffentlicher Dienstleistungen am Lean-Leitbild.", [["Die defizit\u00e4re Entwicklung hat zwar mit dem Versagen von Schl\u00fcsselpersonen zu tun, aber es gibt daf\u00fcr tiefere, n\u00e4mlich die skizzierten systemischen Ursachen, die das Handeln der Verantwortlichen leiten: Mit der neoklassischen bzw", "SPECIES", 0, 229], ["neoliberalen Wirtschaftspolitik r\u00fcckt der Markt als Probleml\u00f6ser zu Lasten staatlichen Handelns in den Fokus, und infolge dessen orientieren sich die Akteure im Bereich \u00f6ffentlicher Dienstleistungen am Lean-Leitbild", "SPECIES", 231, 446], ["neoliberalen", "TREATMENT", 231, 243]]], ["Krankenh\u00e4user und Pflegeheime sind ein offenkundiges Beispiel daf\u00fcr, wie \u00f6ffentliche Dienstleistungen nach betriebswirtschaftlichen Kennziffern umorganisiert wurden und werden, sodass den geforderten \u2013 fr\u00fcher unbekannten \u2013 Gewinnerwartungen entsprochen werden kann.", [["Krankenh\u00e4user und Pflegeheime sind ein offenkundiges Beispiel daf\u00fcr, wie \u00f6ffentliche Dienstleistungen nach betriebswirtschaftlichen Kennziffern umorganisiert wurden und werden, sodass den geforderten \u2013 fr\u00fcher unbekannten \u2013 Gewinnerwartungen entsprochen werden kann", "SPECIES", 0, 264]]], ["Gem\u00e4\u00df dieser Managementlehre wurden und werden kostenintensive Bereiche wie das Personal und die medizinischen Ressourcen abgebaut, \u00fcberdies erfolgt(e) \u2013 zumindest teilweise \u2013 eine Privatisierung.", [["Gem\u00e4\u00df dieser Managementlehre wurden und werden kostenintensive Bereiche wie das Personal und die medizinischen Ressourcen abgebaut, \u00fcberdies erfolgt(e) \u2013 zumindest teilweise \u2013 eine Privatisierung", "SPECIES", 0, 195]]], ["Der in der Corona-Katastrophe gravierende Mangel, beispielsweise an Schutzkleidung, Gesichtsmasken, Beatmungsger\u00e4ten, Medikamenten und Rohstoffen f\u00fcr Pharmazeutika, ist \u2013 wie bereits vermerkt \u2013 ein Resultat der zunehmenden Internationalisierung der Produktion seit den neunziger Jahren.", [["Medikamenten und Rohstoffen f\u00fcr Pharmazeutika, ist \u2013 wie bereits vermerkt \u2013 ein Resultat der zunehmenden Internationalisierung der Produktion seit den neunziger", "SPECIES", 118, 278]]], ["Zusammen mit der mangelnden Vorratshaltung erreicht das Defizit an medizinischem Material ein gigantisches Ausma\u00df.", [["Zusammen mit der mangelnden Vorratshaltung erreicht das Defizit an medizinischem Material ein gigantisches", "SPECIES", 0, 106], ["Zusammen mit der mangelnden", "TREATMENT", 0, 27]]], ["In der Krise kommt es daher zu einer, vermutlich tempor\u00e4ren Konversion in der nationalen Produktion: Beispielsweise haben Unternehmen der Textilbranche, die seit den siebziger Jahren des vergangenen Jahrhunderts zun\u00e4chst nach S\u00fcdeuropa und anschlie\u00dfend nach Asien outgesourct wurden und die folglich kaum noch in Deutschland pr\u00e4sent sind, ihre Fertigung auf medizinisch notwendigen Produkte, etwa Gesichtsmasken, umgestellt.", [["Beispielsweise haben Unternehmen der Textilbranche, die seit den siebziger Jahren des vergangenen Jahrhunderts zun\u00e4chst nach S\u00fcdeuropa und anschlie\u00dfend nach Asien outgesourct wurden und die folglich kaum noch in Deutschland pr\u00e4sent sind, ihre Fertigung auf medizinisch notwendigen", "SPECIES", 101, 381]]], ["Andere Unternehmen nutzen ihre weltweiten Beziehungen, um Schutzmaterial im Auftrag der Regierung zu kaufen.", [["Andere Unternehmen nutzen ihre weltweiten Beziehungen, um Schutzmaterial im Auftrag der Regierung zu kaufen", "SPECIES", 0, 107]]], ["Sie alle tragen zur Behebung der Mangelwirtschaft bei, was allemal mehr ist als nur ein symbolischer Beitrag.Dysfunktionale Folgen der Lean-Modelle und Wege aus dem DilemmaDie Pandemie, die die desastr\u00f6sen M\u00e4ngel im Gesundheitssystem und in der Versorgung offen legt, erzwingt eine Revision bisheriger Praxis, denn diese gef\u00e4hrdet die Sicherheit der Menschen fundamental.", [["Sie alle tragen zur Behebung der Mangelwirtschaft bei, was allemal mehr ist als nur ein symbolischer Beitrag", "SPECIES", 0, 108], ["Folgen der Lean-Modelle und Wege aus dem DilemmaDie Pandemie, die die desastr\u00f6sen M\u00e4ngel im Gesundheitssystem und in der Versorgung offen legt, erzwingt eine Revision bisheriger Praxis, denn diese gef\u00e4hrdet die Sicherheit der Menschen", "SPECIES", 124, 358]]], ["Es ist keineswegs auszuschlie\u00dfen, dass sich eine solche verheerende Naturkatastrophe zuk\u00fcnftig wiederholt.Dysfunktionale Folgen der Lean-Modelle und Wege aus dem DilemmaMit der \u00d6konomisierung des Gesundheitssystems einschlie\u00dflich der skizzierten Folgen wird eine verl\u00e4ssliche Daseinsvorsorge und F\u00fcrsorge gef\u00e4hrdet, die \u00f6ffentliche Dienstleistungen garantieren sollen.", [["Folgen der Lean-Modelle und Wege aus dem DilemmaMit der \u00d6konomisierung des Gesundheitssystems einschlie\u00dflich der skizzierten Folgen wird eine verl\u00e4ssliche Daseinsvorsorge und F\u00fcrsorge gef\u00e4hrdet", "SPECIES", 121, 314], ["Modelle und Wege aus dem DilemmaMit der \u00d6konomisierung des", "TREATMENT", 137, 195], ["einschlie\u00dflich der skizzierten", "TREATMENT", 215, 245]]], ["In der gesellschaftlichen Debatte wird bereits jetzt, mitten in der Krise eine R\u00fcckf\u00fchrung, ein insourcing von \u201esystemrelevanten\u201c Produkten einschlie\u00dflich der Fertigung in die nationale bzw. europ\u00e4ische Wirtschaft gefordert, um die fragile globale Abh\u00e4ngigkeit zu mildern und lebensnotwendige Ressourcen zu sichern.", [["europ\u00e4ische Wirtschaft gefordert, um die fragile globale Abh\u00e4ngigkeit zu mildern und lebensnotwendige Ressourcen zu sichern", "SPECIES", 191, 314]]], ["Diese d\u00fcrften bei einem technikzentrierten Ansatz, der als Mainstream gelten kann, gr\u00f6\u00dfer sein als bei einem arbeitsorientierten, der die Arbeit durch Digitalisierung unterst\u00fctzen und nicht eliminieren, also automatisieren will (vgl.", [["Diese d\u00fcrften bei einem technikzentrierten Ansatz, der als Mainstream gelten kann, gr\u00f6\u00dfer sein als bei einem arbeitsorientierten, der die Arbeit durch Digitalisierung unterst\u00fctzen und nicht eliminieren", "SPECIES", 0, 201], ["Diese d\u00fcrften bei einem technikzentrierten Ansatz", "TREATMENT", 0, 49]]], ["Solche Anstrengungen sind zudem geboten, um den Fachkr\u00e4ftemangel dauerhaft zu beheben.", [["Solche Anstrengungen sind zudem geboten, um den Fachkr\u00e4ftemangel dauerhaft zu beheben", "SPECIES", 0, 85], ["Solche", "TREATMENT", 0, 6]]], ["Die Forderung nach einer Erh\u00f6hung l\u00e4sst sich nicht so leicht umsetzen, wie vielfach suggeriert, denn Entgelte \u2013 wie die Gesamtheit der Arbeitsbedingungen \u2013 sind \u201eKampf- und Kompromissprodukte, also Erzeugnisse von Machtkonstellationen\u201c (Weber 1921/1964, S. 77).", [["denn Entgelte \u2013 wie die Gesamtheit der Arbeitsbedingungen \u2013 sind \u201eKampf- und Kompromissprodukte, also Erzeugnisse von Machtkonstellationen\u201c (Weber 1921/1964, S. 77", "SPECIES", 96, 259]]], ["Die Mitgliedschaft des Pflegepersonals in den Gewerkschaften ist gering und folglich auch ihre Konfliktf\u00e4higkeit mit den Arbeitgebern.", [["Die Mitgliedschaft des Pflegepersonals in den Gewerkschaften ist gering und folglich auch ihre Konfliktf\u00e4higkeit mit den Arbeitgebern", "SPECIES", 0, 133], ["Mitgliedschaft des Pflegepersonals", "TREATMENT", 4, 38]]], ["Mit anderen Worten: Die Verhandlungsmacht der Besch\u00e4ftigten und ihrer Organisationen ist schwach.", [["Mit anderen Worten: Die Verhandlungsmacht der Besch\u00e4ftigten und ihrer Organisationen ist schwach", "SPECIES", 0, 96]]], ["Das sind in der Summe wichtige Faktoren, die das aktuell niedrige Entgelt zu erkl\u00e4ren verm\u00f6gen.Pl\u00e4doyer f\u00fcr ein erweitertes Verst\u00e4ndnis von RationalisierungDie praktischen, weltweiten Erfahrungen mit lean production/lean administration, die auf Grund ihrer ambivalenten Wirkungen Korrekturen erfordern, halten noch eine Botschaft f\u00fcr die ArbeitswissenschaftlerInnen bereit.", [["Pl\u00e4doyer f\u00fcr ein erweitertes Verst\u00e4ndnis von RationalisierungDie praktischen, weltweiten Erfahrungen mit lean production/lean administration, die auf Grund ihrer ambivalenten Wirkungen Korrekturen erfordern, halten noch eine Botschaft f\u00fcr die ArbeitswissenschaftlerInnen bereit", "SPECIES", 95, 372], ["Pl\u00e4doyer", "TREATMENT", 95, 103], ["lean administration", "TREATMENT", 216, 235]]], ["Seit ihren Anf\u00e4ngen thematisiert die Arbeitswissenschaft den Prozess der Rationalisierung, allerdings vornehmlich als betriebliches Geschehen, als Kooperation zwischen Arbeitgeber bzw.", [["Seit ihren Anf\u00e4ngen thematisiert die Arbeitswissenschaft den Prozess der Rationalisierung, allerdings vornehmlich als betriebliches Geschehen, als Kooperation zwischen Arbeitgeber bzw", "SPECIES", 0, 183]]], ["Management und Arbeitskraft, wobei volkswirtschaftliche Bez\u00fcge eher unterbelichtet bleiben.", [["Management", "TREATMENT", 0, 10]]], ["Diese einzelwirtschaftliche Sicht war und ist unverzichtbar, aber zu eng:Pl\u00e4doyer f\u00fcr ein erweitertes Verst\u00e4ndnis von RationalisierungManche der fr\u00fcheren Defizite der Arbeitsbedingungen sind durch die Entwicklung des Sozialstaats, so durch gesetzliche Bestimmungen und, soweit existent, durch Tarifvertr\u00e4ge gemildert, wenn nicht gar beseitigt worden.", [["Diese einzelwirtschaftliche Sicht war und ist unverzichtbar, aber zu eng:Pl\u00e4doyer f\u00fcr ein erweitertes Verst\u00e4ndnis von RationalisierungManche der fr\u00fcheren Defizite der Arbeitsbedingungen sind durch die Entwicklung des Sozialstaats", "SPECIES", 0, 229]]], ["Jedoch m\u00fcssen die sozialen Standards immer wieder verteidigt werden.", [["Jedoch", "TREATMENT", 0, 6]]], ["Die Verbesserungen gelten aber kaum f\u00fcr Unternehmen der Entwicklungs- und Schwellenl\u00e4nder, den sogenannten Billig-Lohn-L\u00e4ndern, wo der Arbeits- und Gesundheitsschutz \u2013 h\u00e4ufig erst nach betrieblichen Unf\u00e4llen bis hin zu Katastrophen \u2013 eingefordert wird.", [["Die Verbesserungen gelten aber kaum f\u00fcr Unternehmen der Entwicklungs- und Schwellenl\u00e4nder, den sogenannten Billig-Lohn-L\u00e4ndern, wo der Arbeits- und Gesundheitsschutz \u2013 h\u00e4ufig erst nach betrieblichen Unf\u00e4llen bis hin zu Katastrophen \u2013 eingefordert wird", "SPECIES", 0, 251]]], ["\u00dcber die klassische Interessenorientierung hinaus sind die Interessen dieser L\u00e4nder und nicht zuletzt diejenigen der L\u00e4nder der EU ebenfalls in den Blick zu nehmen.", [["\u00dcber die klassische Interessenorientierung hinaus sind die Interessen dieser L\u00e4nder und nicht zuletzt diejenigen der L\u00e4nder der EU ebenfalls in den Blick zu nehmen", "SPECIES", 0, 163]]], ["In der Pandemie zeigt sich, wie sehr die nationale bzw. europ\u00e4ische Sicherheit durch Outsourcing im Gesundheitssektor bedroht werden kann, sodass potentielle Auslagerungen prinzipiell der \u00dcberpr\u00fcfung bed\u00fcrfen.", [["wie sehr die nationale bzw", "SPECIES", 28, 54], ["europ\u00e4ische", "TREATMENT", 56, 67]]], ["Es geht um umweltvertr\u00e4gliche Produktionsverfahren und Produkte, um den Klimawandel in Schach zu halten und auf dem Globus akzeptable Lebensbedingungen f\u00fcr Mensch, Tier und Natur erhalten zu k\u00f6nnen bzw. wieder herzustellen.", [["Es geht um umweltvertr\u00e4gliche Produktionsverfahren und Produkte, um den Klimawandel in Schach zu halten und auf dem Globus akzeptable Lebensbedingungen f\u00fcr Mensch, Tier und Natur erhalten zu k\u00f6nnen bzw", "SPECIES", 0, 201], ["herzustellen", "PROBLEM", 210, 222]]], ["Optimismus hinsichtlich der praktischen Umsetzung dieser Leitlinien durch diverse (politische) Akteure ist unangebracht, ganz im Gegenteil: Es handelt sich um ein \u00e4u\u00dferst schwieriges, gleichwohl notwendiges Unterfangen.", [["Optimismus hinsichtlich der praktischen Umsetzung dieser Leitlinien durch diverse (politische)", "TREATMENT", 0, 94], ["Akteure ist unangebracht", "TREATMENT", 95, 119], ["ganz", "ANATOMY", 121, 125]]], ["Dabei kann der Beitrag der Arbeitswissenschaft darin bestehen, die Perspektive von Rationalisierung im Sinne genannter Prinzipien zu erweitern, d. h. die damit verbundene Vielfalt von Interessen, Konflikten und Spannungsfeldern klar zu benennen und zu thematisieren.", [["Dabei kann der Beitrag der Arbeitswissenschaft darin bestehen, die Perspektive von Rationalisierung im Sinne genannter Prinzipien zu erweitern, d. h. die damit verbundene Vielfalt von Interessen, Konflikten und Spannungsfeldern klar zu benennen und zu thematisieren", "SPECIES", 0, 265]]]], "67466fd44aa1843c57174386e917578f0d83d71a": [["IntroductionThe 2015 epidemic of Middle East respiratory syndrome (MERS) in the Republic of Korea has been the largest outbreak outside Middle East since the first case was identified in Jeddah, Saudi Arabia, in June 2012 [1] [2] [3] [4] .", [["Middle East respiratory syndrome", "DISEASE", 33, 65], ["MERS", "DISEASE", 67, 71], ["Middle East respiratory syndrome", "PROBLEM", 33, 65], ["Middle", "ANATOMY_MODIFIER", 33, 39], ["respiratory syndrome", "OBSERVATION", 45, 65], ["largest", "OBSERVATION_MODIFIER", 111, 118]]], ["A total of 1,413 laboratory-confirmed cases infected by MERS-CoV, including 502 deaths, had been reported globally as of August 19, 2015 [5] , and mortality rate was about 35% [6] .", [["deaths", "DISEASE", 80, 86], ["MERS-CoV", "ORGANISM", 56, 64], ["MERS-CoV", "SPECIES", 56, 64], ["mortality rate", "TEST", 147, 161]]], ["Most cases emerged in the Middle East, sporadic cases had been reported in UK, Italy, France, Spain, United States and so on [7] [8] [9] [10] .", [["[7] [8] [9] [10]", "SIMPLE_CHEMICAL", 125, 141]]], ["Due to poor pre-control measures, the number of additional confirmed cases gradually increased during the period from May 20, 2015 to June 8, 2015 .", [["poor pre-control measures", "TREATMENT", 7, 32], ["gradually", "OBSERVATION_MODIFIER", 75, 84], ["increased", "OBSERVATION_MODIFIER", 85, 94]]], ["Then the Korean Government took effective control measures and the number of additional confirmed cases gradually decreased during the period from June 9 to July 4 [12, 13] .", [["effective control measures", "TREATMENT", 32, 58], ["decreased", "OBSERVATION_MODIFIER", 114, 123]]], ["Therefore, the Korean Government and WHO announced the end of MERS epidemic in the Republic of Korea in the middle of July.IntroductionIt is necessary to learn about the source of infection and transmission mechanism of MERS.", [["infection", "DISEASE", 180, 189], ["infection", "PROBLEM", 180, 189], ["middle", "ANATOMY_MODIFIER", 108, 114], ["infection", "OBSERVATION", 180, 189]]], ["The most probable source of Middle East respiratory syndrome coronavirus (MERS-CoV) is bats, and MERS-CoV-related viruses have been detected in bats.", [["Middle East respiratory syndrome coronavirus", "DISEASE", 28, 72], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 28, 72], ["MERS-CoV", "ORGANISM", 74, 82], ["MERS-CoV", "ORGANISM", 97, 105], ["Middle East respiratory syndrome coronavirus", "SPECIES", 28, 72], ["MERS-CoV", "SPECIES", 74, 82], ["MERS-CoV", "SPECIES", 97, 105], ["Middle East respiratory syndrome coronavirus", "PROBLEM", 28, 72], ["related viruses", "PROBLEM", 106, 121], ["most probable source of", "UNCERTAINTY", 4, 27], ["Middle", "ANATOMY_MODIFIER", 28, 34], ["respiratory syndrome", "OBSERVATION", 40, 60]]], ["However, people have little chance to contact with them directly.", [["people", "ORGANISM", 9, 15], ["people", "SPECIES", 9, 15]]], ["It is generally considered that dromedary camels are the intermediate reservoirs for MERS-CoV transmission from bats to human, but the accurate role of camels in transmission of MERS-CoV has not been available [1, 10, 14, 15] .", [["dromedary camels", "ORGANISM", 32, 48], ["MERS-CoV", "ORGANISM", 85, 93], ["bats", "ORGANISM", 112, 116], ["human", "ORGANISM", 120, 125], ["camels", "ORGANISM", 152, 158], ["MERS-CoV", "ORGANISM", 178, 186], ["human", "SPECIES", 120, 125], ["MERS-CoV", "SPECIES", 85, 93], ["human", "SPECIES", 120, 125], ["MERS-CoV", "SPECIES", 178, 186], ["dromedary camels", "PROBLEM", 32, 48]]], ["Generally, there are two main transmission routes [4, 8, [16] [17] [18] : one is animal-to-human transmission, the other one is human-to-human transmission.", [["human", "ORGANISM", 91, 96], ["human", "ORGANISM", 128, 133], ["human", "ORGANISM", 137, 142], ["human", "SPECIES", 91, 96], ["human", "SPECIES", 128, 133], ["human", "SPECIES", 137, 142], ["human", "SPECIES", 91, 96], ["human", "SPECIES", 128, 133], ["human", "SPECIES", 137, 142], ["two", "OBSERVATION_MODIFIER", 21, 24], ["main", "OBSERVATION_MODIFIER", 25, 29]]], ["The MERS-CoV can cause diseases ranging from the common cold to Severe Acute Respiratory Syndrome (SARS).", [["Acute Respiratory Syndrome", "DISEASE", 71, 97], ["SARS", "DISEASE", 99, 103], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 4, 12], ["MERS-CoV", "SPECIES", 4, 12], ["diseases", "PROBLEM", 23, 31], ["Severe Acute Respiratory Syndrome", "PROBLEM", 64, 97], ["Severe", "OBSERVATION_MODIFIER", 64, 70], ["Acute", "OBSERVATION_MODIFIER", 71, 76], ["Respiratory Syndrome", "OBSERVATION", 77, 97]]], ["The patients infected by MERS-CoV will have symptoms including fever, cough and shortness of breath, and the severe patients may have renal failure [1, 6, 7, 14, 19] .", [["renal", "ANATOMY", 134, 139], ["fever", "DISEASE", 63, 68], ["cough", "DISEASE", 70, 75], ["shortness of breath", "DISEASE", 80, 99], ["renal failure", "DISEASE", 134, 147], ["patients", "ORGANISM", 4, 12], ["MERS-CoV", "ORGANISM", 25, 33], ["patients", "ORGANISM", 116, 124], ["renal", "ORGAN", 134, 139], ["patients", "SPECIES", 4, 12], ["patients", "SPECIES", 116, 124], ["MERS-CoV", "SPECIES", 25, 33], ["symptoms", "PROBLEM", 44, 52], ["fever", "PROBLEM", 63, 68], ["cough", "PROBLEM", 70, 75], ["shortness of breath", "PROBLEM", 80, 99], ["renal failure", "PROBLEM", 134, 147], ["infected", "OBSERVATION", 13, 21], ["severe", "OBSERVATION_MODIFIER", 109, 115], ["renal", "ANATOMY", 134, 139], ["failure", "OBSERVATION", 140, 147]]], ["However, humans do not immediately show clinical symptoms after being infected and they undergo a incubation period from 2 to 14 days, during which time they are not infectious [11, 16] .IntroductionWhy the MERS broke out in the Republic of Korea rather than other countries such as UK, France, Italy is worth researching.", [["humans", "ORGANISM", 9, 15], ["humans", "SPECIES", 9, 15], ["humans", "SPECIES", 9, 15], ["clinical symptoms", "PROBLEM", 40, 57], ["infectious", "OBSERVATION", 166, 176]]], ["The first laboratory-confirmed patient was reported on May 20, 2015.", [["patient", "ORGANISM", 31, 38], ["patient", "SPECIES", 31, 38]]], ["Until May 11 he showed symptoms and sought for three hospitals before he was finally confirmed and isolated.", [["symptoms", "PROBLEM", 23, 31]]], ["During the period from being infected to being confirmed he had a close contact with many visitors, relatives, inpatients and health care workers.", [["infected", "OBSERVATION", 29, 37]]], ["The new cases continued to be reported in the next few days, and they all had corrections with the first confirmed case.", [["new", "OBSERVATION_MODIFIER", 4, 7]]], ["Through analyzing the actual transmission process, several factors appear to have contributed to the initial spread of this virus [22] :Introduction1.", [["this virus", "PROBLEM", 119, 129], ["Introduction1", "TREATMENT", 136, 149]]], ["The appearance of MERS-CoV was unexpected and unfamiliar to most physicians; 2.", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 18, 26], ["MERS-CoV", "SPECIES", 18, 26], ["MERS", "OBSERVATION", 18, 22]]], ["The custom of many friends and relatives to visit the patient is also a contribution factor.IntroductionA lot of work has been done in studying MERS.", [["patient", "ORGANISM", 54, 61], ["MERS", "PROTEIN", 144, 148], ["patient", "SPECIES", 54, 61]]], ["Lee et al [8] characterized the transmission chains of MERS-CoV infection in South Korean's outbreak.", [["MERS-CoV infection", "DISEASE", 55, 73], ["MERS-CoV", "ORGANISM", 55, 63], ["MERS-CoV", "SPECIES", 55, 63], ["MERS", "PROBLEM", 55, 59], ["CoV infection", "PROBLEM", 60, 73], ["CoV", "ANATOMY", 60, 63], ["infection", "OBSERVATION", 64, 73]]], ["Nishura et al [21] estimated the expected size of MERS clusters and the number of generations using a stochastic epidemic model.", [["a stochastic epidemic model", "TREATMENT", 100, 127], ["size", "OBSERVATION_MODIFIER", 42, 46]]], ["Chowell et al [16] studied a MERS-CoV transmission model with index and secondary cases.", [["a MERS", "TEST", 27, 33]]], ["Rivers et al [23] divided the susceptible populations into the high-risk group S 1 and the normal or low risk group S 2 .IntroductionIn order to describe the propagation process of MERS in the Republic of Korea during this period, we propose a deterministic SEAIHR model to study the spread of MERS among humans.", [["MERS", "DISEASE", 294, 298], ["humans", "ORGANISM", 305, 311], ["humans", "SPECIES", 305, 311], ["humans", "SPECIES", 305, 311], ["high", "OBSERVATION_MODIFIER", 63, 67], ["normal", "OBSERVATION", 91, 97], ["low risk", "OBSERVATION_MODIFIER", 101, 109]]], ["Because there is no zoonotic infections of MERS-CoV in the Republic of Korea, only one transmission route (human-to-human infection) is considered in model.", [["infections", "DISEASE", 29, 39], ["human-to-human infection", "DISEASE", 107, 131], ["MERS-CoV", "ORGANISM", 43, 51], ["human", "ORGANISM", 107, 112], ["human", "ORGANISM", 116, 121], ["human", "SPECIES", 107, 112], ["human", "SPECIES", 116, 121], ["MERS-CoV", "SPECIES", 43, 51], ["human", "SPECIES", 107, 112], ["human", "SPECIES", 116, 121], ["zoonotic infections of MERS", "PROBLEM", 20, 47], ["CoV", "PROBLEM", 48, 51], ["human infection", "PROBLEM", 116, 131], ["no", "UNCERTAINTY", 17, 19], ["zoonotic", "OBSERVATION_MODIFIER", 20, 28], ["infections", "OBSERVATION", 29, 39], ["infection", "OBSERVATION", 122, 131]]], ["Since the disease is almost distributed throughout the Republic of Korea, all the Korean are viewed as research subject.", [["the disease", "PROBLEM", 6, 17], ["disease", "OBSERVATION", 10, 17], ["almost", "OBSERVATION_MODIFIER", 21, 27], ["distributed", "OBSERVATION_MODIFIER", 28, 39], ["Republic", "OBSERVATION_MODIFIER", 55, 63]]], ["Based on infection status, the population is divided into the following categories: susceptible individual, exposed individual, asymptomatic individual, symptomatic infected individual, hospitalized case and removed case [16] .", [["infection", "DISEASE", 9, 18], ["infection status", "PROBLEM", 9, 25], ["infection", "OBSERVATION", 9, 18], ["symptomatic", "OBSERVATION_MODIFIER", 153, 164], ["infected", "OBSERVATION_MODIFIER", 165, 173]]], ["According to the practical situation, there is no effective control measures included in our model before June 8, 2015.Materials and Methods DataTime series of reported cases were reported by the WHO [24] and [32].", [["effective control measures", "PROBLEM", 50, 76], ["no", "UNCERTAINTY", 47, 49], ["effective", "OBSERVATION_MODIFIER", 50, 59]]], ["They provide detailed data of the epidemic in the Republic of Korea, including patient's age, gender, data of symptoms, data of first hospitalization, data of laboratory confirmation and so on.", [["patient", "ORGANISM", 79, 86], ["patient", "SPECIES", 79, 86], ["symptoms", "PROBLEM", 110, 118], ["laboratory confirmation", "TEST", 159, 182]]], ["We can make a related analysis of MERS based on the nice data.Propagation MechanismThe spread process (Table 1 ) of the disease is considered as follows: when a susceptible individual is infected, he or she turns to be an exposed case.", [["MERS", "DNA", 34, 38], ["The spread process", "PROBLEM", 83, 101], ["the disease", "PROBLEM", 116, 127], ["spread", "OBSERVATION_MODIFIER", 87, 93], ["disease", "OBSERVATION", 120, 127], ["infected", "OBSERVATION", 187, 195]]], ["Few days later, parts of the exposed cases turn to be asymptomatic cases (although no symptom, they have the ability to infect others), the remainings turn to be symptomatic cases.", [["asymptomatic cases", "PROBLEM", 54, 72], ["symptom", "PROBLEM", 86, 93], ["symptomatic cases", "PROBLEM", 162, 179]]], ["The symptomatic cases will go to hospital for treatment soon.", [["treatment", "TREATMENT", 46, 55]]], ["After treatment, some of them will recover, and about 21% will die [25] .", [["treatment", "TREATMENT", 6, 15]]], ["The asymptomatic cases will self-recover without any treatment.Dynamical model without effective control measuresIn order to facilitate research and make our model more reasonable, some assumptions are made:Dynamical model without effective control measures1.", [["any treatment", "TREATMENT", 49, 62], ["Dynamical model", "TREATMENT", 63, 78], ["effective control measures", "TREATMENT", 87, 113], ["Dynamical model", "TREATMENT", 207, 222], ["effective control measures", "TREATMENT", 231, 257], ["without", "UNCERTAINTY", 79, 86], ["effective", "OBSERVATION_MODIFIER", 87, 96]]], ["The whole population is initially susceptible except the first confirmed case;Dynamical model without effective control measures2.", [["Dynamical model", "TREATMENT", 78, 93], ["effective control measures2", "TREATMENT", 102, 129]]], ["There is no zoonotic infections of MERS-CoV in the Republic of Korea, only considering the epidemic spread in the human beings;Dynamical model without effective control measures3.", [["infections", "DISEASE", 21, 31], ["MERS-CoV", "ORGANISM", 35, 43], ["human", "ORGANISM", 114, 119], ["human", "SPECIES", 114, 119], ["MERS-CoV", "SPECIES", 35, 43], ["human", "SPECIES", 114, 119], ["zoonotic infections of MERS", "PROBLEM", 12, 39], ["Dynamical model", "TREATMENT", 127, 142], ["effective control measures3", "TREATMENT", 151, 178], ["no", "UNCERTAINTY", 9, 11], ["zoonotic", "OBSERVATION_MODIFIER", 12, 20], ["infections", "OBSERVATION", 21, 31], ["CoV", "OBSERVATION_MODIFIER", 40, 43]]], ["There is no effective control measures before June 8, 2015.Dynamical model without effective control measuresBased on the above assumptions, the spread of MERS in the human begins is shown in Fig 1.", [["MERS", "DISEASE", 155, 159], ["MERS", "GENE_OR_GENE_PRODUCT", 155, 159], ["human", "ORGANISM", 167, 172], ["MERS", "DNA", 155, 159], ["human", "SPECIES", 167, 172], ["human", "SPECIES", 167, 172], ["Dynamical model", "TREATMENT", 59, 74], ["effective control measures", "TREATMENT", 83, 109], ["no", "UNCERTAINTY", 9, 11], ["effective", "OBSERVATION_MODIFIER", 12, 21], ["without", "UNCERTAINTY", 75, 82], ["effective", "OBSERVATION_MODIFIER", 83, 92]]], ["And the corresponding dynamical model is given in Eq (1): where S denotes the number of susceptible individuals; E, the number of exposed individuals; A, the number of asymptomatic infected cases; I, the total number of mild infected person and severe patients.", [["patients", "ORGANISM", 252, 260], ["person", "SPECIES", 234, 240], ["patients", "SPECIES", 252, 260], ["mild infected person", "PROBLEM", 220, 240], ["asymptomatic", "OBSERVATION_MODIFIER", 168, 180], ["infected", "OBSERVATION", 181, 189], ["mild", "OBSERVATION_MODIFIER", 220, 224], ["infected", "OBSERVATION", 225, 233], ["severe", "OBSERVATION_MODIFIER", 245, 251]]], ["N, the total number of human population in the Republic of Korea. \u03b2 1 is the transmission coefficient of the asymptomatic infected cases, \u03b2 2 is the transmission coefficient of the symptomatic infected cases (mild infected person and severe patients) to the susceptible, \u03b2 3 is the transmission coefficient of the hospitalized cases to the susceptible, 1 s is the mean time of incubation period, 1 l is the mean time from data of symptoms onset to data of hospitalization, 1 k 1 is the mean infectious period of asymptomatic infected person for survivors, 1 k 2 is the mean duration for hospitalized cases for survivors, 1 d is the mean duration from hospitalization to death, \u03b3 is clinical outbreak rate in all the infected cases.", [["death", "DISEASE", 670, 675], ["human", "ORGANISM", 23, 28], ["\u03b2 1", "GENE_OR_GENE_PRODUCT", 66, 69], ["\u03b2 2", "GENE_OR_GENE_PRODUCT", 138, 141], ["patients", "ORGANISM", 241, 249], ["\u03b2 3", "GENE_OR_GENE_PRODUCT", 271, 274], ["\u03b2 1", "PROTEIN", 66, 69], ["human", "SPECIES", 23, 28], ["person", "SPECIES", 223, 229], ["patients", "SPECIES", 241, 249], ["person", "SPECIES", 534, 540], ["human", "SPECIES", 23, 28], ["the symptomatic infected cases", "PROBLEM", 177, 207], ["symptoms", "PROBLEM", 430, 438], ["death", "PROBLEM", 670, 675], ["clinical outbreak rate", "PROBLEM", 682, 704], ["total", "OBSERVATION_MODIFIER", 7, 12], ["number", "OBSERVATION_MODIFIER", 13, 19], ["symptomatic", "OBSERVATION_MODIFIER", 181, 192], ["infected", "OBSERVATION", 193, 201], ["mild", "OBSERVATION_MODIFIER", 209, 213], ["infected", "OBSERVATION", 214, 222], ["infectious", "OBSERVATION_MODIFIER", 491, 501], ["asymptomatic", "OBSERVATION_MODIFIER", 512, 524], ["infected", "OBSERVATION", 525, 533], ["infected", "OBSERVATION", 716, 724]]], ["The unit in Model (1) is taken as days \u22121 .Estimation of basic reproduction number R 0 in the Republic of KoreaThe transmission coefficients \u03b2 1 , \u03b2 2 , \u03b2 3 and \u03b3 are unknown.", [["\u03b2 1", "GENE_OR_GENE_PRODUCT", 141, 144], ["\u03b2 2", "GENE_OR_GENE_PRODUCT", 147, 150], ["\u03b2 3", "GENE_OR_GENE_PRODUCT", 153, 156], ["\u03b3", "GENE_OR_GENE_PRODUCT", 161, 162]]], ["The accumulated confirmed incidence (I total ) in the Republic of Korea is fitted to estimate four parameters (\u03b2 1 , \u03b2 2 , \u03b2 3 and \u03b3):Estimation of basic reproduction number R 0 in the Republic of KoreaDenoting the actual data of accumulated confirmed patients from May 20 to June 8, 2015 as I total .", [["\u03b2 2", "GENE_OR_GENE_PRODUCT", 117, 120], ["\u03b2 3", "GENE_OR_GENE_PRODUCT", 123, 126], ["patients", "ORGANISM", 252, 260], ["patients", "SPECIES", 252, 260]]], ["Through the least-squares method, the optimal set of parameter values is \u03b2 1 = 0.8756, \u03b2 2 = 0.7833, \u03b2 3 = 0.4568 and \u03b3 = 0.0348.Estimation of basic reproduction number R 0 in the Republic of KoreaSubstituting the parameter values (they can be found in Table 2 ) into the expression of the basic reproduction number R 0 (see S1 File), and estimate R 0 = 4.422 > 1 in the early epidemic.", [["parameter values", "TEST", 53, 69], ["early", "OBSERVATION_MODIFIER", 371, 376], ["epidemic", "OBSERVATION", 377, 385]]], ["It is well-known that if R 0 is bigger than one, disease will spread in the human beings.", [["R 0", "GENE_OR_GENE_PRODUCT", 25, 28], ["human", "ORGANISM", 76, 81], ["human", "SPECIES", 76, 81], ["human", "SPECIES", 76, 81], ["disease", "PROBLEM", 49, 56], ["bigger", "OBSERVATION_MODIFIER", 32, 38], ["disease", "OBSERVATION", 49, 56]]], ["This indicates that the disease spread quickly due to insufficient control measures and other reasons.The model with control measures in the Republic of KoreaThe number of additional confirmed cases performs downward trend (Fig 3) from June 9, 2015.", [["the disease spread", "PROBLEM", 20, 38], ["insufficient control measures", "TREATMENT", 54, 83], ["control measures", "TREATMENT", 117, 133], ["disease", "OBSERVATION", 24, 31]]], ["There is no additional confirmed cases from July 5, 2015, which illustrates that the 5.", [["no", "UNCERTAINTY", 9, 11]]], ["Washing your hands regularly with soap and water and maintaining good personal hygiene;The model with control measures in the Republic of Korea6.", [["soap and water", "TREATMENT", 34, 48], ["control measures", "TREATMENT", 102, 118], ["Korea6", "TREATMENT", 138, 144]]], ["Avoiding close contact with people who are sick;The model with control measures in the Republic of Korea7.", [["people", "ORGANISM", 28, 34], ["people", "SPECIES", 28, 34], ["control measures", "TREATMENT", 63, 79], ["Korea7", "TREATMENT", 99, 105]]], ["Covering your mouth and nose with a tissue or your sleeve when coughing or sneezing.The model with control measures in the Republic of KoreaIt is found that the main reasons of successfully controlling and eliminating disease can divide into two categories: \u2460: improving of self-protecting ability of susceptible. \u2461: isolating or monitoring all the close contacts, where asymptomatic cases and exposed cases are all belong to close contacts, and the confirmed cases and hospitalized cases are forcefully isolated.", [["mouth", "ANATOMY", 14, 19], ["nose", "ANATOMY", 24, 28], ["tissue", "ANATOMY", 36, 42], ["coughing", "DISEASE", 63, 71], ["sneezing", "DISEASE", 75, 83], ["mouth", "ORGANISM_SUBDIVISION", 14, 19], ["nose", "ORGAN", 24, 28], ["tissue", "TISSUE", 36, 42], ["your sleeve", "TREATMENT", 46, 57], ["coughing", "PROBLEM", 63, 71], ["sneezing", "PROBLEM", 75, 83], ["control measures", "TREATMENT", 99, 115], ["disease", "PROBLEM", 218, 225], ["mouth", "ANATOMY", 14, 19], ["nose", "ANATOMY", 24, 28]]], ["Based on this situation we establish a dynamical Model (3) with control measures as follows: where d 1 , d 2 , d 3 and d 4 are isolation or monitoring rates in E, A, I and H compartment, respectively. l 1 , l 2 and l 3 are self-protection coefficients with asymptomatic cases, symptomatic cases and hospitalized cases, respectively.Sensitivity and uncertainty analysis of basic reproduction number R 0The basic reproduction number is the threshold whether disease will outbreak and be prevalent in the crowd.", [["l 3", "GENE_OR_GENE_PRODUCT", 215, 218], ["monitoring rates", "TEST", 140, 156], ["asymptomatic cases", "PROBLEM", 257, 275], ["Sensitivity", "TEST", 332, 343], ["uncertainty analysis", "TEST", 348, 368], ["disease", "PROBLEM", 456, 463]]], ["When R 0 > 1, the disease will spread in the population; when R 0 < 1, the disease will gradually disappear [18, 29, 31] .", [["the disease", "PROBLEM", 14, 25], ["the disease", "PROBLEM", 71, 82], ["disease", "OBSERVATION", 18, 25], ["disease", "OBSERVATION", 75, 82]]], ["So it is important to study the sensitivity and uncertainty analysis of basic reproduction number R 0 on crucial parameters.", [["the sensitivity", "TEST", 28, 43], ["uncertainty analysis", "TEST", 48, 68]]], ["Here we adopt Latin hypercube sampling (LHS) to study the correlation between five crucial parameters (\u03b2 1 , \u03b2 2 , \u03b2 3 , \u03b3, \u03bb) and R 0 to asses the effect of corresponding control measures.", [["\u03b2 3", "GENE_OR_GENE_PRODUCT", 115, 118], ["\u03b2", "TEST", 109, 110], ["\u03b2", "TEST", 115, 116]]], ["Randomly choosing 1000 samples of the five crucial parameters (\u03b2 1 , \u03b2 2 , \u03b2 3 , \u03b3, \u03bb), which follow a normal distribution.", [["\u03b2 2", "GENE_OR_GENE_PRODUCT", 69, 72], ["\u03b2 3", "GENE_OR_GENE_PRODUCT", 75, 78], ["\u03b3", "GENE_OR_GENE_PRODUCT", 81, 82], ["\u03b2", "TEST", 69, 70], ["\u03b2", "TEST", 75, 76], ["normal", "OBSERVATION", 103, 109], ["distribution", "OBSERVATION_MODIFIER", 110, 122]]], ["Based on the 1000 samples, we perform the sensitivity and uncertainty analysis through rank correlation coefficient(PRCC), there is such a relationship: the bigger the absolute value of PRCC, the stronger the correlation between the chosen parameter and R 0 .", [["PRCC", "CANCER", 186, 190], ["the sensitivity", "TEST", 38, 53], ["uncertainty analysis", "TEST", 58, 78]]], ["From Table 3 , it is easy to find that the absolute value of PRCC between \u03b2 1 and R 0 is biggest, which shows that \u03b2 1 is the most important in determining R 0 .", [["\u03b2 1", "GENE_OR_GENE_PRODUCT", 74, 77], ["R 0", "GENE_OR_GENE_PRODUCT", 82, 85], ["\u03b2 1", "GENE_OR_GENE_PRODUCT", 115, 118], ["R 0", "GENE_OR_GENE_PRODUCT", 156, 159], ["\u03b2 1", "PROTEIN", 115, 118], ["PRCC", "TEST", 61, 65]]], ["It also indicates that the key factor of the rapid spread of the epidemic in the early stage is no timely isolating close contacts with the patients.", [["patients", "ORGANISM", 140, 148], ["patients", "SPECIES", 140, 148], ["rapid", "OBSERVATION_MODIFIER", 45, 50], ["spread", "OBSERVATION_MODIFIER", 51, 57], ["epidemic", "OBSERVATION_MODIFIER", 65, 73], ["no", "UNCERTAINTY", 96, 98]]], ["The parameter \u03bb has a negative correction with R 0 , i.e., when shorting the time from the onset to hospitalization, the value of R 0 will decrease.Parameter estimationIn this section, as the same method in estimating \u03b2 1 , \u03b2 2 and \u03b2 3 , we apply the least squares method to estimate l 1 , l 2 , l 3 , d 1 , d 2 , d 3 and d 4 (see Table 4 ).", [["\u03b2 2", "GENE_OR_GENE_PRODUCT", 224, 227], ["\u03b2 3", "GENE_OR_GENE_PRODUCT", 232, 235], ["the value", "TEST", 117, 126], ["Parameter estimation", "TEST", 148, 168], ["method", "TEST", 265, 271]]], ["We assume that d 1 , d 2 , d 3 and d 4 are the same, and the fitting curve is shown in Fig 4.", [["d 1 , d 2 , d 3 and d 4", "TEST", 15, 38], ["the fitting curve", "TEST", 57, 74]]], ["Substituting parameter values into the expression of R c (see S1 File), and get R c = 0.385 which is less than one, this also illustrates that MERS epidemic in the Republic of Korea will eventually disappear, which is consistent with the actual situation that there is no additional confirmed cases form July 5, 2015.", [["R c", "GENE_OR_GENE_PRODUCT", 53, 56], ["R c", "GENE_OR_GENE_PRODUCT", 80, 83], ["R c", "PROTEIN", 53, 56], ["parameter values", "TEST", 13, 29], ["consistent with", "UNCERTAINTY", 218, 233]]], ["[A] denotes that the initial value (S(0), E(0), A(0), I(0), H(0), R(0)) is obtained from Model (3).Parameter estimationI total is accumulated confirmed cases.Parameter estimationdoi:10.1371/journal.pone.0144778.t004Sensitivity analysis of the basic reproduction number R cIn this section, we apply two-dimension figures to explain how parameters affect the value of R c .", [["R c", "GENE_OR_GENE_PRODUCT", 366, 369], ["R c", "PROTEIN", 366, 369], ["the initial value", "TEST", 17, 34], ["Parameter estimationI", "TEST", 99, 120]]], ["From Fig 5, it is apparent that when a transmission coefficient is fixed, how the other two transmission coefficients determine the value of R c .", [["R c", "GENE_OR_GENE_PRODUCT", 141, 144], ["R c", "PROTEIN", 141, 144]]], ["The region on the left of the red line represents R c < 1.", [["left", "ANATOMY", 18, 22], ["red line", "ANATOMY", 30, 38], ["region", "ANATOMY_MODIFIER", 4, 10], ["left", "ANATOMY_MODIFIER", 18, 22], ["red line", "OBSERVATION", 30, 38], ["R", "ANATOMY_MODIFIER", 50, 51]]], ["The region on the right of the red line represents R c > 1.", [["red line", "ANATOMY", 31, 39], ["region", "ANATOMY_MODIFIER", 4, 10], ["right", "ANATOMY_MODIFIER", 18, 23], ["red line", "OBSERVATION", 31, 39], ["R", "ANATOMY_MODIFIER", 51, 52]]], ["In Fig 6, it shows the change of R c with respect to d 1 , d 2 , d 3 and d 4 , respectively.", [["R c", "GENE_OR_GENE_PRODUCT", 33, 36], ["R c", "PROTEIN", 33, 36]]], ["It is also easy to notice that when the isolating or monitoring rate increases, the basic reproduction number R c will reduce, where d 1 and d 2 have a bigger influence on R c than d 3 and d 4 .", [["R c", "GENE_OR_GENE_PRODUCT", 110, 113], ["R c", "GENE_OR_GENE_PRODUCT", 172, 175], ["monitoring rate", "TEST", 53, 68]]], ["It tells us that quickly finding and isolating exposed and asymptomatic cases can effectively control the spread of epidemic.Sensitivity analysis of the basic reproduction number R cThe relationship between self-protective coefficient, transmission coefficient and the final size of accumulated confirmed cases From Fig 7, it is obvious that the bigger value the self-protective coefficient, the smaller the final size of accumulated confirmed cases.", [["R c", "GENE_OR_GENE_PRODUCT", 179, 182], ["asymptomatic cases", "PROBLEM", 59, 77], ["epidemic", "PROBLEM", 116, 124], ["Sensitivity analysis", "TEST", 125, 145], ["smaller", "OBSERVATION_MODIFIER", 396, 403], ["size", "OBSERVATION_MODIFIER", 414, 418]]], ["Moreover, the bigger the transmission coefficient, the bigger size the final size of accumulated infected cases.", [["accumulated infected cases", "PROBLEM", 85, 111], ["bigger", "OBSERVATION_MODIFIER", 14, 20], ["bigger", "OBSERVATION_MODIFIER", 55, 61], ["size", "OBSERVATION_MODIFIER", 62, 66], ["final", "OBSERVATION_MODIFIER", 71, 76], ["size", "OBSERVATION_MODIFIER", 77, 81], ["accumulated", "OBSERVATION_MODIFIER", 85, 96], ["infected cases", "OBSERVATION", 97, 111]]], ["The parameters l 1 and \u03b2 1 have a bigger influence on the final size of accumulated confirmed cases, and this is consistent with the sensitivity analysis results of R 0 .", [["\u03b2 1", "GENE_OR_GENE_PRODUCT", 23, 26], ["The parameters", "TEST", 0, 14], ["the sensitivity analysis", "TEST", 129, 153], ["bigger", "OBSERVATION_MODIFIER", 34, 40], ["size", "OBSERVATION_MODIFIER", 64, 68], ["consistent with", "UNCERTAINTY", 113, 128]]], ["Through calculating, we get the theoretical expression of final accumulated confirmed cases size which is shown in S1 File.DiscussionCombining with the actual propagation situation and patients' data from May 20 to July 4, 2015 in the Republic of Korea, we establish two dynamical Models (1) and (3) study the process of MERS in the Republic of Korea.", [["patients", "ORGANISM", 185, 193], ["S1", "PROTEIN", 115, 117], ["patients", "SPECIES", 185, 193], ["patients' data", "TEST", 185, 199], ["size", "OBSERVATION_MODIFIER", 92, 96]]], ["When the novel disease emerged, there were no effective control measures for many reasons, in this case the basic reproduction number R 0 = 4.42, i.e., the epidemic spread quickly.", [["the novel disease", "PROBLEM", 5, 22], ["effective control measures", "TREATMENT", 46, 72], ["disease", "OBSERVATION", 15, 22], ["no", "UNCERTAINTY", 43, 45], ["effective", "OBSERVATION_MODIFIER", 46, 55]]], ["Since South Korean Government isolated or monitored all the close contacts with the patients infected by MERS-CoV, the additional confirmed cases gradually reduced and epidemic was controlled quickly.", [["patients", "ORGANISM", 84, 92], ["MERS-CoV", "ORGANISM", 105, 113], ["patients", "SPECIES", 84, 92], ["MERS-CoV", "SPECIES", 105, 113], ["epidemic", "PROBLEM", 168, 176]]], ["After July 5, there is no additional confirmed cases reported anymore.", [["no", "UNCERTAINTY", 23, 25]]], ["(1) and (3), it comes to a consistent conclusion through the sensitivity of the basic reproduction and the final size of accumulated confirmed cases: isolating all the close contacts and strengthening the self-protection ability of susceptible are the most effective control measures.DiscussionDuring this period, the spread situation of MERS in China also confirmed the above results.", [["size", "OBSERVATION_MODIFIER", 113, 117], ["most effective", "OBSERVATION_MODIFIER", 252, 266]]], ["The patient is a Korean in his mid-40s, who traveled to Guangdong province, China via Hong Kong on May 26.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11]]], ["Subsequently, the China Government isolated all close contacts as soon as possible and publicized the progress of the event to the society, killed the source of disease in the bud.", [["bud", "ANATOMY", 176, 179], ["bud", "ORGANISM_SUBDIVISION", 176, 179], ["disease in the bud", "PROBLEM", 161, 179], ["disease", "OBSERVATION", 161, 168]]], ["Therefore, MERS cannot spread across population under proper control measures.DiscussionBased on the successful experience in control MERS, we give some specific suggestions in face with emerging diseases: \u2460: Limit or stop taking fairs, rallies and theaters performances; \u2461: Provide necessary personal protective equipment to staff participated in emergency response; \u2462: Timely publish the information of emergence disease to the community, including the number confirmed cases, suspected cases, hospitalized cases and so on; \u2463: Carry out targeted health care education, raise public awareness and slef-protection and eliminate public mental disorder.DiscussionThe MERS mainly occurs in the Middle East countries, where the epidemic is most severe in Saudi Arabia.", [["mental disorder", "DISEASE", 635, 650], ["MERS", "PROTEIN", 11, 15], ["MERS", "PROBLEM", 11, 15], ["proper control measures", "TREATMENT", 54, 77], ["slef-protection", "TREATMENT", 598, 613], ["public mental disorder", "PROBLEM", 628, 650], ["Middle", "ANATOMY_MODIFIER", 691, 697], ["severe", "OBSERVATION_MODIFIER", 741, 747]]], ["There was a large-scale outbreak from early April to late June in Saudi Arabia in 2014, while the outbreak in the Republic of Korea mainly emerged from mid-May to early July in 2015.", [["a large-scale outbreak", "PROBLEM", 10, 32], ["large", "OBSERVATION_MODIFIER", 12, 17], ["-scale", "OBSERVATION_MODIFIER", 17, 23]]], ["Why the outbreaks of MERS are centralized from April to July and whether the outbreak of MERS has relation with season [34] are needed to be checked by more investigations.", [["MERS", "DISEASE", 21, 25], ["MERS", "DISEASE", 89, 93]]], ["In addition, it is also a good method in studying infectious disease on complex networks [35] [36] [37] and we will try to study disease-behavior dynamics on complex networks in the future study.DiscussionSupporting Information S1 File.", [["infectious disease", "DISEASE", 50, 68], ["the future study", "TEST", 178, 194]]], ["Mathematical analysis.", [["Mathematical analysis", "TEST", 0, 21]]]], "2e9cd40093b325469abb88e0eab820d550a11188": [["IntroductionCoronavirus disease 2019 (COVID-2019) caused by a novel coronavirus [severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)] emerged in Wuhan, China in December 2019 [1] and spread worldwide in 212 countries and territories causing more than 2,8 million cases and 194,000 deaths within a period of 4 months.", [["IntroductionCoronavirus disease", "DISEASE", 0, 31], ["coronavirus", "DISEASE", 68, 79], ["acute respiratory syndrome coronavirus", "DISEASE", 88, 126], ["deaths", "DISEASE", 290, 296], ["coronavirus", "ORGANISM", 68, 79], ["severe acute respiratory syndrome coronavirus-2", "ORGANISM", 81, 128], ["SARS-CoV-2", "ORGANISM", 130, 140], ["coronavirus", "SPECIES", 68, 79], ["severe acute respiratory syndrome coronavirus", "SPECIES", 81, 126], ["SARS-CoV-2", "SPECIES", 130, 140], ["IntroductionCoronavirus disease", "PROBLEM", 0, 31], ["a novel coronavirus", "PROBLEM", 60, 79], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 81, 126], ["severe", "OBSERVATION_MODIFIER", 81, 87], ["acute", "OBSERVATION_MODIFIER", 88, 93], ["respiratory syndrome", "OBSERVATION", 94, 114]]], ["[2] The transmission potential of SARS-Cov-2 is high as a consequence of the high basic reproduction number (R0) and the lack of previous immunity in humans.", [["SARS", "DISEASE", 34, 38], ["SARS-Cov-2", "GENE_OR_GENE_PRODUCT", 34, 44], ["humans", "ORGANISM", 150, 156], ["humans", "SPECIES", 150, 156], ["humans", "SPECIES", 150, 156], ["SARS", "PROBLEM", 34, 38], ["Cov", "TEST", 39, 42], ["SARS", "OBSERVATION", 34, 38]]], ["[3, 4] Fatality rates of COVID-19 are higher in older populations and low-income countries with underdeveloped hospital infrastructure and critical care facilities.", [["Fatality rates", "TEST", 7, 21], ["COVID", "TEST", 25, 30]]], ["[5, 6] The goal of public health authorities is the strongest possible mitigation in order to suppress the epidemic curve until sufficient population immunity and/or availability of effective therapies/vaccine.", [["the epidemic curve", "PROBLEM", 103, 121], ["effective therapies", "TREATMENT", 182, 201], ["vaccine", "TREATMENT", 202, 209]]], ["Central strategies include travel-related and a variety of case-based and social distancing interventions.", [["Central strategies", "TREATMENT", 0, 18], ["social distancing interventions", "TREATMENT", 74, 105]]], ["A nationwide lockdown took place on March 23 ( Figure 1 ) (SI Appendix, Table S1 ).", [["A nationwide lockdown", "TREATMENT", 0, 21], ["Appendix", "ANATOMY", 62, 70]]], ["By the end of April, the first wave of the epidemic has waned and withdrawal of physical distancing interventions is a social priority.IntroductionGreece has been referred as an example of a country with successful response against COVID-19, despite the severe financial crisis experienced in the recent years and its aged population.", [["the epidemic", "PROBLEM", 39, 51], ["physical distancing interventions", "TREATMENT", 80, 113], ["COVID", "TEST", 232, 237], ["the severe financial crisis", "PROBLEM", 250, 277], ["severe", "OBSERVATION_MODIFIER", 254, 260]]], ["[8] However, given the substantial risk of re-emergence of a second wave, careful consideration and close monitoring is needed to inform strategies on how to withdraw social distancing and resume social and economic activities.IntroductionPrevious impact assessments of the first epidemic wave were published for Wuhan and major Chinese cities.", [["close monitoring", "TEST", 100, 116]]], ["[7, 9, 10] In this paper, we provide estimates for the first wave of the epidemic in Greece based on modelling and report an assessment of the effect of social distancing measures.", [["[7, 9, 10]", "SIMPLE_CHEMICAL", 0, 10], ["an assessment", "TEST", 122, 135], ["social distancing measures", "TREATMENT", 153, 179]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 28, 2020. . https://doi.org/10.1101/2020.05.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["27.20114017 doi: medRxiv preprint The number of confirmed cases by date of sampling for laboratory testing and the timeline of the various social distancing measures in Greece are depicted in Figure 1 .", [["laboratory testing", "TEST", 88, 106]]], ["By April 26 th , 2020, there were 2,517 diagnosed cases (23\u00b70% were imported) and 134 deaths [11] .", [["deaths", "DISEASE", 86, 92]]], ["The corresponding naive case fatality rate (CFR) in Greece is 5\u00b73%.Model predictionsR0 was estimated 2\u00b738 (95% CI: 2\u00b701, 2\u00b780).", [["CI", "TEST", 111, 113]]], ["The initial decline resulted from the fist social distancing measures (closure of schools, shops, restaurants etc.) and the second drop from the implementation of restrictions of all non-essential movement throughout the country (lockdown).", [["the second drop", "PROBLEM", 120, 135]]], ["The estimated Rt during lockdown is 0\u00b746 (95% CrI: 0\u00b735, 0\u00b757).Model predictionsAt the end of the simulations period (April 26 th ), it is estimated that there are 25 new infections per day (95% CrI: 6, 97) and 329 infectious cases (95% CrI: 97, 1027) ( Figures 2B, 2C ).", [["infections", "DISEASE", 171, 181], ["CrI", "TEST", 46, 49], ["CrI", "TEST", 195, 198], ["infectious cases", "TEST", 215, 231], ["CrI", "TEST", 237, 240], ["Figures", "TEST", 254, 261], ["Rt", "ANATOMY_MODIFIER", 14, 16], ["new", "OBSERVATION_MODIFIER", 167, 170], ["infections", "OBSERVATION", 171, 181]]], ["The infection attack rate is 0\u00b712% (95% CrI: 0\u00b706%, 0\u00b726%).", [["infection", "DISEASE", 4, 13], ["The infection attack rate", "TEST", 0, 25], ["CrI", "TEST", 40, 43], ["infection", "OBSERVATION", 4, 13]]], ["This corresponds to 13,189 infections in total since the start of the epidemic (95% CrI: 6,206, 27,700) ( Figure 2D ).", [["infections", "DISEASE", 27, 37], ["infections", "PROBLEM", 27, 37], ["CrI", "TEST", 84, 87], ["infections", "OBSERVATION", 27, 37]]], ["The case ascertainment is estimated 19\u00b71% (95% CrI: 9\u00b71%, 40\u00b76%).Model predictionsBased on the number of deaths and critically ill patients reported by April 26 th and using as denominator the number of infections obtained from the model with the appropriate time lag, the IFR and the cumulative proportion of critically ill patients in Greece is 1\u00b712% (95% CrI: 0\u00b755%, 2\u00b731%) and 1\u00b755% (95% CrI: 0\u00b775%, 3\u00b722%), respectively.", [["deaths", "DISEASE", 105, 111], ["critically ill", "DISEASE", 116, 130], ["infections", "DISEASE", 203, 213], ["critically ill", "DISEASE", 310, 324], ["patients", "ORGANISM", 131, 139], ["patients", "ORGANISM", 325, 333], ["patients", "SPECIES", 131, 139], ["patients", "SPECIES", 325, 333], ["CrI", "TEST", 47, 50], ["infections", "PROBLEM", 203, 213], ["CrI", "TEST", 358, 361], ["CrI", "TEST", 392, 395], ["infections", "OBSERVATION", 203, 213]]], ["To validate the model, we compared the reported number of deaths to that estimated by applying an age-adjusted published estimate of IFR to the number of infections predicted by the model.", [["deaths", "DISEASE", 58, 64], ["infections", "DISEASE", 154, 164], ["infections", "PROBLEM", 154, 164], ["infections", "OBSERVATION", 154, 164]]], ["By April 26 th , the reported number of deaths was 134; the predicted number of deaths is 137 (95% CrI: 66, 279).", [["deaths", "DISEASE", 40, 46], ["deaths", "DISEASE", 80, 86], ["CrI", "TEST", 99, 102]]], ["The predicted daily number of deaths versus the observed is shown in Figure S1 .Model predictionsAs a sensitivity analysis, we simulated the epidemic and calculated these quantities assuming a shorter serial interval, finding very similar results concerning the infection attack rate and the IFR ( Figure S2 ).Disentangling the relative contribution of social distancing measuresIn total, 602 persons provided contact diaries; 12,463 and 1,743 contacts were reported in the periods before the pandemic and during lockdown, respectively ( Table 1 ).", [["deaths", "DISEASE", 30, 36], ["infection", "DISEASE", 262, 271], ["persons", "ORGANISM", 393, 400], ["persons", "SPECIES", 393, 400], ["a sensitivity analysis", "TEST", 100, 122], ["the epidemic", "PROBLEM", 137, 149], ["the infection attack rate", "PROBLEM", 258, 283], ["social distancing measures", "TREATMENT", 353, 379], ["infection", "OBSERVATION", 262, 271]]], ["The mean daily number of contacts declined from 20\u00b77 to 2\u00b79 for the lockdown period (adjusted for the age distribution of the Greek population: 19\u00b79 vs 2\u00b76, reduction: 86\u00b79%).Disentangling the relative contribution of social distancing measures.", [["social distancing measures", "TREATMENT", 218, 244], ["mean", "OBSERVATION_MODIFIER", 4, 8], ["social distancing", "OBSERVATION", 218, 235]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)Disentangling the relative contribution of social distancing measuresThe copyright holder for this preprint this version posted May 28, 2020. . https://doi.org/10.1101/2020.05.27.20114017 doi: medRxiv preprintDisentangling the relative contribution of social distancing measuresThe change in age-mixing patterns is shown in the contact matrices of Figure 3A .", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["social distancing measures", "TREATMENT", 245, 271], ["The copyright holder", "TREATMENT", 271, 291], ["medRxiv", "TREATMENT", 395, 402], ["social distancing measures", "TREATMENT", 454, 480], ["med", "ANATOMY", 105, 108], ["change", "OBSERVATION_MODIFIER", 484, 490]]], ["In the pre-pandemic period, the diagonal of the contact matrix depicts the assortativity by age as participants tend to associate more often with other people of similar age.", [["matrix", "CELLULAR_COMPONENT", 56, 62], ["people", "ORGANISM", 152, 158], ["participants", "SPECIES", 99, 111], ["people", "SPECIES", 152, 158], ["diagonal", "ANATOMY_MODIFIER", 32, 40], ["contact matrix", "OBSERVATION", 48, 62]]], ["When social distancing measures were put into effect, the assortativity by age disappeared and contacts occurred mainly between household members ( Figures 3B-3D ).Disentangling the relative contribution of social distancing measuresBased on the age-specific contact matrices of the two periods, the estimated reduction of R0 resulting from lockdown is 81\u00b70% (95% CrI: 71\u00b77%, 86\u00b71%) ( Figure 4) .", [["social distancing measures", "TREATMENT", 207, 233], ["CrI", "TEST", 364, 367]]], ["Thus, lockdown would have reduced Rt to below 1\u00b70 even if the initial R0 had been as high as 5\u00b73 (95% CrI: 3\u00b75, 7\u00b72).Disentangling the relative contribution of social distancing measuresThe impact of each measure separately as well as of combinations of measures is shown in Figure 4 .Disentangling the relative contribution of social distancing measuresThe reduction in R0 attributed to each one of these measures is estimated 18\u00b75% (95% CI: 10\u00b77%,26\u00b73%) for school closure, 10\u00b73% (95% CI: 5\u00b72%, 20\u00b73%) for the decline in work contacts and 24\u00b71% (95% CI: 14\u00b78%, 34\u00b73%) for the decline in contacts in leisure activities.", [["CrI", "TEST", 102, 105], ["social distancing measures", "TREATMENT", 160, 186], ["social distancing measures", "TREATMENT", 328, 354], ["The reduction in R0", "TREATMENT", 354, 373], ["CI", "TEST", 439, 441], ["school closure", "TEST", 460, 474], ["CI", "TEST", 487, 489], ["the decline in work contacts", "PROBLEM", 508, 536], ["CI", "TEST", 552, 554], ["the decline", "PROBLEM", 574, 585], ["high", "OBSERVATION_MODIFIER", 85, 89], ["reduction", "OBSERVATION_MODIFIER", 358, 367], ["R0", "OBSERVATION_MODIFIER", 371, 373]]], ["Combination of measures could be effective for higher R0 (work and school: 1\u00b778 , work and leisure: 1\u00b772, school and leisure: 1\u00b743).Disentangling the relative contribution of social distancing measuresWe assessed alternative scenarios with less disruptive social distancing measures.", [["social distancing measures", "TREATMENT", 175, 201]]], ["For example, a reduction of 50% in school contacts (e.g. smaller classrooms), 20% in work contacts (e.g. teleworking) and 20% in leisure activities could reduce Rt to below 1\u00b70 for initial levels as high as 1\u00b732 (95% CrI: 1\u00b727, 1\u00b738).", [["initial levels", "TEST", 181, 195], ["CrI", "TEST", 217, 220], ["reduction", "OBSERVATION_MODIFIER", 15, 24]]], ["An even higher decline in leisure activities (50%), could be successful for an initial R0 as high as 1\u00b748 (95% CrI: 1\u00b735, 1\u00b762).Disentangling the relative contribution of social distancing measuresFinally, we estimated the increase in Rt anticipated following the partial lift of lockdown measures assuming that contacts at work, school and leisure activities will return to levels that are 50%, 50% and 60% lower compared to pre-epidemic levels, respectively, and that the implementation of infection control measures (hand hygiene, masks, keeping distances) may reduce susceptibility to infection by 5%-30%.", [["hand", "ANATOMY", 520, 524], ["infection", "DISEASE", 492, 501], ["infection", "DISEASE", 589, 598], ["hand", "ORGANISM_SUBDIVISION", 520, 524], ["an initial R0", "TEST", 76, 89], ["CrI", "TEST", 111, 114], ["social distancing measures", "TREATMENT", 171, 197], ["the partial lift of lockdown measures", "TREATMENT", 260, 297], ["infection control measures", "TREATMENT", 492, 518], ["susceptibility to infection", "PROBLEM", 571, 598], ["higher", "OBSERVATION_MODIFIER", 8, 14], ["decline", "OBSERVATION_MODIFIER", 15, 22], ["increase", "OBSERVATION_MODIFIER", 223, 231], ["infection", "OBSERVATION", 492, 501], ["infection", "OBSERVATION", 589, 598]]], ["Rt will remain below 1 assuming at least 20% reduction in susceptibility as a result of these measures ( Figure 5 ).DiscussionAs the first wave of the SARS-CoV-2 epidemic is waning in many countries, it is important to assess the burden of infection and of death in the population and to quantify the impact of social distancing.DiscussionFirst, because these stringent measures have a major economic impact and restrict individual .", [["SARS", "DISEASE", 151, 155], ["infection", "DISEASE", 240, 249], ["death", "DISEASE", 257, 262], ["the SARS", "PROBLEM", 147, 155], ["infection", "PROBLEM", 240, 249], ["death", "PROBLEM", 257, 262], ["infection", "OBSERVATION", 240, 249]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 28, 2020. . https://doi.org/10.1101/2020.05.27.20114017 doi: medRxiv preprint freedom.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["medRxiv preprint freedom", "TREATMENT", 325, 349], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["Second, lockdown leads to low infection attack rates in many countries raising the possibility of a second wave following the resumption of some of the economic activities and travel; thus, some type of location-specific physical distancing measures may need to be re-implemented in the near future.(which was not certified by peer review)As of May 18 th , 2020, Greece has one of the lowest number of reported COVID-19 deaths in Europe (15\u00b72 deaths per million population) [2] (SI Appendix, Table S2 ).", [["infection", "DISEASE", 30, 39], ["deaths", "DISEASE", 420, 426], ["deaths", "DISEASE", 443, 449], ["low infection attack rates", "PROBLEM", 26, 52], ["low", "OBSERVATION_MODIFIER", 26, 29], ["infection", "OBSERVATION", 30, 39], ["Appendix", "ANATOMY", 482, 490]]], ["Accordingly, our estimate of the infection attack rate was very low (0\u00b712%).", [["infection", "DISEASE", 33, 42], ["the infection attack rate", "TEST", 29, 54], ["infection", "OBSERVATION", 33, 42]]], ["To simulate the outbreak in Greece, we estimated R0, assessed its decline over time, as a result of social distancing measures, and applied those in a mathematical model to estimate infections and deaths.", [["infections", "DISEASE", 182, 192], ["deaths", "DISEASE", 197, 203], ["social distancing measures", "TREATMENT", 100, 126], ["infections", "OBSERVATION", 182, 192]]], ["Other research groups have applied back calculation of infections from reported deaths in a Bayesian framework.", [["infections", "DISEASE", 55, 65], ["deaths", "DISEASE", 80, 86], ["infections", "PROBLEM", 55, 65], ["infections", "OBSERVATION", 55, 65]]], ["[12, 13] The resulting infection attack rate under the two approaches was almost identical (0\u00b712% vs. 0.13%).(which was not certified by peer review)[13] This attack rate is one of the lowest in Europe [13] and reflects the substantial impact of preventive measures in mitigating transmission.", [["infection", "DISEASE", 23, 32], ["[12, 13]", "SIMPLE_CHEMICAL", 0, 8], ["The resulting infection attack rate", "PROBLEM", 9, 44], ["This attack rate", "TEST", 154, 170], ["preventive measures", "TREATMENT", 246, 265], ["infection", "OBSERVATION", 23, 32], ["substantial", "OBSERVATION_MODIFIER", 224, 235], ["impact", "OBSERVATION_MODIFIER", 236, 242]]], ["A consequence of this low attack rate is the possibility of continuing transmission if measures are lifted, as this is the case even for countries that were more severely hit.(which was not certified by peer review)According to our estimates, the number of infectious cases has subsided considerably towards the end of April and social distancing measures can be lifted gradually.", [["this low attack rate", "PROBLEM", 17, 37], ["infectious cases", "PROBLEM", 257, 273], ["social distancing measures", "TREATMENT", 329, 355], ["infectious", "OBSERVATION", 257, 267]]], ["However, even in this period with low transmission levels, two local outbreaks were identified, the first in a refugee camp and the second in a private health care unit, thus increasing the number of diagnosed cases in the respective days ( Figure 1 ).", [["low transmission levels", "PROBLEM", 34, 57]]], ["An increasing number of reports around the world suggest the significance of super spreading events [14-17] and caution should be exercised to prevent them or recognize them early.(which was not certified by peer review)In the validation of the model, the resulting number of deaths (137 (95% CrI: 66, 279) was in agreement with the observed (134 deaths).", [["deaths", "DISEASE", 276, 282], ["deaths", "DISEASE", 347, 353], ["super spreading events", "PROBLEM", 77, 99], ["CrI", "TEST", 293, 296], ["increasing", "OBSERVATION_MODIFIER", 3, 13], ["number", "OBSERVATION_MODIFIER", 14, 20]]], ["In addition, the estimated IFR of 1\u00b712% was similar to that anticipated for the Greek population based on a published estimate, adjusted for non-homogenous attack rates by age and for demography.", [["the estimated IFR", "TEST", 13, 30]]], ["[5] The IFR of 0\u00b766% estimated for mainland China [5] is 1\u00b714% after standardizing for the age distribution of the Greek population.(which was not certified by peer review)We assessed the impact of social distancing by directly measuring individuals' contact patterns during lockdown using a social contacts survey in a sample including children.", [["children", "ORGANISM", 337, 345], ["children", "SPECIES", 337, 345], ["The IFR", "TEST", 4, 11]]], ["Only two other social contacts surveys have been implemented during COVID-19 lockdown (in China and UK) and only one of those included children.", [["children", "ORGANISM", 135, 143], ["children", "SPECIES", 135, 143]]], ["[18, 19] These studies had common findings: there was a large reduction in the number of contacts (86\u00b79% in Greece, 90\u00b73% in Shanghai, 86\u00b74% in Wuhan and 73\u00b71% in UK; the latter refers to adults only), the assortativity by age -i.e. contacts between people of the same age groupdisappeared and contacts during that period were mainly among household members.", [["people", "ORGANISM", 250, 256], ["people", "SPECIES", 250, 256], ["These studies", "TEST", 9, 22], ["a large reduction", "PROBLEM", 54, 71], ["large", "OBSERVATION_MODIFIER", 56, 61], ["reduction", "OBSERVATION_MODIFIER", 62, 71], ["number", "OBSERVATION_MODIFIER", 79, 85]]], ["Other studies .", [["Other studies", "TEST", 0, 13]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 28, 2020. . https://doi.org/10.1101/2020.05.27.20114017 doi: medRxiv preprint have assessed the impact of social distancing indirectly using social contacts data from pre-epidemic periods and assuming that interventions reduce social mixing in different contexts.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["[23, 24] In our analysis, we assumed lower susceptibility to infection among children as there is growing body of evidence supporting this.", [["infection", "DISEASE", 61, 70], ["children", "ORGANISM", 77, 85], ["children", "SPECIES", 77, 85], ["our analysis", "TEST", 12, 24], ["lower susceptibility to infection", "PROBLEM", 37, 70], ["lower susceptibility", "OBSERVATION_MODIFIER", 37, 57], ["infection", "OBSERVATION", 61, 70]]], ["[18, [25] [26] [27] [28] We further attempted to disentangle the impact of each measure.", [["[18, [25] [26] [27] [28", "SIMPLE_CHEMICAL", 0, 23]]], ["Each measure -when implemented at the levels observed during lockdown in Greece -can reduce Rt to levels below 1\u00b70 for initial R0 around 1\u00b72.", [["Rt to levels", "TEST", 92, 104]]], ["We should note that there is an interrelation between the different measures and the approach we have used might be an approximation; for example, school closure might result in increases in leisure contacts or decline in work contacts as parents need to attend younger children.(which was not certified by peer review)However, it provides some information about the individual impact of each measure.", [["children", "ORGANISM", 270, 278], ["children", "SPECIES", 270, 278], ["school closure", "TREATMENT", 147, 161], ["increases", "OBSERVATION_MODIFIER", 178, 187]]], ["We also assessed a scenario with less disruptive social distancing measures that could reduce Rt below 1\u00b70 for initial levels as high as 1\u00b733.", [["initial levels", "TEST", 111, 125]]], ["Concerning the course of the epidemic postlockdown, the effectiveness of infection control measures in reducing transmission is not known.", [["postlockdown", "DISEASE", 38, 50], ["infection", "DISEASE", 73, 82], ["the epidemic postlockdown", "TREATMENT", 25, 50], ["infection control measures", "TREATMENT", 73, 99], ["infection", "OBSERVATION", 73, 82]]], ["We considered scenarios with levels varying between 5%-30%.", [["levels", "TEST", 29, 35]]], ["It seems that an effectiveness of infection control measures higher than 15% in combination with less disruptive social distancing may keep Rt below 1\u00b70.(which was not certified by peer review)Our analysis has some limitations.", [["infection", "DISEASE", 34, 43], ["infection control measures", "TREATMENT", 34, 60], ["Our analysis", "TEST", 193, 205], ["infection", "OBSERVATION", 34, 43]]], ["First, the lack of baseline pre-epidemic data since this was the first social contacts survey implemented in Greece.", [["baseline pre-epidemic data", "PROBLEM", 19, 45]]], ["We asked respondents to report their contacts approximately two months earlier than the survey to make sure that these contacts were not affected by increased awareness of the pandemic.", [["the pandemic", "PROBLEM", 172, 184]]], ["Our analysis has focused on the number of contacts, their ages (using wide age groups) and the place of the contact and not in the duration or the type of contact (physical or not) where the bias might be higher.", [["Our analysis", "TEST", 0, 12]]], ["[30] In addition, the majority of the population lives in urban areas (Athens and other cities account for 35% and 79% of the Greek population, respectively) and the observed reduction of social contacts during lockdown was similar to other surveys conducted in China and UK.", [["reduction", "OBSERVATION_MODIFIER", 175, 184]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 28, 2020. . https://doi.org/10.1101/2020.05.27.20114017 doi: medRxiv preprint the estimate of R0 depends on the serial interval and the number of imported cases.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["medRxiv", "TREATMENT", 325, 332], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["As there was no data from a local study of pairs infector-infectee, the distribution of the serial interval was based on previous estimates.", [["a local study", "TEST", 26, 39], ["infectee", "PROBLEM", 58, 66], ["distribution", "OBSERVATION_MODIFIER", 72, 84]]], ["[12, [32] [33] [34] The estimated R0 was in accordance with the epidemics in China [4] and Italy [35] and in our simulations we accounted for the uncertainty in this value.", [["[12, [32] [33] [34", "SIMPLE_CHEMICAL", 0, 18], ["The estimated R0", "TEST", 20, 36]]], ["In addition, we repeated the analysis assuming a shorter serial interval [36] ; this resulted in a lower R0 and Rt (i.e. a more optimistic scenario in terms of epidemic control through social distancing).", [["the analysis", "TEST", 25, 37], ["a lower R0", "TREATMENT", 97, 107], ["lower", "ANATOMY_MODIFIER", 99, 104]]], ["Fourth, the environmental component of R0 (fomites etc.) was not considered due to the lack of data.", [["environmental", "OBSERVATION_MODIFIER", 12, 25], ["component", "OBSERVATION_MODIFIER", 26, 35]]], ["However, from the study of 318 outbreaks in China, in only one the role of outdoor environmental transmission was noted.", [["the study", "TEST", 14, 23]]], ["Close monitoring of Rt is essential in order to adapt interventions over time.", [["Close monitoring", "TEST", 0, 16], ["adapt interventions", "TREATMENT", 48, 67]]], ["Its estimation is based on routine surveillance data and the delay between infection and diagnosis, resulting from the incubation time and reporting delays, can be considerable.", [["infection", "DISEASE", 75, 84], ["routine surveillance data", "TEST", 27, 52], ["infection", "PROBLEM", 75, 84], ["infection", "OBSERVATION", 75, 84]]], ["Measuring social mixing patterns as well as adherence to infection control measures through repeated surveys can be an additional tool for real-time monitoring of the epidemic potential in the months to come.Estimation of R0Estimation of R0 was based on the number of confirmed cases with infection onset dates before the first social distancing measures were adopted (up to March 9 th , 2020) using a maximum likelihood method and accounting for imported cases.", [["infection", "DISEASE", 57, 66], ["infection", "DISEASE", 289, 298], ["infection control measures", "TREATMENT", 57, 83], ["infection onset dates", "PROBLEM", 289, 310], ["infection", "OBSERVATION", 57, 66], ["infection", "OBSERVATION", 289, 298]]], ["[38] We have used the daily number of cases by date of symptom onset and inferred infection dates assuming that infection occurred approximately 5 days ago (mean incubation period [3, 39] ).", [["infection", "DISEASE", 82, 91], ["infection", "DISEASE", 112, 121], ["symptom onset", "PROBLEM", 55, 68], ["inferred infection", "PROBLEM", 73, 91], ["infection", "PROBLEM", 112, 121], ["infection", "OBSERVATION", 82, 91], ["infection", "OBSERVATION", 112, 121]]], ["[32] [33] [34] As a sensitivity analysis, we estimated R0 assuming a shorter serial interval (SI Appendix, Figure S2 ).", [["a sensitivity analysis", "TEST", 18, 40], ["a shorter serial interval (SI Appendix", "PROBLEM", 67, 105]]], ["[A SEIR model to simulate the epidemic in Greece (February-April 2020)We simulated the outbreak of SARS-CoV-2 in Greece from the beginning of local transmission until April 26, 2020.", [["SARS", "DISEASE", 99, 103], ["SARS-CoV", "SPECIES", 99, 107], ["SARS", "PROBLEM", 99, 103]]], ["We assumed that local transmission initiated on February 15 th as the earliest reported date of symptom onset among locally infected cases was February 20 th .A SEIR model to simulate the epidemic in Greece (February-April 2020)A Susceptible-Exposed-Infectious-Recovered (SEIR) model was used to simulate the outbreak ( Figure 6 ).", [["symptom", "PROBLEM", 96, 103], ["Infectious", "OBSERVATION", 250, 260]]], ["The population is divided into six compartments: Susceptible (S), Exposed (E), Infectious before .", [["Infectious", "OBSERVATION_MODIFIER", 79, 89]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 28, 2020. . https://doi.org/10.1101/2020.05.27.20114017 doi: medRxiv preprint developing symptoms (Ipre), Infectious and clinically ill (Isymp), true asymptomatic and partially infectious (Iasymp) and Recovered (R).", [["CC", "CHEMICAL", 0, 2], ["Infectious and clinically ill", "DISEASE", 370, 399], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["developing symptoms", "PROBLEM", 342, 361], ["true asymptomatic", "PROBLEM", 409, 426], ["partially infectious (Iasymp)", "PROBLEM", 431, 460], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108], ["Infectious", "OBSERVATION_MODIFIER", 370, 380], ["partially", "OBSERVATION_MODIFIER", 431, 440], ["infectious", "OBSERVATION", 441, 451]]], ["We assumed that a proportion p=80% of infected cases will develop symptoms [40] and that infectiousness may occur 1\u00b75 days before the onset of symptoms (Table 2) .", [["infectiousness", "DISEASE", 89, 103], ["infected cases", "PROBLEM", 38, 52], ["symptoms", "PROBLEM", 66, 74], ["infectiousness", "PROBLEM", 89, 103], ["symptoms", "PROBLEM", 143, 151]]], ["[41] [42] [43] To estimate the effective reproduction number Rt in the presence of social distancing measures, we assessed the reduction in R0 using social contacts data collected from a survey implemented during lockdown (described in the next section).", [["social distancing measures", "TREATMENT", 83, 109]]], ["The impact of measures was modelled by multiplying the infection rate \u03b2 by a parameter \u03b4 corresponding to the reduction of Rt in two major periods of measures: the period of initial measures including closure of schools and entertainment venues and shops (expect from super markets, groceries and pharmacies) until the day before lockdown (11 March-22 March) and the period of lockdown (23) (24) (25) (26) .", [["infection", "DISEASE", 55, 64], ["the reduction of Rt", "TREATMENT", 106, 125], ["initial measures", "TREATMENT", 174, 190], ["closure of schools", "TREATMENT", 201, 219], ["infection", "OBSERVATION", 55, 64]]], ["More information about the model is provided in the SI Appendix.(which was not certified by peer review)To simulate the outbreak, we used the estimated R0 based on diagnosed cases in the country, other epidemiological parameters from the literature ( Table 2 ) and the estimated reduction in transmission resulting from social distancing measures.", [["the estimated reduction in transmission", "PROBLEM", 265, 304], ["social distancing measures", "TREATMENT", 320, 346], ["Appendix", "ANATOMY", 55, 63], ["reduction", "OBSERVATION_MODIFIER", 279, 288]]], ["One symptomatic case was seeded to the population at day 0 (February 15 th ) and the epidemic was further seeded by 700 imported cases over the first 40 days.(which was not certified by peer review)This assumption was based on the number of approximately 500 imported cases diagnosed by April 7 th in Greece.(which was not certified by peer review)[44] We incorporated uncertainty in R0 by drawing R0 values uniformly from the estimated 95% CI (2\u00b701, 2\u00b780).", [["CI", "TEST", 441, 443], ["symptomatic", "OBSERVATION_MODIFIER", 4, 15]]], ["To account for the uncertainty in the reduction of R0, \u03b4 was drawn from a normal distribution with mean (SD) of 42\u00b77% (1\u00b77%) and 81\u00b70% (1\u00b76%) for the period of initial measures and lock-down, respectively, based on the social contacts data.", [["normal", "OBSERVATION", 74, 80], ["distribution", "OBSERVATION_MODIFIER", 81, 93]]], ["One thousand simulations were performed and median estimates as well as 95% credible intervals (95% CrI) were obtained.(which was not certified by peer review)We obtained the infection fatality ratio (IFR) and the cumulative proportion of critically ill patients by dividing the reported number of deaths and of critically ill patients [11] to the total number of cases predicted by the model using a lag of 18 and 14 days, respectively (this lag was based on unpublished data from hospitalised patients in Greece).", [["infection", "DISEASE", 175, 184], ["critically ill", "DISEASE", 239, 253], ["deaths", "DISEASE", 298, 304], ["critically ill", "DISEASE", 312, 326], ["patients", "ORGANISM", 254, 262], ["patients", "ORGANISM", 327, 335], ["patients", "ORGANISM", 495, 503], ["patients", "SPECIES", 254, 262], ["patients", "SPECIES", 327, 335], ["patients", "SPECIES", 495, 503], ["median estimates", "TEST", 44, 60], ["infection", "OBSERVATION", 175, 184]]], ["As patients who die on any given day are infected earlier, we have used this time lag so that the denominator reflects the total number of patients infected at the same time as those who died.", [["patients", "ORGANISM", 3, 11], ["patients", "ORGANISM", 139, 147], ["patients", "SPECIES", 3, 11], ["patients", "SPECIES", 139, 147], ["infected", "OBSERVATION", 41, 49], ["infected", "OBSERVATION", 148, 156]]], ["[45] To validate our findings, we used a reverse approach; we applied a published estimate of the IFR [5] to the number of infections predicted by the model and compared the resulting number of deaths to the observed (assuming again a lag of 18 days between infection and death).", [["infections", "DISEASE", 123, 133], ["deaths", "DISEASE", 194, 200], ["infection", "DISEASE", 258, 267], ["death", "DISEASE", 272, 277], ["a reverse approach", "TREATMENT", 39, 57], ["infections", "PROBLEM", 123, 133], ["infection", "PROBLEM", 258, 267], ["infections", "OBSERVATION", 123, 133]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 28, 2020. . https://doi.org/10.1101/2020.05.27.20114017 doi: medRxiv preprintAssessing the impact of social distancing measuresA social contacts phone survey was implemented during the period of lockdown (March 31-April 7, 2020) (SI Appendix, Figure S3 ).", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["medRxiv", "TREATMENT", 325, 332], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108], ["Appendix", "ANATOMY", 497, 505]]], ["In line with the POLYMOD study [46] , a contact was defined as either a skin-to-skin contact (physical contact, e.g. handshake) or a two-way conversation with three or more words in the physical presence of another person (nonphysical contact).", [["skin", "ANATOMY", 72, 76], ["skin", "ANATOMY", 80, 84], ["skin", "ORGAN", 72, 76], ["skin", "ORGAN", 80, 84], ["person", "SPECIES", 215, 221], ["the POLYMOD study", "TEST", 13, 30], ["skin", "ANATOMY", 72, 76], ["skin", "ANATOMY", 80, 84]]], ["For each contact, information on the age of the person and location this contact took place (home, school, workplace, transportation, leisure, other) was recorded.", [["person", "SPECIES", 48, 54]]], ["We planned to recruit 600 people of all ages residing in Athens using proportional quota sampling and oversampling in the group aged between 0 and 17 years old.", [["people", "ORGANISM", 26, 32], ["people", "SPECIES", 26, 32], ["proportional quota sampling", "TREATMENT", 70, 97]]], ["Participants provided oral informed consent to the interviewers.Assessing the impact of social distancing measuresParental-proxy completion was used for all children 0-11 years old as well as for children/adolescents 12-17 years old if the parent did not consent to provide information on their own (SI Appendix).Assessing the impact of social distancing measuresWe assessed the impact of social distancing measures on Rt through the social contact matrices obtained before and during lockdown.", [["oral", "ANATOMY", 22, 26], ["oral", "ORGANISM_SUBDIVISION", 22, 26], ["children", "ORGANISM", 157, 165], ["children", "ORGANISM", 196, 204], ["Participants", "SPECIES", 0, 12], ["children", "SPECIES", 157, 165], ["children", "SPECIES", 196, 204], ["adolescents", "SPECIES", 205, 216], ["social distancing measures", "TREATMENT", 88, 114], ["social distancing measures", "TREATMENT", 337, 363], ["social distancing measures", "TREATMENT", 389, 415]]], ["The next-generation matrix K=( ) can be parameterised using the social contact matrix as follows:Assessing the impact of social distancing measureswhere i,j=1,..6 denote the age group of the participants and their contacts, respectively, pj and (1-pj)Assessing the impact of social distancing measuresis the proportion of symptomatic and true asymptomatic cases in individuals in age group j, q is the relative infectiousness of asymptomatic cases and E(d) is the average duration of infectiousness (assumed to be similar in symptomatic and asymptomatic cases).", [["K", "CHEMICAL", 27, 28], ["participants", "SPECIES", 191, 203], ["The next-generation matrix K", "TEST", 0, 28], ["infectiousness", "PROBLEM", 484, 498]]], ["We introduce an age-dependent proportionality factor si measuring susceptibility to infection of individuals in age group i.", [["infection", "DISEASE", 84, 93], ["infection", "OBSERVATION", 84, 93]]], ["From contact tracing on clusters of confirmed cases, children are found less susceptible to infection compared to adults (SI Appendix, Table S4 ).", [["infection", "DISEASE", 92, 101], ["children", "ORGANISM", 53, 61], ["children", "SPECIES", 53, 61], ["contact tracing", "TEST", 5, 20], ["infection", "PROBLEM", 92, 101], ["infection", "OBSERVATION", 92, 101], ["Appendix", "ANATOMY", 125, 133]]], ["We performed the analysis using a conservative estimate, i.e. that the susceptibility to infection among individuals 0-17 years old is 0\u00b734 compared to adults.", [["infection", "DISEASE", 89, 98], ["the analysis", "TEST", 13, 25], ["a conservative estimate", "TREATMENT", 32, 55], ["the susceptibility to infection", "PROBLEM", 67, 98], ["infection", "OBSERVATION", 89, 98]]], ["[18] As R0 is the largest eigenvalue of the next generation matrix K, to determine its relative change during lockdown (R0,during) compared to the period before measures (R0, pre) we calculated the following ratio [47] :Assessing the impact of social distancing measures.", [["[18] As", "CHEMICAL", 0, 7], ["matrix K", "GENE_OR_GENE_PRODUCT", 60, 68], ["social distancing measures", "TREATMENT", 244, 270], ["largest", "OBSERVATION_MODIFIER", 18, 25]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 28, 2020.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["[1] where S is a diagonal matrix accounting for the age-dependent susceptibility to infection with elements equal to 0\u00b734 for children (i=1,2,3) and 1 for adults (i=4, 5, 6) .", [["infection", "DISEASE", 84, 93], ["matrix", "CELLULAR_COMPONENT", 26, 32], ["children", "ORGANISM", 126, 134], ["children", "SPECIES", 126, 134], ["a diagonal matrix", "TREATMENT", 15, 32], ["dependent susceptibility to infection", "PROBLEM", 56, 93], ["infection", "OBSERVATION", 84, 93]]], ["A nonparametric bootstrap on the contact data by participant was performed to estimate 95% CrI for the relative change in R0(which was not certified by peer review)(n=1,000 bootstrap samples).(which was not certified by peer review)As multiple social distancing measures were implemented simultaneously, to disentangle the impact of each measure on R0 we used the information from the contacts reported on a regular weekday (January 2020) and \"mimicked\" the impact of each intervention separately by excluding or reducing subsets of the corresponding social contacts data (SI Appendix).", [["CrI", "PROTEIN", 91, 94], ["participant", "SPECIES", 49, 60], ["the relative change in R0", "PROBLEM", 99, 124], ["bootstrap samples", "TEST", 173, 190]]], ["[47, 48] As a contact with a particular person can take place in multiple settings (e.g. school and leisure), we assigned contacts at multiple locations to a single location using the following hierarchical order: home, work, school, leisure activities, transportation and other locations.", [["person", "SPECIES", 40, 46]]], ["[48] Then, we applied equation [1] using the social contacts matrix before the pandemic (Cpre) and the \"synthetic\" matrix corresponding to each measure (or combination of measures).", [["matrix", "CELLULAR_COMPONENT", 61, 67], ["matrix", "CELLULAR_COMPONENT", 115, 121], ["the \"synthetic\" matrix", "TREATMENT", 99, 121]]], ["Using the above methodology, we also assessed scenarios with less disruptive social distancing measures as well as scenarios assessing the increase in Rt when measures are partially lifted after lockdown.", [["disruptive social distancing measures", "TREATMENT", 66, 103], ["increase", "OBSERVATION_MODIFIER", 139, 147]]], ["For the scenarios after lifting lockdown, we assumed a reduction in susceptibility to infection in all age groups of 5%-30%, as a result of intensive infection control measures post lockdown (hand hygiene, use of masks, keeping distances) (SI Appendix).(which was not certified by peer review).", [["hand", "ANATOMY", 192, 196], ["infection", "DISEASE", 86, 95], ["infection", "DISEASE", 150, 159], ["hand", "ORGANISM_SUBDIVISION", 192, 196], ["a reduction in susceptibility to infection", "PROBLEM", 53, 95], ["intensive infection control measures", "TREATMENT", 140, 176], ["lockdown (hand hygiene", "TREATMENT", 182, 204], ["masks", "TREATMENT", 213, 218], ["reduction", "OBSERVATION_MODIFIER", 55, 64], ["infection", "OBSERVATION", 86, 95], ["intensive", "OBSERVATION_MODIFIER", 140, 149], ["infection", "OBSERVATION", 150, 159]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 28, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 28, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 28, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["Each cell represents the average number of reported contacts, stratified by the age group of the participants and their corresponding contacts.", [["cell", "ANATOMY", 5, 9], ["cell", "CELL", 5, 9], ["participants", "SPECIES", 97, 109], ["average", "OBSERVATION_MODIFIER", 25, 32], ["number", "OBSERVATION_MODIFIER", 33, 39]]], ["In Figure 3A (all contacts), the diagonal of the contact matrix corresponds to contacts between people of the same age group, the bottom left corner of the matrix corresponds to contacts between school age children and the central part to contacts mainly at the work environment.B. Contacts at home.", [["matrix", "CELLULAR_COMPONENT", 57, 63], ["people", "ORGANISM", 96, 102], ["matrix", "CELLULAR_COMPONENT", 156, 162], ["children", "ORGANISM", 206, 214], ["people", "SPECIES", 96, 102], ["children", "SPECIES", 206, 214], ["diagonal", "ANATOMY_MODIFIER", 33, 41], ["contact matrix", "OBSERVATION", 49, 63], ["bottom", "ANATOMY_MODIFIER", 130, 136], ["left", "ANATOMY_MODIFIER", 137, 141], ["corner", "ANATOMY_MODIFIER", 142, 148]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 28, 2020. . https://doi.org/10.1101/2020.05.27.20114017 doi: medRxiv preprint Figure 4 .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["Estimated ratio Rt/R0 to assess the impact of lockdown as well as the relative contribution of each measure or combination of measures as implemented during lockdown in Greece.", [["Estimated ratio Rt/R0", "TREATMENT", 0, 21]]], ["The lowest ratio, corresponding to the period of lockdown, was obtained by comparing the social contacts data collected for the two periods (April 2020 vs January 2020).", [["The lowest ratio", "TEST", 0, 16]]], ["Estimated Rt following the partial lift of social distancing measures at the end of the first SARS-CoV-2 wave in Greece depending on the efficacy and adherence to infection control measures (hand hygiene, use of masks, keeping distances).", [["hand", "ANATOMY", 191, 195], ["SARS", "DISEASE", 94, 98], ["infection", "DISEASE", 163, 172], ["hand", "ORGANISM_SUBDIVISION", 191, 195], ["social distancing measures", "TREATMENT", 43, 69], ["infection control measures", "TREATMENT", 163, 189], ["infection", "OBSERVATION", 163, 172]]], ["Modified SEIR model.", [["Modified SEIR model", "TREATMENT", 0, 19], ["SEIR model", "OBSERVATION", 9, 19]]], ["Individuals are classified into Susceptible (S), Exposed (I), Infectious (before developing symptoms: Ipre, clinically ill: Isymp or true asymptomatic: Iasymp) and Recovered (R) states.", [["symptoms", "PROBLEM", 92, 100], ["Infectious", "OBSERVATION", 62, 72]]], ["We assumed that a proportion p of exposed cases will develop symptoms and that infectiousness may occur before the onset of symptoms (see also Table 1 ).(which was not certified by peer review).", [["infectiousness", "DISEASE", 79, 93], ["symptoms", "PROBLEM", 61, 69], ["infectiousness", "PROBLEM", 79, 93], ["symptoms", "PROBLEM", 124, 132]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)(which was not certified by peer review)The copyright holder for this preprint this version posted May 28, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 242, 262], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["[41] [42] [43] Duration of infectious period from the development of symptoms to recovery(1/\u03c3s)4\u00b75 daysTo obtain a serial interval of ~6 days [3, 34, 39] True asymptomatic cases Reduction factor of transmissibility among asymptomatic cases (q) 50% [43] Duration of infectious period until recovery (1/\u03c3asymp)daysThe same duration of infectiousness as for symptomatic cases (1/\u03b3s+1/\u03c3s)", [["symptoms", "PROBLEM", 69, 77], ["True asymptomatic cases", "PROBLEM", 154, 177], ["transmissibility among asymptomatic cases", "PROBLEM", 198, 239], ["infectiousness", "PROBLEM", 333, 347], ["symptomatic cases", "PROBLEM", 355, 372], ["\u03b3s", "TEST", 376, 378], ["infectious", "OBSERVATION", 27, 37]]]]}